{"add": {"doc": {"field": [{"@name": "docid", "#text": "BR-TU.05997"}, {"@name": "filename", "#text": "10482_arquivo5042_1.pdf"}, {"@name": "filetype", "#text": "PDF"}, {"@name": "text", "#text": "UNIVERSIDADE FEDERAL DE PERNAMBUCO\n\nCENTRO DE CI\u00caNCIAS BIOL\u00d3GICAS\n\nDOUTORADO EM CI\u00caNCIAS BIOL\u00d3GICAS\n\nNANOC\u00c1PSULAS DE PLGA CONTENDO \u00c1CIDO \u00daSNICO DE\n\nCladonia substellata (VAINIO) COM POTENCIAL A\u00c7\u00c3O\n\nANTITUMORAL\n\nNOEMIA PEREIRA DOS SANTOS\n\nRecife/PE- Brasil\n\n2003\n\nNOEMIA PEREIRA DOS SANTOS\n\n\n\n2\n\nNANOC\u00c1PSULAS DE PLGA CONTENDO \u00c1CIDO \u00daSNICO DE\n\nCladonia substellata (VAINIO) COM POTENCIAL A\u00c7\u00c3O\n\nANTITUMORAL\n\nTese apresentada ao Curso de Doutorado\n\nem Ci\u00eancias Biol\u00f3gicas da Universidade\n\nFederal de Pernambuco, como parte dos\n\nrequisitos para obten\u00e7\u00e3o do grau de\n\nDoutor em Ci\u00eancias Biol\u00f3gicas  na \u00e1rea de\n\nBiotecnologia.\n\nOrientadora:\nProfa. Dra. Nereide Stela Santos Magalh\u00e3es\n\nCo-Orientadora:\nProfa. Dra. Silene Carneiro Nascimento\n\n\n\n3\n\nNANOC\u00c1PSULAS DE PLGA CONTENDO \u00c1CIDO \u00daSNICO DE\n\nCladonia substellata (VAINIO) COM POTENCIAL A\u00c7\u00c3O\n\nANTITUMORAL\n\nNOEMIA PEREIRA DOS SANTOS\n\nBANCA EXAMINADORA\n\n___________________________________________________________\n\nProfa. Dra. Nereide Stela Santos Magalh\u00e3es\nUniversidade Federal de Pernambuco\n\n_____________________________________________________________________\nProf. Dr. S\u00f3crates Ervaldo Tabosa do Egito\n\nUniversidade Federal do Rio Grande do Norte\n\nProf. Dra. Eug\u00eania Cristina  Gon\u00e7alves Pereira\nUniversidade Federal de Pernambuco\n\n_____________________________________________________________________\nProf. Dr. Jos\u00e9 Luiz de Lima Filho\n\nUniversidade Federal de Pernambuco\n\n_____________________________________________________________________\nProfa. Dra. Silene Carneiro Nascimento\nUniversidade Federal de Pernambuco\n\n\n\n4\n\n\n\n5\n\n\u201c... N\u00e3o se glorie o s\u00e1bio na sua\n\nsabedoria, nem se glorie o forte\n\nna sua for\u00e7a, n\u00e3o se glorie o\n\nrico nas suas riquezas; mas o\n\nque se gloriar, glorie-se nisto:\n\nem me conhecer e saber que eu\n\nsou o Senhor que fa\u00e7o\n\nbenef\u00edci\u00eancia, ju\u00edzo e justi\u00e7a na\n\nterra\u201d;\n\nJeremias 9:23,24.\n\n\n\n6\n\nDedico\n\nAos meus pais Antonio Luiz dos\n\nSantos (In memorian) e Severina\n\nPereira dos Santos (In\n\nmemorian), como\n\nreconhecimento ao seu  apoio e\n\ndedica\u00e7\u00e3o proporcionada na\n\nconstru\u00e7\u00e3o de meus ideais e\n\nobjetivos.\n\nSUM\u00c1RIO\n\nAGRADECIMENTOS\n\nLISTA DE FIGURAS\n\nLISTA DE TABELAS\n\nRESUMO\n\nABSTRACT\n\nP\u00e1gs\n\nINTRODU\u00c7\u00c3O.................................................................................................................... 18\n\n\n\n7\n\n1.1C\u00e2ncer.............................................................................................................................. 19\n\n1.1.1Generalidades............................................................................................................... 19\n\n1.1.2 Cancerologia experimental....................................................................................... 20\n\n1.2 Liquens.......................................................................................................................... 22\n\n1.2.1 As subst\u00e2ncias liqu\u00eanicas........................................................................................... 23\n\n1.2.2\u00c1cido \u00fasnico................................................................................................................. 24\n\n1.1.2 1 As propriedades biol\u00f3gicas do \u00e1cido \u00fasnico.......................................................... 27\n\n1.1.2.1.1 A\u00e7\u00e3o antibi\u00f3tica.................................................................................................... 27\n\n1.1.2.1.2 A\u00e7\u00e3o citot\u00f3xica e antitumoral.............................................................................. 28\n\n1.1.2.1.3 A\u00e7\u00e3o antiviral........................................................................................................ 30\n\n1.1.2.1.4 A\u00e7\u00e3o antiinflamat\u00f3ria, antipir\u00e9tica e analg\u00e9sica............................................... 31\n\n1.1.2.2 Mecanismo de a\u00e7\u00e3o proposto do \u00e1cido \u00fasnico...................................................... 32\n\n1.3 Sistemas de libera\u00e7\u00e3o controlada de f\u00e1rmacos........................................................... 33\n\n1.31.Sistemas nanoparticulados......................................................................................... 34\n\n1.3.1.1 Nanoc\u00e1psulas........................................................................................................... 35\n\n1.3.2 Nanotecnologia farmac\u00eautica e o tratamento do c\u00e2ncer........................................ 36\n\n1.4. Objetivos....................................................................................................................... 40\n\n1.4.1 Geral............................................................................................................................ 40\n\n1.4.2 Espec\u00edficos.................................................................................................................. 40\n\nCAP\u00cdTULO I\n\nUsnic acid-loaded PLGA nanocapsules: preparation, physicochemical\n\ncharacterisation and in vitro kinetics release\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026 41\n\n\n\n8\n\nCAP\u00cdTULO II\n\nAvalia\u00e7\u00e3o citot\u00f3xica in vitro de nanoc\u00e1psulas de PLGA contendo \u00e1cido \u00fasnico sobre\n\nc\u00e9lulas do c\u00e2ncer de pulm\u00e3o, linhagem NCI \u2013H292......................................................... 68\n\nCAP\u00cdTULO III\n\nAtividade antitumoral in vivo de nanoc\u00e1psulas de PLGA contendo \u00e1cido \u00fasnico\n\ncontra o tumor s\u00f3lido Sarcoma-180................................................................................... 87\n\n3. CONCLUS\u00d5ES .............................................................................................................. 111\n\n4. REFER\u00caNCIAS BIBLIOGR\u00c1FICAS.......................................................................... 113\n\nANEXOI...............................................................................................................................\n\nNormas de publica\u00e7\u00e3o dos peri\u00f3dicos selecionados\n\n123\n\nANEXO II.............................................................................................................................\n\nResumos apresentados em congressos decorrentes da Tese de Doutorado\n\n141\n\nANEXO III...........................................................................................................................\n\nParecer do comit\u00ea de \u00e9tica\n\n145\n\nAGRADECIMENTOS\n\nA Deus, o criador de todas as coisas, o qual me proporcionou a vida, sa\u00fade, intelig\u00eancia e\n\nfortalecimento na f\u00e9, a fim de perseverar sempre a busca do objetivo almejado.\n\n\n\n9\n\nA CAPES, pela concess\u00e3o de bolsa de estudo utilizada como fonte financeira para realiza\u00e7\u00e3o\n\ndo presente trabalho.\n\n\u00c0 Profa. Dra. Nereide Stela Santos-Magalh\u00e3es, pela prestimosa orienta\u00e7\u00e3o cient\u00edfica, moral e\n\nconfian\u00e7a transmitida.\n\n\u00c0 Profa. Dra. Silene C. Nascimento, pela compet\u00eancia, conhecimentos transmitidos, e\n\ninestim\u00e1vel orienta\u00e7\u00e3o proporcionada.\n\nAo Prof. Dr. Nic\u00e1cio H. da Silva, pela esmera dedica\u00e7\u00e3o, est\u00edmulo, apoio, amizade e\n\ncolabora\u00e7\u00e3o prestada.\n\n\u00c0 Profa. Dra. Eug\u00eania Cristina, pelo carinho, incentivo, trocas de id\u00e9ias e colabora\u00e7\u00e3o\n\nprestada.\n\nA Dra. Nely Kika Honda, da Universidade Federal de Mato Grosso do Sul, pela preciosa\n\ncolabora\u00e7\u00e3o, extraindo, purificando e caracterizando o \u00e1cido \u00fasnico.\n\nA Dra. Ana Souto Maior, por facultar as instala\u00e7\u00f5es do Laborat\u00f3rio de Qu\u00edmica de Produtos\n\nNaturais do Departamento de Antibi\u00f3ticos, para realiza\u00e7\u00e3o das dosagens qu\u00edmicas em\n\nCromatografia liquida de Alta Efici\u00eancia.\n\nAo Dr. Jos\u00e9 Figueredo-Silva, do Setor de Patologia - LIKA, pelo apoio e colabora\u00e7\u00e3o na\n\ninterpreta\u00e7\u00e3o dos exames histopatol\u00f3gicos.\n\nAo Dr. Cosme Rafael M. Salina, do Setor de Biotecnologia \u2013 LIKA, pela valiosa sugest\u00e3o\n\nconcedida nos c\u00e1lculos estat\u00edsticos.\n\nA Dra. C\u00e9lia Maria M. B. Castro, do Setor de Microbiologia \u2013 LIKA, pela valiosa\n\ncolabora\u00e7\u00e3o na realiza\u00e7\u00e3o dos ensaios hematol\u00f3gicos.\n\nAos t\u00e9cnicos do Laborat\u00f3rio de Farmacologia e Cancerologia Experimental, Maria Rodrigues\n\ne Suzete Mendon\u00e7a , pelo suporte e dedica\u00e7\u00e3o dispensada.\n\n\u00c0 Carmelita B. Lima e M\u00e1rio Ribeiro, do setor de Patologia - LIKA, pela amizade e efici\u00eancia\n\nno seu trabalho.\n\n\n\n10\n\nA todos funcion\u00e1rios do LIKA, pela amizade, dedica\u00e7\u00e3o e apoio t\u00e9cnico.\n\nAos funcion\u00e1rios da secretaria do Doutorado, pelo apoio e ajuda prestada durante todos estes\n\nanos.\n\nAos amigos do Setor de Bioqu\u00edmica - LIKA, pela amizade, aten\u00e7\u00e3o e trocas de experi\u00eancias.\n\nAos amigos do Grupo de Sistema de libera\u00e7\u00e3o controlada - LIKA, pela amizade,\n\ncompanheirismo e aux\u00edlio m\u00fatuo.\n\n\u00c0s alunas de Inicia\u00e7\u00e3o Cient\u00edfica, L\u00edlian, Daniele e Marcela pela  ajuda e precioso apoio\n\nfornecido.\n\nAs companheiras Jaqueline Rodrigues e Roseane  Ribeiro Costa pelo carinho, incentivo,\n\ndedica\u00e7\u00e3o, troca de conhecimentos e sugest\u00f5es, importantes na concretiza\u00e7\u00e3o deste trabalho.\n\nAos meus familiares, e em especial as minhas irm\u00e3s Mirian, Rute e Severina pelo apoio,\n\ndedica\u00e7\u00e3o e confian\u00e7a, fundamentais para vencer esta nova etapa da minha vida.\n\n Ao meu noivo Valter Pedro pelo apoio, compreens\u00e3o, companheirismo e incentivo,\n\nimportante na conquista de nossos objetivos.\n\nFinalmente, expresso minha gratid\u00e3o a todos que direta ou indiretamente contribu\u00edram na\n\nexecu\u00e7\u00e3o deste trabalho e no alcance de novos horizontes.\n\nLISTA DE FIGURAS\n\nINTRODU\u00c7\u00c3O\n\n\n\n11\n\nFigura 1. Modelo esquem\u00e1tico da anatomia de um talo liqu\u00eanico (Nash, 1996): A= Algas;\n\nB= Medula; C= C\u00f3rtex ........................................................................................................... 23\n\nFigura 2. Estrutura qu\u00edmica do \u00e1cido \u00fasnico: a) (+)-(9b-R) e (-)-(9b-S)  b) \u00e1cido iso\u00fasnico\n\n(+)-(9b-R) e (-)-(9b-S) Ing\u00f3lfsd\u00f3ttir (2002)............................................................................ 25\n\nFigura 3. Vias da bios\u00edntese do \u00e1cido \u00fasnico proposta por Taguchi et al., (1969)................. 26\n\nCAP\u00cdTULO I\n\nFigura 1. Microfotografia eletr\u00f4nica de varredura de nanoc\u00e1psulas de PLGA contendo\n\n\u00e1cido \u00fasnico ap\u00f3s prepara\u00e7\u00e3o (NC10) 3.500 X...................................................................... 60\n\nFigura 2. Evolu\u00e7\u00e3o do pH de nanoc\u00e1psulas de PLGA contendo \u00e1cido \u00fasnico armazenado a\n\n4\u00baC \u00b1 1\u00baC (NC10).................................................................................................................... 61\n\nFigura 3. Evolu\u00e7\u00e3o do conte\u00fado de \u00e1cido \u00fasnico dentro de nanoc\u00e1psulas de PLGA\n\nestocados a 4\u00baC\u00b11\u00baC (NC10): a) Dosagens da forma suspens\u00e3o b) Dosagens da forma\n\nLiofilizada................................................................................................................................ 62\n\nFigura 4. Perfil cin\u00e9tico de libera\u00e7\u00e3o in vitro de \u00e1cido \u00fasnico a partir de nanoc\u00e1psulas de\n\nPLGA (NC10)\u2026\u2026..\u2026............................................................................................................ 64\n\n\n\n12\n\nCAP\u00cdTULO II\n\nFigura 1. Determina\u00e7\u00e3o da IC 50 do \u00e1cido \u00fasnico livre e encapsulado em nanoc\u00e1psulas de\n\nPLGA sobre c\u00e9lulas NCI -H 292 utilizando o teste de Turkey, admitindo-se um intervalo\n\nde confian\u00e7a de 99% (p &lt;0,05): UA= \u00e1cido \u00fasnico livre, UA-NC= nanoc\u00e1psulas de\n\nPLGA contendo \u00e1cido \u00fasnico, NC= nanoc\u00e1psulas de PLGA brancas................................... 86\n\nFigure 2. Aspectos morfol\u00f3gicos de c\u00e9lulas NCI H-292 (40 X) ap\u00f3s tratamento com\n\n\u00e1cido \u00fasnico livre: controle (a) 100X (b) 200X; \u00e1cido \u00fasnico a 2,5\u00b5g/ml (c); \u00e1cido \u00fasnico\n\na 5\u00b5g/ml (d). Legenda: RMC= Redu\u00e7\u00e3o da monocamada celular; VC= Vacuoliza\u00e7\u00e3o\n\ncitoplasm\u00e1tica CD= C\u00e9lulas desnudas; NC= Necrose celular................................................ 87\n\nFigure 3. Aspectos morfol\u00f3gicos de c\u00e9lulas NCI H-292 (40 X) ap\u00f3s tratamento com\n\nnanoc\u00e1psulas contendo \u00e1cido \u00fasnico: nanoc\u00e1psulas de PLGA brancas (a); nanoc\u00e1psulas de\n\nPLGA contendo \u00e1cido \u00fasnico (5\u00b5g/ml) (b). Legenda: MC= Monocamada celular; CMIT=\n\nC\u00e9lulas mit\u00f3ticas....................................................................................................................\n\nCAP\u00cdTULO III\n\n88\n\nFigura 1.  Varia\u00e7\u00e3o da massa tumoral dos  animais tratados com \u00e1cido \u00fasnico livre e\n\nencapsulado contra tumor s\u00f3lido sarcoma-180: NC= nanoc\u00e1psulas de PLGA brancas;\n\nUA= \u00e1cido \u00fasnico livre; UA-NC= nanoc\u00e1psulas de PLGA contendo \u00e1cido \u00fasnico. Os\n\nefeitos dos tratamentos foram avaliados pelo teste F (p &lt;0,05). As compara\u00e7\u00f5es das\n\nm\u00e9dias foram realizadas pelo teste de Turkey (p &lt;0,05). Letras iguais n\u00e3o diferem\n\nsignificativamente (p &lt;0,05)................................................................................................. 104\n\nFigura 2. Avalia\u00e7\u00e3o da atividade antitumoral do \u00e1cido \u00fasnico livre e encapsulado contra\n\ntumor Sarcoma-180: NC= nanoc\u00e1psulas de PLGA brancas; UA= \u00e1cido \u00fasnico livre; UA-\n\nNC = nanoc\u00e1psulas de PLGA contendo acido \u00fasnico............................................................. 105\n\n\n\n13\n\nFigura 3. An\u00e1lises histol\u00f3gicas do tumor sarcoma-180 nos animais tratados (H &amp; E \u2013\n\n50X): a) controle; b) \u00e1cido \u00fasnico livre; c) nanoc\u00e1psulas de PLGA contendo \u00e1cido \u00fasnico.\n\nLegenda: NP= N\u00facleos picn\u00f3ticos, NC= Necrose...................................................................\n\n106\n\nFigura 4.  An\u00e1lises histol\u00f3gicas do f\u00edgado nos animais tratados (H &amp; E \u2013 50X): a)\n\ncontrole; b) \u00e1cido \u00fasnico livre; c) nanoc\u00e1psulas de PLGA contendo \u00e1cido \u00fasnico.\n\nLegenda: IL= Infiltrado leucocit\u00e1rio,  HD= Hepat\u00f3citos descaracterizados, VC=\n\nVacuoliza\u00e7\u00e3o citoplasm\u00e1tica................................................................................................... 107\n\nFigura 5. Contagem de hem\u00e1cias totais (Hem/mm3) da amostra de sangue de\n\ncamundongos submetidos a tratamentos  com \u00e1cido \u00fasnico livre e encapsulado comparado\n\na animais n\u00e3o tratados. As compara\u00e7\u00f5es das m\u00e9dias foram realizadas pelo teste de Turkey\n\n(p &lt;0,05). Letras iguais n\u00e3o diferem significativamente (p &lt;0,05).\n\nLegenda: Controle (+) = animais transplantados  com sarcoma-180 n\u00e3o tratados; UA =\n\n\u00e1cido \u00fasnico livre; UA-NC = nanoc\u00e1psulas de PLGA contendo \u00e1cido \u00fasnico; NC=\n\nnanoc\u00e1psulas de PLGA brancas; Controle (-) = animais sadios do laborat\u00f3rio...................... 108\n\nFigura 6. Contagem diferencial de linf\u00f3citos (103/mm3) da amostra de sangue de\n\ncamundongos submetidos a tratamentos  com \u00e1cido \u00fasnico livre e encapsulado comparado\n\na animais n\u00e3o tratados. As compara\u00e7\u00f5es das m\u00e9dias foram realizadas pelo teste de Turkey\n\n(p &lt;0,05). Letras iguais n\u00e3o diferem significativamente (p &lt;0,05).\n\nLegenda: Controle (+)= animais transplantados  com sarcoma-180 n\u00e3o tratados; UA=\n\n\u00e1cido \u00fasnico livre; UA-NC= nanoc\u00e1psulas de PLGA contendo \u00e1cido \u00fasnico; NC=\n\nnanoc\u00e1psulas de PLGA brancas; Controle (-) = animais sadios do laborat\u00f3rio...................... 109\n\nFigura 7. Avalia\u00e7\u00e3o da sobrevida de camundongos vivos transplantados com sarcoma-180\n\nap\u00f3s tratamento com \u00e1cido \u00fasnico livre, encapsulado com rela\u00e7\u00e3o ao controle (animais n\u00e3o\n\ntratados).................................................................................................................................... 110\n\n\n\n14\n\nLISTA DE TABELAS\n\nCAP\u00cdTULO I\n\nTabela 1. Otimiza\u00e7\u00e3o de nanoc\u00e1psulas de PLGA contendo \u00e1cido \u00fasnico.............................. 65\n\nTabela 2.  Estabilidade acelerada de nanoc\u00e1psulas PLGA contendo \u00e1cido \u00fasnico\n\u2026............................................................................................................................................. 66\n\nTabela 3.  Caracteriza\u00e7\u00e3o f\u00edsico-qu\u00edmica de nanoc\u00e1psulas PLGA contendo \u00e1cido \u00fasnico\n(NC10)\u2026.................................................................................................................................... 67\n\nCAP\u00cdTULO III\n\nTabela 1. Valores leucocit\u00e1rios de camundongos segundo a literatura.................................. 103\n\n\n\n15\n\nRESUMO\n\nO \u00e1cido \u00fasnico [2,6-Diacetil-7,9-dihidroxi-8,9b-dimetil-1,3[2H,9bH]-dibenzo-furadiona]\n\n(UA), composto natural obtido de diversas esp\u00e9cies de liquens, apresenta diferentes atividades\n\nbiol\u00f3gicas e fisiol\u00f3gicas que podem apresentar grande relev\u00e2ncia na farmacologia e cl\u00ednica.\n\nDevido sua relevante a\u00e7\u00e3o antimit\u00f3tica e antiproliferativa, existe potencial interesse de seu\n\nuso na terapia do c\u00e2ncer. N\u00e3o obstante, o sucesso de sua aplica\u00e7\u00e3o cl\u00ednica \u00e9 limitado a sua\n\ndotada a\u00e7\u00e3o t\u00f3xica e pouca solubilidade em \u00e1gua e solventes org\u00e2nicos de alta polaridade.\n\nNanopart\u00edculas s\u00e3o carreadores polim\u00e9ricos que podem modificar o perfil de distribui\u00e7\u00e3o do\n\nf\u00e1rmaco no organismo. Estes vetores medicamentosos proporcionam a libera\u00e7\u00e3o do f\u00e1rmaco\n\nno s\u00edtio de a\u00e7\u00e3o desejada, potencializando a a\u00e7\u00e3o terap\u00eautica e minimizando os efeitos\n\ncolaterais. O principal objetivo deste estudo consiste em obter e caracterizar f\u00edsico-\n\nquimicamente nanoc\u00e1psulas de copol\u00edmero de \u00e1cido l\u00e1tico e glic\u00f3lico (PLGA) contendo \u00e1cido\n\n\u00fasnico e investigar a atividade citot\u00f3xica e antitumoral do \u00e1cido \u00fasnico em compara\u00e7\u00e3o com a\n\nforma n\u00e3o encapsulada. Nanoc\u00e1psulas contendo \u00e1cido \u00fasnico (UA-NC) foram preparadas pelo\n\nm\u00e9todo de deposi\u00e7\u00e3o interfacial do pol\u00edmero. An\u00e1lises f\u00edsico-qu\u00edmicas foram realizadas\n\nimediatamente ap\u00f3s a prepara\u00e7\u00e3o das nanoc\u00e1psulas. Subseq\u00fcentemente, elas foram\n\nsubmetidas a ambos os testes de estabilidade acelerada e a longo termo. A morfologia e\n\ntamanho das part\u00edculas de UA-NC foram estudados utilizando a microscopia eletr\u00f4nica de\n\nvarredura (MEV). O teor  de \u00e1cido \u00fasnico nas nanoc\u00e1psulas foi obtido atrav\u00e9s de ensaios\n\ncromatogr\u00e1ficos e a taxa de encapsula\u00e7\u00e3o foi determinada ap\u00f3s ultrafiltra\u00e7\u00e3o e centrifuga\u00e7\u00e3o.\n\nO perfil de libera\u00e7\u00e3o in vitro do \u00e1cido \u00fasnico a partir das UA-NC foi determinado utilizando o\n\nm\u00e9todo de di\u00e1lise direta. O estudo da atividade citot\u00f3xica foi realizado pelo m\u00e9todo de cultura\n\nde tecidos com c\u00e9lulas da linha cont\u00ednua NCI-H 292. A viabilidade celular, foi determinada\n\npelo Azul de Tripan e a a\u00e7\u00e3o citot\u00f3xica do UA e UA-NC foi avaliada pelo m\u00e9todo\n\ncolorim\u00e9trico de MTT (3-[4,5-dimetiltiazol-2-il]-2,5-difeniltetraz\u00f3lio). Altera\u00e7\u00f5es\n\nmorfol\u00f3gicas nas c\u00e9lulas NCI H292 tratadas com UA e UA-NC foram analisadas por\n\nmicroscopia \u00f3ptica utilizando a t\u00e9cnica de Giemsa. A atividade antitumoral foi realizada em\n\ncamundongos albinos Su\u00ed\u00e7os (mus-musculus), frente ao tumor experimental sarcoma-180.\n\nDecorridos 24 h de implanta\u00e7\u00e3o do tumor, foram administrados, intraperitonealmente,\n\ninje\u00e7\u00f5es de UA, UA-NC e placebo em dose equivalente a 15 mg/ 10 g de peso do animal.\n\nAp\u00f3s uma semana de tratamento, foram realizadas coletas de sangue para an\u00e1lises\n\nhematol\u00f3gicas e os animais foram sacrificados. Tumores foram removidos, mensurados e\n\npesados e os \u00f3rg\u00e3os (f\u00edgado, rins e ba\u00e7o) foram dissecados e submetidos a estudos\n\n\n\n16\n\nhistopatol\u00f3gicos. A inibi\u00e7\u00e3o tumoral foi determinada a partir do peso m\u00e9dio da massa tumoral\n\ndos grupos de animais tratados em  rela\u00e7\u00e3o ao grupo controle (n\u00e3o tratado). O \u00e1cido \u00fasnico\n\napresentou limitada solubilidade em \u00f3leo de girassol, podendo ser encapsulado numa\n\nconcentra\u00e7\u00e3o m\u00e1xima de 1 mg/ml. A formula\u00e7\u00e3o manteve um aspecto inicial macrosc\u00f3pico\n\nleitoso com reflexo azul opalescente durante 120 dias quando mantida a temperatura de 4\u00b0 C\n\n\u00b1 1\u00b0C. As  formula\u00e7\u00f5es liofilizadas de UA-NC  permaneceram est\u00e1veis por um per\u00edodo\n\nsuperior a 36 meses mantendo um aspecto inicial similar. A an\u00e1lise por microscopia de\n\nvarredura demonstrou part\u00edculas bem dispersas, esf\u00e9ricas e homog\u00eaneas, com di\u00e2metro m\u00e9dio\n\nde 367 \u00b1  81 nm. UA-NC em suspens\u00e3o ap\u00f3s prepara\u00e7\u00e3o apresentaram um conte\u00fado de \u00e1cido\n\n\u00fasnico de 101,7 \u00b1 1,7 % e uma taxa de encapsula\u00e7\u00e3o de 99,4 \u00b1 0,16%. O perfil cin\u00e9tico de\n\nlibera\u00e7\u00e3o revelou que as UA-NC  podem ser utilizadas como sistema de libera\u00e7\u00e3o controlada.\n\nAs concentra\u00e7\u00f5es requeridas para inibir 50% do crescimento celular, IC50, foram de\n\naproximadamente 10 e 11,5 \u00b5g/ml para o \u00e1cido \u00fasnico livre e encapsulado, respectivamente.\n\nCitoplasma irregular, com intensas \u00e1reas de vacuoliza\u00e7\u00e3o contendo material bas\u00f3filo foram\n\nevidenciados nas c\u00e9lulas quando submetidas a tratamento com \u00e1cido \u00fasnico (5\u00b5g/ml). Esta\n\ncultura quando tratada com \u00e1cido \u00fasnico encapsulado demonstrou uma monocamada quase\n\nsemelhante ao controle. A encapsula\u00e7\u00e3o do UA em nanoc\u00e1psulas de PLGA promoveu uma\n\ninibi\u00e7\u00e3o tumoral de 68% quando comparado ao tratamento com o \u00e1cido \u00fasnico livre. An\u00e1lises\n\nhistopatol\u00f3gicas dos tumores tratados revelaram intensas \u00e1reas de necroses. A\u00e7\u00f5es t\u00f3xicas\n\nrepresentadas ao n\u00edvel de hepat\u00f3citos foram evidenciadas no tratamento com UA livre. Estas\n\nles\u00f5es foram significativamente reduzidas quando os animais foram tratados com \u00e1cido \u00fasnico\n\nnanoencapsulado. Nenhuma altera\u00e7\u00e3o histopatol\u00f3gica foi evidenciada nos rins e ba\u00e7o dos\n\nanimais tratados. Em conclus\u00e3o, a encapsula\u00e7\u00e3o do \u00e1cido \u00fasnico em nanoc\u00e1psulas de PLGA\n\npode ser uma alternativa promissora a ser explorada para a terapia do c\u00e2ncer.\n\n\n\n17\n\nABSTRACT\n\nThe usnic acid (UA) is a low-molecular weight dibenzofuran derivative [2,6-Diacetyl-7,9-\n\ndihydroxy-8,9b-dimethyl-1,3[2H,9bH]-dibenzo-furandione] produced by some lichen genera\n\nsuch as Alectoria, Cladonia, Usnea, Lecanora, Ramalina and Evernia. The UA has\n\nextensively been studied mainly because it presents substantial antimitotic activity. Its\n\nantibacterial and antimycotic properties, as well as activity against human neoplasic cell lines\n\nare well known. However, applications of UA in anticancer therapy have been rather limited\n\ndue to its high in vivo toxicity. Alternative nanoparticulated carriers have been developed\n\naiming to decrease toxic effects of anticancer compounds towards normal tissues and to\n\nincrease their efficiency against tumors.  A several limitation to usnic acid practical use is its\n\nlow solubility in water and some organic solvents. Alternative nanoparticulated carriers have\n\nbeen developed aiming to decrease toxic effects of anticancer compounds towards normal\n\ntissues and to increase their efficiency against tumors. The objective of this work was the\n\npreparation of the encapsulated UA into nanocapsules using the biodegradable artificial\n\npolymer derived from glycolic and lactic acids (PLGA) and to investigate the citotoxicity and\n\nthe antitumoral activity of UA-NC in comparison with free usnic acid. PLGA-nanocapsules\n\ncontaining usnic acid (UA-NC) was prepared by interfacial deposition of preformed polymer\n\nmethod. The physicochemical analyses were performed immediately after nanocapsules\n\npreparation. Morphological and structure of the UA-NC was studied using a scanning electron\n\nmicroscope (SEM). Cytotoxicity of free and encapsulated usnic acid was analysed on NCI-H\n\n292 cells. The cytotoxic effects of UA were evaluated by the MTT colorimetric method after\n\n72 hours of cell incubation. Cell morphological abnormalities were observed by microscopy\n\nusing the Giemsa technique. Antitumoral activity was verified against solid tumour sarcom-\n\n180 in Swiss mice, and it was estimated by the tumour inhibition. UA presents a limited\n\nsolubility in sunflower oil and can be encapsulated into nanocapsules at maximum\n\nconcentration of 1 mg/ml. The formulation maintained an initial similar macroscopic milky\n\naspect with bluish opalescence reflect over 120 days for storage at 4 \u00b0C \u00b1 1 \u00b0C. The stability\n\nof PLGA-nanocapsules suspension stored at 25 \u00b0C \u00b1 1 \u00b0C was maintained for 15 days. The\n\nlyophilised UA-NC formulation was stable for 36 months maintained an initial similar\n\nmacroscopic aspect. It could be seen that UA-NC had a spherical form and well-dispersed\n\nparticles with a mean diameter of 367 \u00b1 81nm. Stable UA-NC suspension presented after\n\npreparation a content of 101.7 \u00b1 1.7 % of UA and an encapsulation rate of 99.4 \u00b1 0.16 %. The\n\nin vitro kinetic profile revealed that UA-NC could be used as a controlled release system.\n\n\n\n18\n\nConcentrations required to inhibit 50% of cell growth were 10 and 11.5 \u00b5g/ml, for free UA\n\nand UA-NC, respectively. The cells treated with encapsulated UA formed a monolayer almost\n\nsimilar to that of the control. However, a cytoplasm vacuolization and a condensed\n\nappearance of mitotic cells were identified. The encapsulation of UA into PLGA-\n\nnanocapsules promoted a 68% increase of tumour inhibition as compared with free UA\n\ntreatment. Vacuolisation of hepatocytes and a mild lymphocyte infiltration in portal spaces\n\nwere observed in animals treated with free UA. However, no histological changes were\n\nnoticed in the kidneys of treated animals. These results suggest the encapsulation can be a\n\npotential alternative to allow the use of UA in cancer therapy.\n\n\n\n19\n\nINTRODU\u00c7\u00c3O\n\n\n\n20\n\n1.1 C\u00e2ncer\n\n1.1.1 Generalidades\n\nO c\u00e2ncer origina-se de uma s\u00e9rie de modifica\u00e7\u00f5es nos diferentes tecidos dos organismos\n\nvivos, que se caracterizam pela exist\u00eancia de um crescimento causado por multiplica\u00e7\u00e3o\n\ncelular descontrolada. As neoplasias resultam de prolifera\u00e7\u00f5es anormais de c\u00e9lulas que\n\ntendem a perder sua diferencia\u00e7\u00e3o, e apresentam crescimento aut\u00f4nomo. As c\u00e9lulas\n\nneopl\u00e1sicas apresentam diferentes graus de comportamento, diferem das c\u00e9lulas normais em\n\nv\u00e1rios aspectos, tais como: crescimento acelerado; altera\u00e7\u00f5es morfol\u00f3gicas, metab\u00f3licas e\n\nantig\u00eanicas; e irregularidades citoplasm\u00e1ticas (Franks &amp; Teich, 1997; Gomes &amp; Milanez,\n\n1997; Brasileiro-Filho, 1998).\n\nDevido \u00e0 import\u00e2ncia epidemiol\u00f3gica dos processos neopl\u00e1sicos, in\u00fameras  abordagens\n\nterap\u00eauticas v\u00eam sendo desenvolvidas. As categorias b\u00e1sicas para o tratamento s\u00e3o: cirurgia,\n\nradioterapia e quimioterapia. Esta \u00faltima apresenta desfavor\u00e1vel aspecto devido a\n\ninespecificidade do f\u00e1rmaco, e a dificuldade em se estabelecer uma dose efetiva para destruir\n\num m\u00e1ximo de c\u00e9lulas com um m\u00ednimo de efeitos colaterais para as c\u00e9lulas normais\n\n(Needham &amp; Dewhirst, 2001).\n\nO aumento mundial do n\u00famero de casos de c\u00e2ncer tem provocado uma corrida dos\n\npesquisadores na busca de solu\u00e7\u00f5es para cura e/ou controle desta patologia. Apesar da\n\nexist\u00eancia de in\u00fameros produtos farmac\u00eauticos, naturais ou sint\u00e9ticos, utilizados no\n\ntratamento das neoplasias, as particularidades biol\u00f3gicas inerentes a cada tipo de tumor,\n\njuntamente com a resist\u00eancia aos quimioter\u00e1picos que as c\u00e9lulas tumorais podem desenvolver,\n\nimpulsionam a pesquisa de novos produtos com a\u00e7\u00e3o antineopl\u00e1sica (Gomes &amp; Milanez,\n\n1997).\n\n\n\n21\n\nAo longo do tempo, a busca por novos quimioter\u00e1picos com menor toxicidade e maior\n\nefic\u00e1cia contra o c\u00e2ncer tem sido o alvo primordial das pesquisas de libera\u00e7\u00e3o controlada de\n\ndrogas. O desenvolvimento de carreadores poder\u00e1 proporcionar n\u00e3o somente o aumento da\n\nquantidade da droga no s\u00edtio de a\u00e7\u00e3o desejada; como tamb\u00e9m permitir uma redu\u00e7\u00e3o da\n\nquantidade de princ\u00edpio ativo liberado para outras partes do corpo, reduzindo, portanto, os\n\nefeitos t\u00f3xicos (Needham &amp; Dewhirst, 2001).\n\n1.1.2 Cancerologia experimental\n\nUma droga ideal para o combate ao c\u00e2ncer seria aquela que fosse t\u00f3xica para c\u00e9lulas\n\ncancerosas, mas pouco prejudicial \u00e0s c\u00e9lulas normais. Na realidade, a grande maioria das\n\ndrogas antineopl\u00e1sicas \u00e9 bastante lesiva para o organismo que a recebe, da\u00ed a validade dos\n\nensaios de citotoxidade como triagem preliminar (F\u00e1varo et al., 1990).\n\nA realiza\u00e7\u00e3o de testes in vitro e in vivo, para detectar a atividade antitumoral de novas\n\nsubst\u00e2ncias, \u00e9 de vital import\u00e2ncia para descoberta de novos quimioter\u00e1picos. Testes in vivo\n\naplicados \u00e0 cancerologia experimental t\u00eam sido os mais recomend\u00e1veis, apesar de serem\n\ndispendiosos, com respostas n\u00e3o muito r\u00e1pidas. Os ensaios in vitro eliminam estes problemas,\n\nmas exigem confirma\u00e7\u00e3o in vivo. N\u00e3o obstante, a necessidade da resposta in vivo, os testes in\n\nvitro auxiliam a triagem de subst\u00e2ncias naturais com potencial a\u00e7\u00e3o antineopl\u00e1sica. Estes\n\nensaios permitem a an\u00e1lise de um grande n\u00famero de amostras, viabilizando a localiza\u00e7\u00e3o dos\n\nprinc\u00edpios ativos em determinadas fra\u00e7\u00f5es obtidas durante o processo de extra\u00e7\u00e3o de produtos\n\nde origem natural (F\u00e1varo et al., 1990; Rodrigues, 2001)\n\nA cultura de c\u00e9lulas tem sido utilizada com freq\u00fc\u00eancia na pesquisa de produtos naturais,\n\nsemi-sint\u00e9ticos e de s\u00edntese, permitindo a an\u00e1lise imediata do impacto destes compostos sobre\n\na c\u00e9lula, fornecendo respostas r\u00e1pidas, importantes na sele\u00e7\u00e3o destes novos f\u00e1rmacos\n\nantineopl\u00e1sicos (Bellamy, 1992; Carvalho, 1996). Diversas linhagens celulares utilizadas nas\n\n\n\n22\n\npesquisas biol\u00f3gicas multiplicam-se facilmente, apresentando grande n\u00famero de c\u00e9lulas\n\nuniformes. A linhagem NCI-H292 foi derivada da met\u00e1stase de n\u00f3dulos linf\u00e1ticos de\n\ncarcinoma mucoepiderm\u00f3ide pulmonar. Estas c\u00e9lulas foram isoladas em um meio definido\n\nquimicamente (HITES), com posteriores adapta\u00e7\u00f5es para crescimento em meio suplementado\n\ncom soro. O sistema celular mant\u00e9m suas caracter\u00edsticas em cultura, determinada pela sua\n\nultraestrutura e express\u00e3o de m\u00faltiplos marcadores de diferencia\u00e7\u00e3o escamosa. Novos\n\nregistros afirmam que esta linhagem originou-se de fragmentos sub-gen\u00f4micos transfectados\n\nno interior de c\u00e9lulas humanas em estudos do papel do HBV, e seus genes individuais na\n\npatog\u00eanese do c\u00e2ncer de f\u00edgado e hepatite viral (Morier et al., 1996).\n\nOutros sistemas tamb\u00e9m empregados na pesquisa do c\u00e2ncer s\u00e3o tumores espont\u00e2neos,\n\ninduzidos por carcinog\u00eanicos e/ ou por v\u00edrus prim\u00e1rios. A utiliza\u00e7\u00e3o destes modelos\n\nexperimentais tem apresentado fundamental import\u00e2ncia na descoberta de novos f\u00e1rmacos\n\nantineopl\u00e1sicos, bem como no aperfei\u00e7oamento dos m\u00e9todos de preven\u00e7\u00e3o, diagn\u00f3stico e\n\ntratamento de doen\u00e7as em medicina humana (Goldin et al., 1979; Giuliani et al., 1979; F\u00e1varo\n\net al., 1990).\n\nUm dos primeiros tumores experimentais  a ser transplantado foi descoberto em 1914\n\ncomo uma massa s\u00f3lida na axila direita de um camundongo albino. Inicialmente foi chamado\n\nde tumor de Crocker e classificado como carcinoma mam\u00e1rio. Ap\u00f3s v\u00e1rias transplanta\u00e7\u00f5es\n\nsubcut\u00e2neas tornou-se um sarcoma, passando a ser denominado sarcoma-180 (S-180), devido\n\na suas caracter\u00edsticas morfol\u00f3gicas e de comportamento evolutivo. O tumor S-180 \u00e9 s\u00f3lido,\n\ncresce rapidamente, atingindo o tamanho de aproximadamente 18\u00d714\u00d710 mm, em 7 dias, e\n\napresenta poucas \u00e1reas necr\u00f3ticas ou hemorr\u00e1gicas. Ocasionalmente pode ocorrer met\u00e1stase\n\npara os pulm\u00f5es quando o camundongo portador sobrevive por 4 ou mais semanas (Young &amp;\n\nHallowea, 1973; Goldin et al., 1979; Sousa, 2000).\n\n\n\n23\n\n1.2 - Liquens\n\nLiquens s\u00e3o seres formados pela associa\u00e7\u00e3o de um fungo (micobionte) com uma ou\n\nmais algas (fotobionte), onde o fungo \u00e9 exohabitante. Apresentam larga distribui\u00e7\u00e3o\n\ngeogr\u00e1fica dos tr\u00f3picos aos p\u00f3los, habitando sobre rochas, solos e troncos de \u00e1rvores (Hale,\n\n1983; Nash, 1996; Muller, 2001).\n\nA morfologia do talo liqu\u00eanico \u00e9 bastante peculiar, onde o micobionte e o ficobionte se\n\ndisp\u00f5em em camadas sucessivas. No talo destaca-se o c\u00f3rtex superior, composto de hifas\n\nentrela\u00e7adas, que serve de prote\u00e7\u00e3o para camada das algas. Centralmente encontra-se uma\n\ncamada de hifas frouxas, a medula, seguida de outro feixe de hifas, o c\u00f3rtex inferior. O fungo\n\ngeralmente \u00e9 respons\u00e1vel n\u00e3o s\u00f3 pela forma, como tamb\u00e9m pela estrutura do l\u00edquen,\n\ncontribuindo as hifas  para a maior parte da sua massa. Cortes transversais de certas esp\u00e9cies\n\nde liquens, observados ao microsc\u00f3pio \u00f3ptico (Figura 1), demonstram as algas distribu\u00eddas ,\n\nmais ou menos homogeneamente, em todo o talo, enquanto as hifas se aglomeram junto \u00e0s\n\nsuperf\u00edcies, superior e inferior da mesma  (Hale, 1983; Nash, 1996).\n\nA associa\u00e7\u00e3o simbi\u00f3tica dos liquens envolve uma estreita integra\u00e7\u00e3o fisiol\u00f3gica, onde o\n\nfungo liqu\u00eanico r\u00e9tem \u00e1gua protegendo o fotobionte contra desseca\u00e7\u00e3o, e os \u00e1cidos liqu\u00eanicos\n\npigmentados aumentam a opacidade do c\u00f3rtex superior, reduzindo a incid\u00eancia de luz na\n\ncamada de alga, servindo como filtro seletivo, permitindo o fotobionte se desenvolver em\n\nambientes de alta luminosidade. Em contrapartida, as algas fornecem vitaminas, nitrog\u00eanio\n\n(simbiose com cianobact\u00e9ria) e subst\u00e2ncias org\u00e2nicas necess\u00e1rias ao desenvolvimento do\n\nmicobionte (Hale, 1983; Nash, 1996).\n\n\n\n24\n\nFigura 1. Modelo esquem\u00e1tico da anatomia de um talo liqu\u00eanico (Nash, 1996): A= Algas; B=\n\nMedula; C= C\u00f3rtex.\n\nA parede celular do fotobionte \u00e9 bastante perme\u00e1vel, quando comparada a das algas n\u00e3o\n\nliquenizadas, o que facilita a transfer\u00eancia de carboidratos para o fungo (Vicente, 1975;\n\nAlexopoulos &amp; Mins, 1979; Hale, 1983; Nash, 1996). Pesquisas t\u00eam demonstrado que os\n\nliquens s\u00e3o capazes de degradar substratos rochosos. Estes efeitos podem ser atribu\u00eddos aos\n\nprocessos qu\u00edmico e f\u00edsico, particularmente \u00e0 excre\u00e7\u00e3o de v\u00e1rios \u00e1cidos org\u00e2nicos tais como o\n\nox\u00e1lico, os quais podem efetivamente reagir com minerais e c\u00e1tions met\u00e1licos quelantes. Este\n\norganismo tamb\u00e9m pode ser utilizado em monitoramento de polui\u00e7\u00e3o do ar, e a bioindica\u00e7\u00e3o\n\nde pureza atmosf\u00e9rica \u00e9 postulada com base nas esp\u00e9cies de liquens presentes (Muller, 2001).\n\n1.2.1 Subst\u00e2ncias liqu\u00eanicas\n\nOs liquens produzem metab\u00f3litos intracelulares e extracelulares, classificados de acordo\n\ncom sua localiza\u00e7\u00e3o no talo. Os produtos intracelulares s\u00e3o carboidratos, caroten\u00f3ides,\n\nvitaminas, amino\u00e1cidos e prote\u00ednas. S\u00e3o freq\u00fcentemente sol\u00faveis em \u00e1gua, podendo ser\n\nextra\u00eddos com \u00e1gua quente. Estes compostos s\u00e3o sintetizados pelas c\u00e9lulas das hifas, sendo\n\nposteriormente utilizados como mecanismo de defesa frente a infec\u00e7\u00f5es externas. Os\n\nmetab\u00f3litos extracelulares s\u00e3o compostos resultantes de seu metabolismo secund\u00e1rio,\n\nclassificados em quatro grupos qu\u00edmicos bioenergeticamente relacionados: deps\u00eddeos,\n\ndepsidonas, dibenzofuranos e \u00e1cidos \u00fasnicos (Culberson, 1972; Nash, 1996). A concentra\u00e7\u00e3o\n\n\n\n25\n\ndestes compostos pode variar de 0.1 a 5% em rela\u00e7\u00e3o ao peso seco do talo liqu\u00eanico, e em\n\nalguns casos mais do que isto. Estes produtos extracelulares s\u00e3o os respons\u00e1veis pela maioria\n\ndos benef\u00edcios advindos dos liquens (Nash, 1996; Muller, 2001).\n\nMais de 630 metab\u00f3litos secund\u00e1rios de liquens s\u00e3o conhecidos. A maioria \u00e9\n\nproduzida unicamente pelos liquens e uma pequena minoria, em torno de 50 a 60, \u00e9 produzida\n\npor fungos de vida livre e plantas superiores. Os deps\u00eddeos, depsidonas, dibenzofuranos,\n\n\u00e1cidos \u00fasnicos e a depsona s\u00e3o derivados fen\u00f3licos encontrados exclusivamente em liquens. O\n\n\u00e1cido \u00fasnico \u00e9 considerado um dos mais importantes metab\u00f3litos liqu\u00eanicos biologicamente\n\nativos, podendo representar mais de 5% do talo seco do liquen (Mitchel et al., 1965; Muller,\n\n2001).\n\n1.2.2 \u00c1cido \u00fasnico\n\nO \u00e1cido \u00fasnico [2,6-diacetil-7,9-dihidroxi-8,9b-dimetil-1,3(2h,9bH)- dibenzeno-\n\nfuradione; C18H16O7], ocorre na natureza em duas formas enantiom\u00e9ricas (+) e (-), as quais\n\ndependem da proje\u00e7\u00e3o do grupo metil angular localizado na posi\u00e7\u00e3o  do carbono quiral 9b\n\n(Figura 2). \u00c9 um constituinte bastante abundante em diversos g\u00eaneros de liquens,\n\nfilogeneticamente distintos, tais como Usnea, Cladonia, Cetraria, Ramalina e Parmelia\n\n(Venkataramana &amp; Krishna, 1992; Muller, 2001; Cochietto et al., 2002; Ing\u00f3lfsd\u00f3ttir, 2002).\n\nIn vivo, o \u00e1cido \u00fasnico \u00e9 provavelmente produzido pelos liquens visando sua defesa. A\n\npresen\u00e7a de agentes poluentes parece estimular sua bios\u00edntese, como indicador de\n\nbiomonitoramento ambiental. Sua concentra\u00e7\u00e3o no talo liqu\u00eanico parece estar relacionada\n\ncom a quantidade integral dos agentes t\u00f3xicos arom\u00e1ticos (Cardarelli et al., 1997; Muller,\n\n2001).\n\n\n\n26\n\nFigura 2. Estrutura qu\u00edmica do \u00e1cido \u00fasnico: a) (+)-(9b-R) e (-)-(9b-S)  b) \u00e1cido\n\niso\u00fasnico (+)-(9b-R) e (-)-(9b-S) (Ing\u00f3lfsd\u00f3ttir, 2002).\n\nO \u00e1cido \u00fasnico apresenta car\u00e1ter hidrof\u00f3bico, sendo insol\u00favel em \u00e1gua e glicerol, e\n\nparcialmente sol\u00favel em etanol e facilmente dilu\u00eddo em \u00e9ter quente, acetona, benzeno e\n\nclorof\u00f3rmio. O ponto de fus\u00e3o dos seus cristais \u00e9 em torno de 203 \u00b0C; seu car\u00e1ter hidrof\u00f3bico\n\n\u00e9 devido \u00e0 presen\u00e7a dos quatro quatros grupos cet\u00f4nicos e do anel furano que liga os dois\n\nan\u00e9is arom\u00e1ticos existentes em sua estrutura. Seus cristais, de colora\u00e7\u00e3o amarela variam de\n\nforma de acordo com o solvente utilizado na sua recristaliza\u00e7\u00e3o (Asahina &amp; Shibata, 1954;\n\nIng\u00f3lfsd\u00f3ttir, 2002).\n\nA bios\u00edntese do \u00e1cido \u00fasnico procede pela da via acetato polimalonato. Inicialmente s\u00e3o\n\nformadas unidades fen\u00f3licas monoc\u00edclicas, originadas a partir de \u00e1cidos carbox\u00edlicos,\n\nderivados do \u00e1cido ac\u00e9tico. Estas unidades fen\u00f3licas s\u00e3o sintetizadas a partir da acetil-CoA e\n\nmalonil-CoA, atrav\u00e9s de sitetases arom\u00e1ticas, que n\u00e3o possuem subunidades desidrogenadas.\n\nOs passos subseq\u00fcentementes de bioss\u00edntese do \u00e1cido \u00fasnico envolvem o acoplamento\n\nestereoespec\u00edfico de duas unidades metilfloroacetona, originando portanto o \u00e1cido \u00fasnico\n\nhidratado e finalmente ocorre a desidrata\u00e7\u00e3o da mol\u00e9cula levando a forma\u00e7\u00e3o da liga\u00e7\u00e3o \u00e9ter\n\n(Taguchi et al., 1969; Ing\u00f3lfsd\u00f3ttir, 2002) (Figura 3).\n\nba\n\n\n\n27\n\nFigura 3. Vias da bios\u00edntese do \u00e1cido \u00fasnico (Ing\u00f3lfsd\u00f3ttir, 2002).\n\n\n\n28\n\n1.2.2.1 Propriedades biol\u00f3gicas do \u00e1cido \u00fasnico\n\n1.2.2.1.1 A\u00e7\u00e3o antibi\u00f3tica\n\nDas classes de compostos de baixo peso molecular, derivados de liquens, o \u00e1cido \u00fasnico\n\ntem sido o mais extensivamente estudado. Nas d\u00e9cadas de 40 e 50 dos diversos compostos\n\nliqu\u00eanicos reportados como ativos contra diversas linhagens de bacilos da tuberculose e\n\norganismos Gram-positivos, o \u00e1cido \u00fasnico destacou-se como sendo o mais potente agente\n\nantibi\u00f3tico antibacteriano, frente a v\u00e1rios microrganismos comuns, desempenhando portanto,\n\nmenor a\u00e7\u00e3o quando comparado \u00e0s drogas padr\u00e3o: rifampicina e estreptomicina (Ing\u00f3lfsd\u00f3ttir\n\net al., 1998; Muller, 2001). \u00c9 bem difundida a propriedade antibi\u00f3tica do \u00e1cido \u00fasnico frente a\n\nbact\u00e9rias Gram-positivas. Trabalhos realizados por Lauterwein et al. (1995) indicam que os\n\n\u00e1cidos \u00fasnico e vulp\u00ednico s\u00e3o ativos contra algumas esp\u00e9cies de bact\u00e9rias Gram-positivas e\n\nfungos, por\u00e9m n\u00e3o apresentam efeitos contra as Gram-negativas. Estes resultados est\u00e3o de\n\nacordo como os reportados por Hale (1983), que relata a inefici\u00eancia do \u00e1cido \u00fasnico e\n\nprotoliquester\u00ednico contra bact\u00e9rias Gram-negativas, como Escherichia, Salmonella e\n\nShighella.\n\nEstudando a atividade antimicrobiana de cinco derivados de \u00e1cido \u00fasnico, Ing\u00f3lfsdottir\n\net al. (1997) relataram que o \u00e1cido \u00fasnico foi o mais ativo contra Mycobacterium aureum,\n\nmesmo com a concentra\u00e7\u00e3o inibit\u00f3ria m\u00ednima (MIC) demonstrada pelo composto sendo\n\nconsideravelmente mais alta do que da drogas refer\u00eancia, tais como estreptomicina,\n\nrifampicina e isoniazida. Em alguns casos antecedentes, ensaios da atividade contra M.\n\ntuberculosis var. homini e var. bovis, apresentaram uma MIC mais satisfat\u00f3ria. Estes\n\nresultados est\u00e3o de acordo com Ventakataramana &amp; Krishna (1992), os quais reportaram que\n\nambas formas do \u00e1cido usnico d (+) e l (-) inibiram in vitro, o crescimento de M. turberculosis\n\ne M. tufu (modelo de M. leprae)  com uma concentra\u00e7\u00e3o relativamente baixa.\n\nCorrech\u00e9 et al. (1998) verificaram que modifica\u00e7\u00f5es qu\u00edmicas nas pontes de hiodrog\u00eanio\n\n\n\n29\n\ndo \u00e1cido \u00fasnico n\u00e3o provocaram mudan\u00e7as nas propriedades antimicrobianas deste composto\n\ncontra Stphylococcus aureus.\n\n1.2.2.1.2 A\u00e7\u00e3o citot\u00f3xica e antitumoral\n\nEstudos preliminares da atividade antitumoral do \u00e1cido \u00fasnico sobre o carcinoma de\n\npulm\u00e3o de Lewis em camundongos, evidenciaram que a sobrevida dos animais aumentou\n\nentre 35-52 % sobre o grupo controle n\u00e3o tratado. Estes achados levaram \u00e0 realiza\u00e7\u00e3o da\n\ns\u00edntese de novos derivados de \u00e1cido \u00fasnico com maior afinidade sobre o sistema Lewis.\n\nTestes citot\u00f3xicos destes novos derivados frente \u00e0 linhagem L1210 revelaram que, dentre os\n\nan\u00e1logos estudados, os de natureza hidrof\u00edlica demonstraram menor citotoxidade. Em ensaios\n\nposteriores com estes derivados, contra o tumor de Lewis, evidenciou-se uma significativa\n\nperda da atividade antitumoral, em decorr\u00eancia da baixa solubilidade em \u00e1gua destes\n\nderivados (Takai et al., 1979).\n\nCardarelli et al. (1997) tamb\u00e9m demonstraram que a propriedade do \u00e1cido \u00fasnico sobre\n\na prolifera\u00e7\u00e3o de c\u00e9lulas da linhagem HE-50 e K562 foi dose e tempo dependente.\n\nConforme Soderberg (1953) e Virtanen &amp; Karki (1956), a dose letal do \u00e1cido \u00fasnico em\n\ndiferentes animais foram: camundongos, intraperitoneal (ip): 25 mg/kg; subcut\u00e2nea (sc): 70\n\nmg/kg; ratos, intravenosas (iv): 30 mg/kg; coelhos, iv: 30 mg/kg; cachorros, iv: 40 mg/kg. No\n\nestudo de toxicidade cr\u00f4nica deste composto em coelhos, evidenciou-se que quando foi\n\nadministrada uma solu\u00e7\u00e3o aquosa a 1 % durante 79 dias, a urina excretada do animal\n\napresentou um pH de 3,2 - 9,0 com atividade antibacteriana, quando alcalina. Os animais\n\napresentaram perdas de apetite, dificuldades respirat\u00f3rias e c\u00e2imbras estomacais. Ensaios\n\nrealizados em porcos, utilizando esta mesma dose, durante 119 dias, evidenciaram que a\n\nurina do animal n\u00e3o apresentou atividade antibacteriana. Os animais permaneceram\n\nsaud\u00e1veis. Testes de toxicidade realizados em gatos revelaram que administrando,\n\n\n\n30\n\nintravenosamente, uma solu\u00e7\u00e3o de usnato de s\u00f3dio a 10mg/kg, alterou o metabolismo do\n\nanimal, provocando hiperventila\u00e7\u00e3o, aumento do consumo de oxig\u00eanio e  varia\u00e7\u00e3o da\n\ntemperatura corporal.\n\nDados concernentes \u00e0 toxicidade do \u00e1cido \u00fasnico em humanos s\u00e3o escassos na\n\nliteratura. Foram reportados apenas efeitos adversos tais como: irrita\u00e7\u00e3o local e dermatite de\n\ncontato al\u00e9rgica. Testes realizados em humanos revelaram que, administrando 0.1-1 g /dia de\n\nsolu\u00e7\u00e3o de usnato de s\u00f3dio n\u00e3o provocaram efeitos t\u00f3xicos. Aumentando-se a dose para 3\n\ng/dia, observou-se que os pacientes apresentaram dores no f\u00edgado (Ing\u00f3lfsd\u00f3ttir, 2002).\n\nCorrech\u00e9 et al. (1998) demonstraram que modifica\u00e7\u00f5es estruturais na mol\u00e9cula de \u00e1cido\n\n\u00fasnico n\u00e3o provocaram altera\u00e7\u00f5es na sua atividade antimicrobiana. Contudo, produziram um\n\naumento na citotoxidade, inibindo completamente o crescimento de linf\u00f3citos de f\u00edgado em\n\ncultura.\n\nUma potente a\u00e7\u00e3o antiproliferativa do \u00e1cido \u00fasnico sobre linhagem celular de\n\nqueratin\u00f3citos humano HaCaT, modelo favor\u00e1vel de elevada prolifera\u00e7\u00e3o na epiderme,\n\ntamb\u00e9m foi relatada por Muller &amp; Kumar (1999). A n\u00e3o altera\u00e7\u00e3o da atividade da lactato\n\ndesidrogenase no meio de cultura foi um leve sinal de danifica\u00e7\u00e3o na membrana, indicando,\n\nportanto que o efeito fora de natureza citost\u00e1tica e n\u00e3o citot\u00f3xica.\n\nLodetti et al., 2000, estudaram mudan\u00e7as in vitro em culturas prim\u00e1rias e cont\u00ednuas de\n\nc\u00e9lulas KB (carcinoma nasofar\u00edngeo), queratin\u00f3citos gengivais e fibroblastos de biopsia\n\nhumana. Este ensaio visava avaliar a a\u00e7\u00e3o citot\u00f3xica do \u00e1cido \u00fasnico sozinho, ou como um\n\ncomponente de formula\u00e7\u00e3o oral contra c\u00e1rie. Resultados demonstraram que o composto,\n\nsozinho ou como parte da formula\u00e7\u00e3o, n\u00e3o apresentou sinais de citotoxicidade, quando\n\ndeterminados pelos m\u00e9todos de MTT [brometo(3-[4,5-dimetiltiazol-2-il]-2,5-\n\ndifeniltetraz\u00f3lio) e vermelho neutro.\n\n\n\n31\n\nA farmacocin\u00e9tica do \u00e1cido \u00fasnico foi estudada por Venkataramana &amp; Krishna, (1992)\n\nem coelhos ap\u00f3s administra\u00e7\u00e3o intravenosa e oral. A medida dos n\u00edveis de \u00e1cido \u00fasnico no\n\nplasma indicou que a cada tratamento, oral ou intravenoso, os n\u00edveis de concentra\u00e7\u00f5es de\n\n\u00e1cido \u00fasnico foram acima do conhecido para inibir o crescimento in vitro de Micobacterium\n\ntuberculosis.\n\n1.2.2.1.3 A\u00e7\u00e3o antiviral\n\nUma s\u00e9rie de testes realizados sobre diversos sistemas biol\u00f3gicos tais como: fungos\n\nfilamentosos, leveduras, c\u00e9lulas de plantas, e culturas de c\u00e9lulas neopl\u00e1sicas humanas,\n\navaliaram, de forma geral, as propriedades do \u00e1cido \u00fasnico sobre organismos\n\nfilogeneticamente distintos. Os resultados demonstraram que as propriedades terap\u00eauticas do\n\n\u00e1cido \u00fasnico (antibacteriana, antimic\u00f3tica e antimit\u00f3tica) conhecidas desde longo tempo e\n\nexploradas na pr\u00e1tica cl\u00ednica, parecem estar relacionadas com sua a\u00e7\u00e3o protetora sobre os\n\nagentes t\u00f3xicos presentes na atmosfera. Dessa forma, o aumento da sua concentra\u00e7\u00e3o \u00e9\n\nproporcional \u00e0 quantidade dos poluentes presentes. Nestes estudos, interessantes analogias\n\ntamb\u00e9m foram efetuadas concernentes \u00e0 a\u00e7\u00e3o antimit\u00f3tica do \u00e1cido \u00fasnico sobre cultura\n\ncelular: o efeito exercido \u00e9 influenciado pela capacidade da subst\u00e2ncia em penetrar na c\u00e9lula\n\n(Cardarelli et al., 1997).\n\nPesquisas sobre novos agentes t\u00edpicos antipsor\u00edase, com a\u00e7\u00e3o antiproliferativa em\n\nqueratin\u00f3citos HaCaT da epiderme, demonstraram que os \u00e1cidos girof\u00f3rico e \u00fasnico\n\napresentam uma IC50 de 2,1 \u00b5M e 2,6 \u00b5M, respectivamente. No estudo da atividade da\n\nlibera\u00e7\u00e3o do LDH (Lipoprote\u00edna de Alta Densidade) dentro do meio de cultura, evidenciou-se\n\nque o \u00e1cido \u00fasnico demonstrou um leve aumento na atividade de LDH, quando comparado \u00e0\n\nves\u00edcula controle. Assim sendo, a atividade destes metab\u00f3litos liqu\u00eanicos \u00e9 devida ao efeito\n\ncitost\u00e1tico e n\u00e3o citot\u00f3xico, e as libera\u00e7\u00f5es de LDH n\u00e3o foram modificadas, quando\n\n\n\n32\n\ncomparado ao f\u00e1rmaco controle (antralin), at\u00e9 a concentra\u00e7\u00e3o de 2 \u00b5M. Este achado pode\n\nestar relacionado \u00e0 habilidade do \u00e1cido \u00fasnico de gerar radicais hidroxilas, considerando que\n\no outro composto testado n\u00e3o apresentou esta propriedade (Muller &amp; Kumar,1999),\n\nEm ensaio de a\u00e7\u00e3o antiviral realizado com cinco compostos liqu\u00eanicos, o \u00e1cido \u00fasnico\n\napresentou-se como o mais ativo frente ao tumor produzido pela indu\u00e7\u00e3o do v\u00edrus Epstein-\n\nBarr (Yamamoto et al., 1995). Estudos posteriores realizados com prepara\u00e7\u00f5es org\u00e2nicas de\n\nUsnea long\u00edssima, contendo o \u00e1cido \u00fasnico em alto teor, apresentou uma significativa redu\u00e7\u00e3o\n\nda ativa\u00e7\u00e3o do referido tumor induzido pela teleocidina B-4 (Yamamoto et al. 1998).\n\nPacientes tratados com solu\u00e7\u00e3o de \u00e1cido \u00fasnico associado ao sulfato de zinco, como adjuvante\n\nterap\u00eautico no tratamento da infec\u00e7\u00e3o do Papilomav\u00edrus genital, apresentaram um aumento no\n\ntempo de reconstitui\u00e7\u00e3o do epit\u00e9lio, um m\u00eas ap\u00f3s a radio-cirurgia. A recupera\u00e7\u00e3o observada\n\nnos indiv\u00edduos tratada foi significante, mesmo seis meses ap\u00f3s a interven\u00e7\u00e3o cir\u00fargica (Scirpa\n\net al., 1999; Cocchietto et al., 2002).\n\nConcernente a poss\u00edvel a\u00e7\u00e3o do \u00e1cido \u00fasnico sobre a prolifera\u00e7\u00e3o antiviral, Campanella\n\net al. (2002) descreveram que o \u00e1cido \u00fasnico apresenta uma relevante inibi\u00e7\u00e3o sobre a\n\nreplica\u00e7\u00e3o do DNA viral. Este processo ocorre dentro da c\u00e9lula hospedeira e \u00e9 uma\n\nconseq\u00fc\u00eancia direta da dr\u00e1stica regress\u00e3o da transcri\u00e7\u00e3o do RNA. Vale ressaltar que esta a\u00e7\u00e3o\n\nocorre mesmo em concentra\u00e7\u00f5es n\u00e3o citot\u00f3xicas do \u00e1cido \u00fasnico. A prolongada perman\u00eancia\n\ndeste composto no meio de cultura torna-se indispens\u00e1vel para manter esta inibi\u00e7\u00e3o.\n\n1.2.2.1.4 A\u00e7\u00e3o antiinflamat\u00f3ria, antipir\u00e9tica e analg\u00e9sica.\n\nO \u00e1cido \u00fasnico isolado da Usnea diffracta desenvolveu a\u00e7\u00e3o antipir\u00e9tica e analg\u00e9sica,\n\natuando contra hipertemia induzida por lipopolissacarideos em camundongos. Neste estudo\n\nobservou-se que este composto atua induzido pelo \u00e1cido acetil salic\u00edlico, de forma dose\n\nindependente (Okuyama et al., 1995; Muller, 2001). Estudos posteriores das propriedades\n\n\n\n33\n\nanalg\u00e9sica e antipir\u00e9tica dos \u00e1cidos difractaico e \u00fasnico obtidos de Usnea diffracta\n\nconfirmaram esta relevante a\u00e7\u00e3o analg\u00e9sica induzida pelo \u00e1cido acetil salic\u00edlico (Yamamoto\n\net al., 1998).\n\nNo estudo de atividade antiinflamat\u00f3ria de (+) \u00e1cido \u00fasnico, isolado de Roccella\n\nmontagnei, em ratos, Vinjayakumar et al. (2000) evidenciaram uma significativa redu\u00e7\u00e3o da\n\natividade ap\u00f3s o tratamento cr\u00f4nico, sugerindo que este composto apresenta efeito\n\nantipir\u00e9tico e analg\u00e9sico dose-dependente. Conforme estes resultados o mecanismo de a\u00e7\u00e3o\n\npode envolver uma inibi\u00e7\u00e3o da s\u00edntese de prostaglandinas.\n\n1.2.2.2 Mecanismo de a\u00e7\u00e3o proposto para o \u00e1cido \u00fasnico\n\nAbo-Khatwa et al. (1996) relataram que os \u00e1cidos \u00fasnico e vulp\u00ednico e a atranorina\n\napresentaram a\u00e7\u00e3o como desacopladores da fosforila\u00e7\u00e3o oxidativa, quando testados em\n\nmitoc\u00f4ndrias de f\u00edgado de rato. Estes compostos atuaram no interior da membrana\n\nmitocondrial atrav\u00e9s de suas propriedades lipof\u00edlicas com caracter\u00edsticas semelhantes ao do\n\n2,4- dinitrofenol. Vavasseur et al. (1991) tamb\u00e9m evidenciaram o potencial inibit\u00f3rio do \u00e1cido\n\n\u00fasnico sobre processos respirat\u00f3rios aer\u00f3bicos em c\u00e9lulas vegetais de Cormmelina communis.\n\nJohnson et al. (1950) descreveram o relevante efeito inibit\u00f3rio do \u00e1cido \u00fasnico na respira\u00e7\u00e3o,\n\nem homogenatos de rim de rato, bem como o desacoplamento da fosforila\u00e7\u00e3o oxidativa em\n\nhomogenato de f\u00edgado de rato em concentra\u00e7\u00f5es  m\u00ednimas de 1,3 - 2,6 \u00b5g/ml.\n\nAdicionalmente, Vicente &amp; Xavier Filho (1983) reportaram que, em concentra\u00e7\u00f5es\n\nbaixas o \u00e1cido \u00fasnico pode inibir completamente a produ\u00e7\u00e3o de ATP na fosforila\u00e7\u00e3o\n\noxidativa. Desta forma, o microrganismo n\u00e3o consegue realizar seus diferentes processos\n\nanab\u00f3licos por falta de energia inibindo, portanto, seu crescimento. Nas concentra\u00e7\u00f5es\n\nsuperiores a 50 \u00b5M, h\u00e1 tamb\u00e9m diminui\u00e7\u00e3o do consumo de oxig\u00eanio inviabilizando os\n\n\n\n34\n\nprocessos oxidativos dos substratos org\u00e2nicos, causando d\u00e9ficit de energia qu\u00edmica, bem\n\ncomo os incapacitando de utilizar os compostos org\u00e2nicos do hospedeiro como fonte de\n\nalimento.\n\nUm outro mecanismo de a\u00e7\u00e3o proposto baseia-se no fato de que o \u00e1cido \u00fasnico\n\napresenta a\u00e7\u00e3o an\u00e1loga em sistemas biol\u00f3gicos filogeneticamente distantes. Os resultados\n\nobtidos por Cardarelli et al. (1997) sobre a a\u00e7\u00e3o deste \u00e1cido em in\u00fameros sistemas biol\u00f3gicos,\n\nsugerem que ele atue similarmente em c\u00e9lulas animais e vegetais, provavelmente interferindo\n\nem um passo importante da divis\u00e3o celular, comum a diferentes c\u00e9lulas.\n\nFinalmente, a redu\u00e7\u00e3o significante no teor de RNA em f\u00edgado de ratos tratados com 100\n\n- 200 mg/kg de \u00e1cido \u00fasnico reportada por Al-Bekairi et al. (1991) poderia ainda sugerir uma\n\na\u00e7\u00e3o deste \u00e1cido diretamente sobre a s\u00edntese prot\u00e9ica.\n\n1.3 Sistemas de Libera\u00e7\u00e3o controlada de f\u00e1rmacos\n\nA tecnologia de libera\u00e7\u00e3o controlada surgiu na d\u00e9cada de 80, como um m\u00e9todo\n\ncomercialmente atrativo para administra\u00e7\u00e3o de f\u00e1rmacos de forma controlada. A partir da\u00ed a\n\nlibera\u00e7\u00e3o pode ser manipulada para a produ\u00e7\u00e3o de sistemas de libera\u00e7\u00e3o r\u00e1pida, controlada ou\n\nprolongada da subst\u00e2ncia bioativa (Swarbrick, 1996).\n\nBasicamente a intensidade da resposta farmacol\u00f3gica \u00e9 diretamente proporcional \u00e0\n\nconcentra\u00e7\u00e3o do f\u00e1rmaco no s\u00edtio de a\u00e7\u00e3o desejado. Sua distribui\u00e7\u00e3o pelo organismo depende\n\nde suas propriedades f\u00edsico-qu\u00edmicas, que n\u00e3o necessariamente s\u00e3o compat\u00edveis com a \u00e1rea\n\nafetada. Assim sendo, grandes quantidades de f\u00e1rmacos geralmente administradas para obter-\n\nse o efeito famacol\u00f3gico desejado, tem por conseq\u00fc\u00eancia o aparecimento da toxicidade frente\n\na outros tecidos (Couvreur et al., 1995; Barratt, 2000).\n\nAtualmente o uso de carreadores polim\u00e9ricos na libera\u00e7\u00e3o de f\u00e1rmacos proporciona a\n\nafinidade espec\u00edfica do f\u00e1rmaco para o tecido alvo. Dois caminhos podem ser utilizados para\n\n\n\n35\n\nesta proposta: a modifica\u00e7\u00e3o qu\u00edmica da droga e/ou modifica\u00e7\u00e3o farmac\u00eautica. O primeiro\n\nrepresentado pelas chamadas prodrogas e a segunda referem ao uso de carreadores coloidais\n\nde f\u00e1rmacos (Jain , 2000; Nishioka &amp; Yoshino, 2001).\n\n1.3.1 Sistemas nanoparticulados\n\nSistemas nanopart\u00edculados s\u00e3o carreadores s\u00f3lidos submicr\u00f4nicos de natureza\n\npolim\u00e9rica com tamanho da ordem de nan\u00f4metros. Conforme o m\u00e9todo e composi\u00e7\u00e3o da\n\nformula\u00e7\u00e3o utilizados na prepara\u00e7\u00e3o destes sistemas, nanoesferas ou nanoc\u00e1psulas podem ser\n\nobtidas. As nanoesferas apresentam uma estrutura matricial, enquanto as nanoc\u00e1psulas\n\napresentam estrutura vesicular. Vale ressaltar que na literatura, em geral, o termo\n\nnanopart\u00edculas \u00e9 associado somente as nanoesferas. No entanto, em um conceito mais amplo,\n\nnanopart\u00edculas podem ser tanto nanoesferas como nanoc\u00e1psulas (Couvreur et al., 1995).\n\nA encapsula\u00e7\u00e3o \u00e9 uma op\u00e7\u00e3o atrativa de libera\u00e7\u00e3o controlada para uma variedade de\n\ndrogas. Por exemplo, ela pode limitar a toxidade sist\u00eamica, proteger a mol\u00e9cula de\n\ndegrada\u00e7\u00e3o no trato digestivo, prover uma libera\u00e7\u00e3o controlada, ou mascarar um gosto\n\nindesej\u00e1vel e preservar a atividade do princ\u00edpio ativo (Perachia et al., 1997 ; Barratt, 2000;\n\nWhelan, 2001).\n\nNumerosos estudos demonstram que a biodisponibilidade de um f\u00e1rmaco no organismo\n\npode ser modificada pelo uso de vetores medicamentosos e part\u00edculas polim\u00e9rico. Estes\n\ncarreadores coloidais proporcionam a libera\u00e7\u00e3o do f\u00e1rmaco no s\u00edtio de a\u00e7\u00e3o desejada (\u00f3rg\u00e3o,\n\ntecido ou c\u00e9lula), eliminando ou minimizando os efeitos colaterais, que normalmente\n\nacompanham a terap\u00eautica convencional. O decr\u00e9scimo do efeito t\u00f3xico de compostos\n\nbioativos, nos tecidos normais, e o aumento de sua efici\u00eancia  contra diversas enfermidades,\n\ntem sido obtido com sucesso atrav\u00e9s do uso destes vetores particulados nos tratamentos\n\n\n\n36\n\nquimioter\u00e1picos (Vauthier-Holtzscherer et al., 1991; Olivier et al., 1995; Gibaud et al.,\n\n1996).\n\nSobre um passado de cinco d\u00e9cadas, o desenvolvimento de nanopart\u00edculas\n\nbiodegrad\u00e1veis tem sido considerado relevante no estudo de libera\u00e7\u00e3o controlada de\n\nf\u00e1rmacos. Estas part\u00edculas polim\u00e9ricas oferecem muitas possibilidades de aplica\u00e7\u00f5es nas\n\n\u00e1reas de medicina veterin\u00e1ria e humana (Vauthier-Holtzscherer et al., 1991; Swarbrick, 1996;\n\nJain, 2000).\n\nV\u00e1rios m\u00e9todos s\u00e3o descritos na literatura para prepara\u00e7\u00e3o de nanopart\u00edculas\n\nbiodegrad\u00e1veis. Estes podem ser classificados em duas principais categorias: aqueles que\n\nrequerem uma rea\u00e7\u00e3o de polimeriza\u00e7\u00e3o, ou aqueles em que se utilizam diretamente\n\nmacromol\u00e9cula ou pol\u00edmero pr\u00e9-formado (Couvreur et al., 1995). Estes m\u00e9todos foram\n\ninicialmente desenvolvidos em qu\u00edmica de pol\u00edmeros e posteriormente adaptados para fins\n\nfarmac\u00eauticos (Vauthier-Holtzscherer, et al., 1991; Soppimath et al., 2001).\n\nA aplica\u00e7\u00e3o da metodologia destas nanopart\u00edculas depende de fatores como sele\u00e7\u00e3o de\n\nmaterial (biocompat\u00edvel e macromol\u00e9culas biodegrad\u00e1veis) e o tamanho de part\u00edcula a ser\n\npreparada (? 1\u00b5m). Estes carreadores geralmente apresentam tamanho entre 10 a 1000 nm. A\n\ndroga \u00e9 dissolvida, armazenada, encapsulada ou ligada na matriz biodegrad\u00e1vel e dependendo\n\ndo m\u00e9todo de prepara\u00e7\u00e3o, pode-se obter nanoc\u00e1psulas ou nanoesferas (Vauthier-Holtzscherer\n\net al., 1991; Jain, 2000; Soppimath et al., 2001).\n\n1.3.1.1 Nanoc\u00e1psulas\n\nAs nanoc\u00e1psulas s\u00e3o ves\u00edculas s\u00f3lidas que apresentam uma cavidade interna oca, ou de\n\nnatureza oleosa, estabilizada por um filme interfacial de agentes tensoativos e revestida\n\nsuperficialmente por uma parede polim\u00e9rica pouco espessa (Fessi et al., 1989; Soppimath et\n\nal., 2001).\n\n\n\n37\n\n O f\u00e1rmaco pode ser incorporado diretamente na cavidade oleosa interna, pode ser\n\nretido na parede polim\u00e9rica, ou adsorvido na superf\u00edcie das nanoc\u00e1psulas. A parede pode ser\n\nobtida pela polimeriza\u00e7\u00e3o interna de um ou mais mon\u00f4meros, ou por deposi\u00e7\u00e3o interfacial de\n\num pol\u00edmero pr\u00e9-formado, sendo respons\u00e1vel pela estabilidade da part\u00edcula em meio coloidal\n\ne controle da libera\u00e7\u00e3o do f\u00e1rmaco (Fessi et al,. 1989; Soppimath et al., 2001; Jain, 2000).\n\nFessi et al. (1989) propuseram um m\u00e9todo para prepara\u00e7\u00e3o de nanoc\u00e1psulas por\n\ndeposi\u00e7\u00e3o interfacial do pol\u00edmero pr\u00e9-formado. Esta t\u00e9cnica utiliza os \u00e1cidos acr\u00edlicos e\n\nmetacr\u00edlicos. A fase org\u00e2nica (acetona), contendo o princ\u00edpio ativo a encapsular, o pol\u00edmero,\n\no \u00f3leo assim como o tensoativo lipof\u00edlico, \u00e9 vertida sobre a fase aquosa contendo o tensoativo\n\nhidrof\u00edlico. A fabrica\u00e7\u00e3o das nanoc\u00e1psulas \u00e9 r\u00e1pida e permite a forma\u00e7\u00e3o de estruturas\n\nvesiculares de di\u00e2metro m\u00e9dio entre 100 e 500 nm, na forma de suspens\u00e3o coloidal est\u00e1vel,\n\napresentando elevadas taxas de encapsula\u00e7\u00e3o para f\u00e1rmacos de caracter\u00edstica lipof\u00edlicas.\n\n O princ\u00edpio da forma\u00e7\u00e3o de nanoc\u00e1psulas baseia-se na diminui\u00e7\u00e3o da solubilidade dos\n\nconstituintes da formula\u00e7\u00e3o, formadores do n\u00facleo oleoso e pol\u00edmero, relacionada \u00e0 difus\u00e3o\n\nde seu solvente na fase aquosa. Esta metodologia tamb\u00e9m \u00e9 empregada para obten\u00e7\u00e3o de\n\nnanoesferas e emuls\u00e3o submicr\u00f4mica. A supress\u00e3o da fase oleosa conduz \u00e0 forma\u00e7\u00e3o de\n\nnanoesferas, enquanto que a supress\u00e3o do pol\u00edmero, \u00e0 forma\u00e7\u00e3o de nanoemuls\u00f5es. Vale\n\nressaltar que na aus\u00eancia dos tensioativos, as nanoc\u00e1psulas ser\u00e3o formadas ap\u00f3s a mistura das\n\nduas fases, todavia n\u00e3o \u00e9 est\u00e1vel. O tensoativo hidrof\u00edlico promove a forma\u00e7\u00e3o de part\u00edculas\n\nmenores e mais homog\u00eaneas. O tensoativo lipof\u00edlico evita a sedimenta\u00e7\u00e3o das part\u00edculas e a\n\npassagem da subst\u00e2ncia ativa encapsulada para a fase externa da suspens\u00e3o (Fessi et al.,\n\n1989).\n\n\n\n38\n\n1.3.2 Nanotecnologia farmac\u00eautica e o tratamento do c\u00e2ncer\n\nO principal objetivo da nanotecnologia \u00e9 desenvolver um modelo de sistema carreador\n\nde compostos bioativos com adequada estabilidade, absor\u00e7\u00e3o, libera\u00e7\u00e3o controlada e\n\ntransfer\u00eancia quantitativa e espec\u00edfica da mol\u00e9cula do f\u00e1rmaco ao tecido doente (Santos-\n\nMagalh\u00e3es et al., 2000).\n\nA encapsula\u00e7\u00e3o de f\u00e1rmacos citot\u00f3xicos em carreadores endocit\u00e1veis pode auxiliar o\n\ndesenvolvimento da capta\u00e7\u00e3o espec\u00edfica para as c\u00e9lulas cancer\u00edgenas e reduzir, portanto, sua\n\ntoxicidade sobre as c\u00e9lulas sadias. Resultados preliminares  da quimioterapia experimental\n\ncom nanoc\u00e1psulas de polimetilcianocrilato, contendo Actiomicina D, frente ao tumor\n\nsarcoma em rato, demonstraram que o uso de carreadores potencializa a a\u00e7\u00e3o terap\u00eautica  da\n\ndroga, reduzindo significativamente o tamanho do tumor (Brasseur et al., 1980).\n\nResultados bastante promissores foram obtidos com f\u00e1rmacos antineopl\u00e1sicos\n\n(Dactonomicina D; Metotrexato e Vinblastina), quando encapsulados em nanopart\u00edculas de\n\npolialquilcianoacrilato (Couvreur et al., 1979; 1980). Nos ensaios antitumorais in vivo\n\nrealizados em ratos, foram observados que estes carreadores proporcionaram uma maior\n\nespecificidade em n\u00edvel de c\u00e9lulas cancerosas promovendo uma relevante redu\u00e7\u00e3o no\n\ntamanho do tumor, al\u00e9m da minimiza\u00e7\u00e3o dos efeitos t\u00f3xicos nas c\u00e9lulas, tecidos e \u00f3rg\u00e3os\n\nsadios.\n\nEm relatos sobre citotoxidade e atividade antitumoral da vincristina livre e encapsulada\n\nem lipossomas, Mayer et al. (1990), descreveram que no estudo de sobrevida dose resposta\n\ndeste f\u00e1rmaco encapsulado, foi evidenciada redu\u00e7\u00e3o de sinais de toxicidade nos animais. A\n\ndose letal m\u00e9dia de 1,9 mg/kg, observada para a vincristina livre, aumentou para 4,8 mg/kg\n\nap\u00f3s administra\u00e7\u00e3o da mesma na forma lipossomal. Evidenciou-se tamb\u00e9m relevante a\u00e7\u00e3o\n\nantitumoral deste f\u00e1rmaco encapsulado, em testes utilizando camundongos transplantados\n\ncom tumores de leucemia linfoc\u00edtica P388 e L1210.\n\n\n\n39\n\nHorowitz et al. (1992) relataram ensaios de citotoxidade in vitro utilizando c\u00e9lulas de\n\ncarcinoma ovariano (OV-1063), com doxorrubicina (DOX) livre e encapsulada em\n\nlipossomas (L-DOX) contendo fosfolip\u00eddios de alta temperatura de transi\u00e7\u00e3o de fase (Tm).\n\nNeste teste observou-se que a a\u00e7\u00e3o citot\u00f3xica de (L-DOX) apresentou-se substancialmente\n\nreduzida quando comparado \u00e0 droga livre. Em contraste, quando fosfolip\u00eddios de baixa\n\ntemperatura de transi\u00e7\u00e3o foram utilizados, n\u00e3o foi evidenciada redu\u00e7\u00e3o significativa. Os\n\nlip\u00eddeos carregados negativamente n\u00e3o tiveram influ\u00eancia significativa sobre esta a\u00e7\u00e3o\n\nestudada.\n\nEstudando a atividade antitumoral de microesferas de PLGA (copol\u00edmero de \u00e1cido-\n\nl\u00e1ctico-co-glic\u00f3lico) contendo Metotrexato (MTX) contra tumor sarcoma-180 em\n\ncamundongo, Singh &amp; Udupa (1997) evidenciaram um duplicado aumento no tempo de\n\nsobrevida do grupo de animais que receberam MTX encapsulado (18 \u00b1 2,7 dias), em rela\u00e7\u00e3o\n\na aqueles que receberam uma simples inje\u00e7\u00e3o subcut\u00e2nea de MTX livre (8 \u00b1 0,7 dias).\n\nEstudos farmacocin\u00e9ticos preliminares, utilizando administra\u00e7\u00e3o subcut\u00e2nea de MTX\n\nencapsulado, demonstraram uma libera\u00e7\u00e3o controlada da droga. Neste estudo foi apresentada\n\na facilidade da utiliza\u00e7\u00e3o de PLGA como um carreador eficaz para drogas antineopl\u00e1sicas\n\nsemelhantes ao MXT.\n\nAnalisando a influ\u00eancia da via de administra\u00e7\u00e3o e o efeito protetor de agentes\n\nantitumorais, mitoxantrona e DOX livres e encapsuladas em lipossomas, Ousorren et al.\n\n(1998) relataram que a velocidade de administra\u00e7\u00e3o \u00e9 um importante fator que influencia na\n\nles\u00e3o do tecido s\u00e3o. Atrav\u00e9s destes ensaios foram evidenciados que f\u00e1rmacos encapsulados\n\nprotegem os tecidos circunvizinhos dos efeitos t\u00f3xicos causados pela droga ap\u00f3s\n\nadministra\u00e7\u00e3o intramuscular. O efeito protetor destes carreadores sobre a toxicidade local da\n\nmitoxantrona tornou-se mais evidente ap\u00f3s administra\u00e7\u00e3o intramuscular do que a subcut\u00e2nea\n\nquando comparado \u00e0 administra\u00e7\u00e3o da  droga livre.\n\n\n\n40\n\nEstudando a atividade antitumoral in vitro e in vivo de nanopart\u00edculas contendo DOX\n\nconjugada quimicamente com PLGA (DOX-PLGA), Yoo et al. (2000) evidenciaram um\n\nsustentado perfil de libera\u00e7\u00e3o (30 dias) de DOX-PLGA encapsulada. Por outro lado, quando\n\nfoi administrado o f\u00e1rmaco livre n\u00e3o conjugado observou-se um r\u00e1pido perfil de libera\u00e7\u00e3o (5\n\ndias). Neste estudo tamb\u00e9m se observou um baixo valor de IC50 frente a linhagem celular\n\nHepG2, quando incubadas com nanopart\u00edculas contendo DOX-PLGA, em compara\u00e7\u00e3o \u00e0\n\ndroga livre. O ensaio de atividade antitumoral apresentou uma significativa redu\u00e7\u00e3o da massa\n\ntumoral, utilizando-se apenas uma simples inje\u00e7\u00e3o de DOX-PLGA, ao inv\u00e9s de di\u00e1rias\n\naplica\u00e7\u00f5es de DOX livre.\n\nMitra et al. (2001) reportaram a atividade antitumoral de DOX livre, complexada a\n\ndextrana (DOX-DXR), e DOX-DXR encapsulada em camundongos. Nestes estudos foram\n\nobtidas nanopart\u00edculas de hidrogel contendo DOX-DXR de 100 - 10nm de di\u00e2metro com\n\nfavor\u00e1vel efici\u00eancia terap\u00eautica. Estes carreadores proporcionaram um aumento na sobrevida\n\ndo animal em 50%, quando comparado aos grupos tratados com DOX-DXR, no mesmo\n\nper\u00edodo estudado.\n\nOligonucleot\u00eddeos antisense (ODN) s\u00e3o fragmentos de DNA com seq\u00fc\u00eancias de base\n\ncomplementares para mRNA alvo, capazes de modular seletivamente a express\u00e3o de genes\n\nindividuais. Estudos recentes demonstram que o desenvolvimento de nanoc\u00e1psulas de\n\npoliisobutilcianoclilato, com uma cavidade aquosa interna s\u00e3o capazes de encapsular\n\neficientemente grande quantidade de oligonucleot\u00eddeos antisense. Estes carreadores\n\nprotegeram os oligonucleot\u00eddeos de a\u00e7\u00e3o degradativa das prote\u00ednas do soro. Nestes ensaios\n\nantitumorais de ODN encapsulados em nanoc\u00e1psulas de poliisobutilcianoclilato tamb\u00e9m\n\nforam evidenciadas relevante inibi\u00e7\u00e3o frente ao sarcoma de Ewing em camundongos, ap\u00f3s\n\ninje\u00e7\u00e3o de uma dose acumulativa t\u00e3o baixa quanto 14,4 nMol. Este achado representa uma\n\n\n\n41\n\nnova e segura solu\u00e7\u00e3o para administra\u00e7\u00e3o da terapia de nucleot\u00eddeos antisense in vivo\n\n(Lambert et al., 2000).\n\n1.4. OBJETIVOS\n\n1.4.1Geral\n\nObter e caracterizar uma forma farmac\u00eautica de nova gera\u00e7\u00e3o: nanoc\u00e1psulas de PLGA\n\ncontendo \u00e1cido \u00fasnico (2,6-Diacetyl-7,9-dihydroxy-8,9b-dimethyl-dibenzofuran-\n\n1,3[2H,9bH]-dione) com potencial a\u00e7\u00e3o antineopl\u00e1sica.\n\n1.4.2 Espec\u00edficos\n\n\u2022 Obter e caracterizar, do ponto de vista f\u00edsico-qu\u00edmico, as nanoc\u00e1psulas de PLGA\n\ncontendo \u00e1cido \u00fasnico.\n\n\u2022 Estudar a cin\u00e9tica de libera\u00e7\u00e3o in vitro do \u00e1cido \u00fasnico, a partir de nanoc\u00e1psulas.\n\n\u2022 Determinar a citotoxidade in vitro de \u00e1cido \u00fasnico livre e encapsulado, em nanoc\u00e1psulas\n\nde PLGA.\n\n\u2022 Determinar a atividade antitumoral in vivo de \u00e1cido \u00fasnico livre e encapsulado em\n\nnanoc\u00e1psulas de PLGA frente ao tumor sarcoma-180.\n\n\u2022 Avaliar a histopatologia de tumores e \u00f3rg\u00e3os de animais tratados com \u00e1cido \u00fasnico livre e\n\nencapsulado.\n\n\u2022 Avaliar os \u00edndices hematim\u00e9ticos de amostras de sangue coletados dos animais tratados\n\ncom o \u00e1cido \u00fasnico livre e encapsulado.\n\n\n\n42\n\nCAP\u00cdTULO I\n\n\n\n43\n\nNANOC\u00c1PSULAS DE PLGA CONTENDO \u00c1CIDO \u00daSNICO:\nPREPARA\u00c7\u00c3O, CARACTERIZA\u00c7\u00c3O F\u00cdSICO-QU\u00cdMICA E PERFIL\n\nCIN\u00c9TICO DE LIBERA\u00c7\u00c3O IN VITRO.\n\nTrabalho submetido ao \u201cJournal of Nanobiotechnology\u201d\n\n\n\n44\n\nUsnic acid loaded-nanocapsules: preparation, physicochemical characterization and in\nvitro kinetic release\n\nNoemia Pereira dos Santos1,2, Eug\u00eania Cristina Gon\u00e7alves Pereira3, Nic\u00e1cio Henrique da\nSilva4, Nely Kika Honda5, Nereide Stela Santos-Magalh\u00e3es1,4\n\n*\n\n1 Universidade Federal de Pernambuco (UFPE), Laborat\u00f3rio de Imunopatologia Keizo Asami\n(LIKA), Av. Prof. Moraes Rego, 1235 Cidade Universit\u00e1ria, 50670-901, Recife-PE, Brasil.\n2 Doutorado em Ci\u00eancias Biol\u00f3gicas - UFPE, Recife-PE, Brasil.\n3 Departamento de Ci\u00eancias Geograficas- UFPE, Recife-PE, Brasil.\n4 Departamento de Bioqu\u00edmica - UFPE, Laborat\u00f3rio de Qu\u00edmica de Produtos Naturais, Recife-\nPE, Brasil.\n5Universidade Federal de Mato Grosso do Sul (UFMS), Departamento de Qu\u00edmica,\nLaborat\u00f3rio de Qu\u00edmica de Produtos Naturais Brasil, Mato Grosso do Sul- MS, Brasil.\n\nKey Words: Nanocapsules, PLGA, usnic acid, lichen, Cladonia substellata, in vitro kinetic\n\nrelease.\n\n*Corresponding author\n\nDr. Nereide Stela Santos Magalh\u00e3es\n\nUniversidade Federal de Pernambuco (UFPE)\n\nLaborat\u00f3rio de Imunopatologia Keizo-Asami (LIKA)\n\nAv. Prof. Moraes Rego, 1235, Cidade Universit\u00e1ria.\n\n50670-901, Recife-PE, Brasil\n\nTel: + 55\u2013081-3271 8587; fax: +55-081\u20133271 8485\n\nE-mail: nssm@ufpe.br\n\n\n\n45\n\nAbstract\n\nThe usnic acid is especially abundant in lichen genera such as Cladonia, Usnea, and\n\nRamalina. In addition to its antimicrobial activity against human and plant pathogens, the\n\nusnic acid has been shown to exhibit antiviral, antiproliferative, anti-inflammatory and\n\nantitumour activity. However, its low solubility in water and hepatotoxicity engender a severe\n\nlimitation to its usage. The nanoencapsulation allows the enhancement of drug stability by\n\nprotecting it from the environment and reducing adverse or toxic effects. The aim of this work\n\nis the developement of the nanocapsules containing usnic acid from Cladonia substellata. The\n\nstability and the in vitro kinetic profile of nanocapsulated usnic acid were also investigated.\n\nThe usnic acid was encapsulated into nanocapsules prepared with the copolymer of lactic and\n\nglycolic acid (PLGA 50/50) and sunflower oil as the oily core. Stable usnic acid loaded-\n\nnanocapsules presented as spherical shaped and well-dispersed particles with a mean diameter\n\nof 367\u00b181nm. The nanocapsule suspension maintained the initial milky macroscopic aspect\n\nwith bluish opalescence reflects over 120 days when stored at 4\u00b0C\u00b11\u00b0C. The usnic acid\n\ncontent after preparation was 101.7\u00b11.7% and an encapsulation ratio of 99.4\u00b10.16% was\n\nachieved at a maximum concentration of 1 mg/ml. The lyophilised nanocapsule formulation\n\nremained stabilized for 36 months and it is easily redispersible in water. The in vitro kinetic\n\nprofile revealed an usnic acid release of 78.3% from nanocapsules within 48h. In conclusion,\n\nusnic acid was, for the first time, efficiently encapsulated into nanocapsules providing an\n\nappropriated dosage form for applying usnic acid in \u201cin vivo\u201d studies.\n\n\n\n46\n\nBackground\n\nLichens, the quintessential symbiosis between a fungal (mycobiont) and algal and/or\n\ncyanobacterial (photobiont) partner, produce a variety of bioactive compounds. These\n\ncompounds typically arise from the secondary metabolism of the fungal partner, which are\n\ndeposited on the surface of the hyphae rather than compartmentalised in the cells [1]. Among\n\ntwenty thousand known species of lichens, only a few have been analysed and identified as\n\nproducers of biologically active secondary metabolites. A prime example is the usnic acid\n\n(UA), a low-molecular weight dibenzofuran derivative [2,6-Diacetyl-7,9-dihydroxy-8,9b-\n\ndimethyl-1,3[2H,9bH]-dibenzo-furandione] produced by certain lichen species. Usnic acid\n\noccurs as a yellowish cortical pigment. Two natural enantiomeric forms of usnic acid,\n\ndiffering in the orientation of the methyl group located in the stereogenic centre at the 9b\n\nposition, have been identified as showing various biological activities [2,3]. Usnic acid is\n\nwidely distributed in species of Cladonia, Usnea, Lecanora, Ramalina, Evernia and\n\nParmelia. Since its former isolation in 1844 the usnic acid has become the most extensively\n\nstudied lichen metabolite and one of the few that is commercially available [1-3].\n\nUsnic acid exhibits many biological and pharmacological properties such as antimicrobial\n\nactivity against human and plant pathogens, antiviral, antiprotozoal, antiproliferative, anti-\n\ninflammatory and analgesic activity. In addition it presents cytotocicity and antitumour\n\nactivity [3,4]. However, the practical use of usnic acid remains rather limited due to its low\n\nsolubility in water and some organic solvents. In particular, the intramolecular hydrogen\n\nbonds contribute to the lipophilic nature of usnic acid and its lipophilicity is relevant for the\n\ncytotoxic effect, which can be attributed to the ?-triketone moiety present in the molecule [2,\n\n4, 5].\n\n\n\n47\n\nPolymeric nanoparticles have become a valuable research area in the field of drug delivery\n\nsystems because they are able to release a broad assortment of drugs to different targets in the\n\nbody for sustained periods of time. Natural polymers have not been widely used for this\n\npurpose since they vary in purity, and often require cross-linking that could denature the\n\nembedded drug. Consequently, synthetic polymers have received extra attention in this area.\n\nThe most widespread polymers for manufacturing nanoparticles are the poly-?-caprolactone\n\n(PCL), the poly (lactic acid) (PLA), the poly(glycolic acid) (PGA) and their copolymers, poly\n\n(lactide-co-glycolide) (PLGA). Such polymers are known for their biocompatibility and\n\nresorbability through natural pathways [6,7]. Nanospheres and nanocapsules can be\n\nmanufactured with different methods involving a polymerisation of monomers, dispersion or\n\nan interfacial deposition of pre-formed polymers. The drug is dissolved, entrapped,\n\nencapsulated or attached to the polymeric matrix, depending on the preparation method.\n\nNanocapsules consist of an oily core incorporating a lipophilic drug and an outer coating layer\n\nformed by an appropriate polymer. Vegetable oils (e.g., sunflower and soybean oil) or some\n\nsemi-synthesized triglycerides with medium and long chain fatty acids are the first choice as\n\ncore vehicle [8-10].\n\nNumerous investigations in the last two decades have suggested the association of drugs with\n\npolymeric systems as a strategy to enhance the drug action. The drug stability can be\n\nimproved by protecting it towards the environment (storage conditions). The main interest of\n\nnanocolloidal vectors is to ameliorate the drug therapeutic index by targeting the active\n\nmolecule and by creating a high local drug concentration. As a consequence, the\n\nnanoencapsulation modifies the drug pharmacokinetic profile, increasing efficiency while\n\ndecreasing the amount of administered drug and the risks of side effects [8,11].\n\n\n\n48\n\nThe goal of this work is the development of PLGA nanocapsules containing usnic acid from\n\nCladonia substellata. Furthermore, accelerated and long-term stability testing of usnic acid\n\nloaded-nanocapsules as well as their in vitro kinetic release were evaluated.\n\nResults and discussion\n\nUsnic acid loaded-nanocapsules\n\nIn an attempt to optimise the amount of usnic acid incorporated in PLGA- nanocapsules (UA-\n\nNC), different experimental conditions for preparing these particles were evaluated. Pre-\n\nformulation studies were performed by varying the concentration of constituents with a view\n\nto improve stability of preparations (Table 1). Several UA-NC formulations were developed\n\nand evaluated according to their original physicochemical and long-term stability\n\ncharacteristics.\n\nIn the optimisation stage, the amount of usnic acid incorporated into the nanocapsules was\n\ngradually increased from 0.5 mg/ml to 5 mg/ml trying to get better drug encapsulation\n\nefficiency. A typical stable UA-NC formulation presented a 1:15 drug/polymer ratio and 1:1\n\ndrug/oil phase ratio (Table 1, NC10). Lipophilic and hydrophilic surfactants were maintained\n\nat the 1:1 ratio (150 mg). The usnic acid can be encapsulated into nanocapsules at a maximum\n\nconcentration of 1 mg/ml. All formulations with UA content above 1mg/ml exhibited\n\naggregates and crystal precipitation 48 h after preparation. The absence of aggregates or\n\nsediment at low usnic acid concentrations (?1mg/ml) attested that the drug was completely\n\ndissolved in sunflower oil.\n\nStability of usnic acid loaded-nanocapsules\n\nThe usnic acid loaded-nanocapsules were subjected to both accelerated (centrifugation,\n\nmechanical stress and freeze-thawing cycles) and long-term stability testing. It was remarked\n\n\n\n49\n\nthat a few preparations presented stability to the transport simulation test by mechanical\n\nagitation (Table 2). The nanocapsules (NC10) maintained the initial macroscopic aspect when\n\nsubmitted to the mechanical stress resistance testing. This formulation remained stabilised\n\nwithout noticed physicochemical changes after centrifugation and fewer than forty-five\n\nfreeze-thawing cycles.\n\nConcerning the long-term stability, the NC10 formulation stored at 4\u00b0C \u00b1 1\u00b0C kept the initial\n\nmacroscopic milky aspect with bluish opalescence reflects over 120 days (Table 3). A gradual\n\ndecrease in pH 7.4 values was observed from 7.40 \u00b1 0.03 to 6.98\u00b10.05 over 120 days (Figure\n\n2). Such a minor pH change, probably due to PLGA degradation, was not able to cause\n\ninstability of nanocapsules or usnic acid degradation. The stability of usnic acid loaded-\n\nnanocapsule suspension stored at 25\u00b0C\u00b11\u00b0C was maintained for 15 days. After this time, the\n\nformulation presented same instability signs such as creaming, oily exudates and darkness due\n\nto usnic acid oxidation.\n\nLyophilisation is often utilised to enhance the physicochemical stability of the nanoparticles\n\nin order to achieve a pharmaceutically acceptable product, especially under unfavourable\n\nstorage conditions [12]. The lyophilised usnic acid loaded-nanocapsule formulation was stable\n\nover 36 months maintaining its initial macroscopic aspect (storage at 4\u00b0C\u00b11\u00b0C) after\n\nredispersion.\n\nPhysicochemical characterization of usnic acid loaded-nanocapsules\n\nThe morphological aspect of the usnic acid loaded-nanocapsules is displayed in Figure 1. As\n\ndepicted, nanocapsules presented submicronic size, well-defined spherical shaped particles\n\nand a relative mono-dispersity of particle size distribution with a mean diameter of 367 \u00b1\n\n81nm.\n\n\n\n50\n\nStable nanocapsules suspension presented a content of 101.7 \u00b1 1.7% of usnic acid. Such a\n\nresult guarantees that usnic acid had its integrity preserved during the manufacture of the\n\ndosage form. However, a significant decrease in the usnic acid content from its initial value to\n\n37.4 \u00b1 1.7% was observed after 120 days when nanocapsules were stored at 4\u00baC \u00b1 1\u00baC (Figure\n\n3A). In contrast, the lyophilised usnic acid loaded-nanocapsules roughly maintained the usnic\n\nacid content (77.1 \u00b1 3.6) after 36 months of storage at 4\u00baC \u00b1 1\u00baC (Figure 3B).\n\nAs expected, a high encapsulation ratio (99.4 \u00b1 0.2%) was achieved since usnic acid is poorly\n\nsoluble in water (solubility &lt;0.1 mg/ml) having, therefore, a tendency to migrate to the oily\n\ncore. Nevertheless, a rather low amount of usnic acid was encapsulated due to its weak\n\nsolubility in both sunflower oil or/and PLGA. At higher usnic acid concentration, the\n\nencapsulation efficiency decreased to 75.5% \u00b1 0.5 and the presence of visible oil droplets was\n\ndetected in the nanocapsule formulation.\n\nResults herein corroborate those ones reported by Cauchetier et al., 2003 [13]. A maximum\n\nencapsulation ratio (100%) of atovaquone, another lipophilic drug, was attained for PLGA-\n\nnanocapsules at a concentration of 1 mg/ml using benzyl benzoate as oily phase. Using this\n\nsame oily phase, the encapsulation of indomethacin into PLA-nanocapsules was 90.0% at a\n\nconcentration of 1.25mg/ml [14]. On the contrary, a high concentration of penicillin G\n\nbenzathine (6 mg/ml) was encapsulated into PLGA-nanocapsules (99.8%) prepared with\n\nsunflower oil [15].\n\nBased on these findings, usnic acid loaded-nanocapsules (1mg/ml) was select for the in vitro\n\nand in vivo evaluation.\n\n\n\n51\n\nIn vitro kinetics release of usnic acid\n\nThe in vitro release profile of usnic acid from PLGA-nanocapsules is depicted in Figure 4. An\n\ninitial burst of 15.1 \u00b1 0.1% occurred at the first hour of the kinetic process. This effect can\n\nprobably be attributed to the prompt release of some usnic acid adsorbed at the polymeric\n\nsurface of nanocapsules. Slowly and gradually, the release reached 78.3 \u00b1 0.08 % of the initial\n\nloaded-usnic acid within 48 h. However, a slight degradation of usnic acid content in the\n\nrelease medium was observed after 96 h. Data reflect the ability of PLGA-nanocapsules to\n\ncontrol the drug release under the buffered phosphate solution at in vitro sink conditions.\n\nIt is well known that several factors have an effect on the release of entrapped drugs in carrier\n\nsystems. Particle size, solubility or affinity of the drug for the oily phase and the polymer, and\n\ndrug loading are common concerning parameters that control the kinetic profile of drugs.\n\nGenerally, larger particles have a smaller initial burst release and a longer sustained release\n\nthan smaller particles [7]. As previously reported [13-15], some lipophilic drugs presented\n\ndifferent profiles when encapsulated into nanocapsules. The Indometacin was fast released\n\nfrom PLA-nanocapsules (85%) within two hours [14]. Similarly, penicillin G benzathine were\n\ncompletely released from PLGA-nanocapsules within 2 hours [15]. In contrast, the release of\n\natovaquone from PLGA-nanocapsules was particularly slow achieving only 18.9% in three\n\nmonths [13]. Therefore, in vitro kinetics of nanoparticulated systems, especially in the case of\n\nnanocapsules, is still a challenge in the evaluation of the drug release. Literature reported\n\ncontroversial results, which are strongly dependent upon the dosage form and experimental\n\nconditions.\n\n\n\n52\n\nConclusions\n\nStable PLGA-nanocapsules containing usnic acid were obtained with a mean diameter of 367\n\n\u00b1 81 nm. The encapsulation efficiency of usnic acid was almost 100% with a usnic acid\n\namount of 1mg/ml. The lyophilisation process of the selected usnic acid loaded-nanocapsules\n\nimproved the stability to over 36 months of storage at 4\u00b0C \u00b1 1\u00b0C. The in vitro kinetic profile\n\nrevealed that PLGA-nanocapsules could be proposed as an alternative usnic acid delivery\n\nsystem. Further studies are currently being undertaken on the cytotoxicity and the antitumour\n\nactivity of usnic acid loaded-nanocapsules.\n\nMaterial and methods\n\n Materials\n\nPoly (D,L-lactic-acid-co-glycolic acid) polymer (PLGA) 50/50 was purchased from\n\nBirmingham Polymers (Alabama, USA); Soya phosphatidylcholine (Epikuron? 200), was\n\nobtained from Lucas Meyer (Germany); Poloxamer 188, (Pluronic? F68) was generously\n\nsupplied by ICI (France); soybean oil was obtained from Sigma Chemical (USA); monobasic\n\npotassium phosphate and sodium hydroxide were purchased from Merck (USA); HPLC grade\n\nmethanol, analytical grade solvents and reagents were obtained from Merck (Darmstadt,\n\nGermany). The cryoprotector threalose and standard usnic acid (UA) were obtained from\n\nSigma-Aldrich (St Louis, USA). Poloxamer (Pluronic? F68) was generously supplied by ICI\n\n(France). Usnic acid was extracted and purified from Cladonia substellata, at the Chemistry\n\nLaboratory of the Federal University of Mato Grosso do Sul (UFMS), Brazil.\n\nThe lichen material was collected on sandy soils of tabuleiro (Savannah like vegetation) of\n\nmamanguape country, Para\u00edba (Ne of Brazil) and identified through morphological and\n\nchemical thalus characterisation.\n\n\n\n53\n\nMethods\n\nFormulation of usnic acid loaded-nanocapsules\n\nPLGA-nanocapsules containing usnic acid (UA-NC) was prepared by the interfacial\n\ndeposition of a preformed polymer method [16]. The organic phase was initially prepared as\n\nfollows. The polymer, sunflower oil, usnic acid and the Soya phospholipid were each\n\nseparately dissolved in 24 ml of acetone. Acetonic phospholipid solution was obtained by\n\nincreasing temperature to 40\u00baC. After dissolution, organic solutions were mixed and\n\nmaintained at 40\u00baC under magnetic stirring at 150 rpm. The aqueous phase consisted of the\n\npoloxamer?188 dissolved in 50 ml of a phosphate buffered solution (pH 7.4) at 0.2 M. The\n\norganic solution was poured into the aqueous phase under magnetic stirring at 150 rpm. The\n\nacetone, which rapidly diffused towards the aqueous phase, was then removed under reduced\n\npressure at 40\u00baC. The colloidal suspension was concentrated to a 10 ml final volume by\n\nremoving water under similar conditions. Finally, the suspension of nanocapsules was\n\nlyophilised with 10% threalose as cryoprotector using a FTSS System (USA) operated at 200\n\nbar during 16 hours.\n\nFormulation parameters such as the nature and the volume of the organic and aqueous phase,\n\nthe nature and the concentration of surfactants and polymer play a relevant role on the particle\n\nsize distribution [17]. Thus, all these parameters were taken into account in the nanocapsules\n\nformulations (Table 1).\n\nStability assessment of usnic acid loaded-nanocapsules\n\nPhysicochemical analyses were performed immediately after nanocapsule preparation.\n\nSubsequently, they were submitted to both accelerated and long-term stability testing.\n\n\n\n54\n\nTherefore, macroscopic characteristics were evaluated; particle size and pH measurements\n\nwere also carried out.\n\nAccelerated stability tests aim to submit preparations to stress conditions in order to simulate\n\nprocesses such as sterilization, transport and storage. The usnic acid loaded-nanocapsules\n\nwere subjected to centrifugation (6.000 rpm for 1 h); mechanical stress (150 strokes/min at\n\n37\u00baC for 48 h) and freeze-thawing cycles (16 h at \u201318\u00baC and 8 h at 25\u00baC) [15].\n\nThe subsequent stage of stability evaluation was conducted by means of a long-term stability\n\ntest aiming to establish the formulation durability. In this stage, nanocapsule physicochemical\n\ncharacteristics were assessed at time intervals of 8, 15, 30, 60, 90, and 120 days or until the\n\nloss of stability. Parameters such as macroscopic aspect, pH variation and chemical assay of\n\nusnic acid content were analysed by high performance liquid chromatography (HPLC).\n\nPhysicochemical characterization of usnic acid loaded-nanocapsules\n\nFormulations were visually observed in order to verify their homogeneity and possible change\n\nin appearance. Colour, viscosity, material deposition, aggregate formation, creaming,\n\nflocculation or eventually phase separation, were evaluated. Morphology of usnic acid loaded-\n\nnanocapsules was evaluated by scanning electron microscopy (SEM) according to a modified\n\npreviously reported technique [18]. A concentrated nanocapsule suspension was dispersed in\n\ndistilled water to obtain a homogeneous suspension and placed in a glass surface, which was\n\nfixed on a metallic support module with carbon-glue. After drying at 37\u00b0C, samples were\n\ndirectly coated with colloidal gold using a sputter module in a high-vacuum evaporator (JFC-\n\n1100, JOEL, Japan). The usnic acid loaded-nanocapsules were then examined and the particle\n\nsize was evaluated.\n\nThe pH evolution was monitored by a digital pH-meter with a glass electrode. The equipment\n\nwas previously calibrated with buffer solutions at pH 4.0, 7.0 and 10.0. A sample aliquot of\n\n\n\n55\n\nnanocapsules was placed in a beaker, then the electrode was directly introduced into the\n\nsample for pH reading.\n\nThe determination of usnic acid content was carried out by HPLC according to a modified\n\nisocratic method [19]. The chromatographic run was performed using a Hewllet-Packard (HP)\n\nChem Station equipped with a UV detector operating at 280nm. A \u00b5Bondapak column (C18\n\n3.9 \u00d7 300 mm 125\u00b0A, Waters) was used with a mobile phase of methanol/phosphate buffered\n\nsolution pH 7.4 (70:30) at a flow-rate of 1.5 ml/mim. The calibration curve was prepared with\n\nsolutions of standard usnic acid (Merck) ranging in concentrations from 2 to 20 \u00b5g/ml. The\n\nextraction of usnic acid from nanocapsules was performed with acetonitrile (1:1) under\n\nultrasonic agitation for 5 mim. Then, a solution was prepared with mobile phase to a\n\ntheoretical concentration of 4 \u00b5g/m, filtered and 20 \u00b5l of this solution were injected into the\n\nHPLC system.\n\nThe encapsulation ratio of usnic acid into nanocapsules was determined after ultrafiltration by\n\ncentrifugation at 25.155 g for 1h using ultrafree? units (Millipore, USA) [20]. The\n\nconcentration of usnic acid in the supernatant was determined by HPLC and the encapsulation\n\nratio was calculated in relation to the total content of acid usnic into nanocapsule suspension.\n\nIn vitro kinetic release profile of usnic acid from nanocapsules\n\nThe in vitro release profile of usnic acid from the nanocapsules was determined by using a sac\n\ndialysis method [14]. An aliquot of 2 ml of usnic acid loaded-nanocapsules was placed into\n\ndialysis bag (cellulose membrane, cut-off =15-20 \u00c5, Merck), which was subsequently sealed\n\nand introduced into 200 ml of a receptor medium (phosphate buffered solution, pH 7.4). The\n\nsystem was thermostated at 37\u00b0C \u00b1 2\u00baC and maintained under magnetic stirring at 180 rpm.\n\n\n\n56\n\nAn aliquot of 2 ml samples of the receptor medium were undertaken at predetermined time\n\nintervals and assessed for usnic acid concentration by HPLC as previously described.\n\nAuthor\u2019s Contributions\n\nNPS, a PhD student, carried out the experiments and participated on data discussion. ECGP,\n\nNHS and NKH are concerned with the extraction, purification and characterization of usnic\n\nacid from Cladonia substellata. NSSM, the thesis director, participated in the design of the\n\nstudy, performed data analysis and discussion, and drafted the manuscript. All authors read\n\nand approved the final manuscript.\n\nAcknowledgements\n\nThe first author is also grateful for the partial financial support from the Brazilian Ministry of\n\nEducation (CAPES). The authors ECP and NSSM also thanks the Brazilian Council for the\n\nDevelopment of Technological and Scientific Research (CNPq) for individual grants.\n\n\n\n57\n\nReferences\n\n1. K Ing\u00f3lfsd\u00f3ttir: Molecules of Interest Usnic acid. Phytochem 2002, 61: 729-736\n\n2. K Muller: Pharmaceutically relevant metabolites from lichens. Appl Microbiol\n\nBiotechnol 2001, 56: 9-16\n\n3. M Cocchietto, N Skert, PL Nimis: A review on usnic acid, an interesting natural\n\ncompound. N. Naturwissenschaften 2002, 89: 137-149\n\n4. L Campanella, M Delfini, P Ercole, A Iacoangeli, G Risuleo: Molecular\n\ncharacterization and action of usnic acid: a drug that inhibits proliferations of mouse\n\npolyomavirus in vitro and whose main target is RNA transcription. Biochimie 2002,\n\n84: 329-334\n\n5. E Erba, D Pocar, LM Rossi: New esters of R- (+)- usnic acid. II farmaco 1998, 53: 718-\n\n720\n\n6. RA Jain: The manufacture techniques of various drug loaded biodegradable poly\n\n(lactide-co-glycolide) (PLGA) devices. Biomaterials 2000, 21: 2475-2490\n\n7. ML Hans, AM Lowman: Biodegradable nanoparticles for drug delivery and targeting.\n\nCur Opin Solid State Mat Sci 2002, 1: 212-218\n\n8. MF Zambaux, F Bonneaux, R Gref, P Maincent, E Dellacherie, MJ Alonso, P Lubrude,\n\nC Vigneron: Influence of experimental parameters on the characteristics of poly (lactid\n\nacid) nanoparticles prepared by a double emulsion method. J Control Rel 1998, 50:\n\n31-40\n\n9. KS Soppimath, TM Aminabhavi, AR Kulkarmi, WEJ Rudzinski, Biodegradable\n\npolymeric nanoparticles as drug delivery devices.  J Control Rel 2001, 70: 1-20\n\n10. Y Nishioka, H Yosshino: Lymphatic targeting with nanoparticulate system. Adv Drug\n\nDel Rev 2001, 47: 55-64\n\n\n\n58\n\n11. S Guinebreti\u00e9re, S Brianon, H Fessi, VS Teodorescu, MG Blanchin: Nanocapsules of\n\nbiodegradable polymers: preparation and characterization by direct high-resolution\n\nelectron microscopy. Mat Sc Engineering 2002, C21: 137-142\n\n12. B Magenheim, S Benita: Nanoparticles characterization: a comprehensive\n\nphysicochemical approach.  STP Pharm  Sci 1991, 1(4): 221-241\n\n13. E Cauchetier, M Deniau, H Fessi, A Astier, M Paul: Atovaquone-loaded nanocasules:\n\ninfluence of the nature of the polymer on their in vitro characteristics. Int J Pharm\n\n2003, 250: 273-281\n\n14. N Ammoury, H Fessi, JP Devissaguet, F Puisieux, S Benita: In vitro release kinetic\n\npattern of indomethacin from Poly (D,L-Lactide) nanocapsules. J Phar Sci 1990, 79\n\n(9): 763-767\n\n15. NS Santos-Magalh\u00e3es, A Pontes, VMW Pereira, MNP Caetano: Colloidal carriers for\n\nbenzantine penicillin G: Nanoemulsions and nanocapsules. Int J Pharm 2000, 208: 71-\n\n80\n\n16. H Fessi, F Puisieux, J Devissaguet, NE Ammoury, S Benita: Nanocapsules formation\n\nby interfacial polymer deposition following solvent displacement. Int J Pharm 1989,\n\n55: P1-R4\n\n17. MC Jullienne, MJ Alonso, AJL Gomes, JP Benoit: Preparation of poly (d,l-\n\nlactide/glicolide) nanoparticles of controlled particles size distribution. Application of\n\nexperimental designs. Drug Dev Ind Pharm 1992, 18: 1063-1077\n\n18. ZBJ Lu, S Wang: A method for the preparation of polymeric nanocapsules without\n\nstabilizer. J Control Rel 1999, 61: 107-112\n\n19. D Venkataramana, DR Krishna: High-performance liquid chromatographic\n\ndetermination of usnic acid in plasma. J  Chromatogr 1992, 575: 167-170\n\n\n\n59\n\n20. SS Guterres, H Fessi, G Barrat, F Puisieux, JP Devissaguet: Poly (D,L-Lactide)\n\nnanocapsules containing non-steroidal anti-inflamatory drugs: gastrointestinal\n\ntolerance following intravenous and oral administration. Pharm Res 1995, 12(10): 1-3\n\n\n\n60\n\nFigure Legends\n\nFigure 1. Scanning electron micrograph of PLGA-nanocapsules containing usnic\n\nacid (NC10) immediately after preparation (3,500 \u00d7).\n\nFigure 2. The pH evolution of the usnic acid-loaded nanocapsule suspension stored\n\nat 4\u00baC \u00b1 1\u00baC (NC10).\n\nFigure 3. Evolution of usnic acid content into PLGA-nanocapules stored at 4\u00baC \u00b1 1\u00baC\n\n(NC10): A) Suspension dosage form; B) Lyophilised dosage form.\n\nFigure 4. The in vitro kinetic release profile of usnic acid from PLGA-nanocapsules\n\n(NC10).\n\n1\u00b5m\n\n\n\n61\n\nFigures\n\nFigure 1\n\n1\u00b5m\n______\n\n\n\n62\n\n0 20 40 60 80 100 120\n6.0\n\n6.2\n\n6.4\n\n6.6\n\n6.8\n\n7.0\n\n7.2\n\n7.4\np\n\nH\n\nTime (days)\n\n Figure 2\n\n\n\n63\n\n0 20 40 60 80 100 120\n0\n\n20\n\n40\n\n60\n\n80\n\n100\nU\n\ns\nn\n\nic\n a\n\nc\nid\n\n c\no\n\nn\nte\n\nn\nt \n\n(%\n)\n\nTime ( days)\n\nA\n\nFigure 3\n\n\n\n64\n\n0 8 16 24 32\n0\n\n20\n\n40\n\n60\n\n80\n\n100\nU\n\ns\nn\n\nic\n a\n\nc\nid\n\n c\no\n\nn\nte\n\nn\nt \n\n(%\n)\n\nTime (months)\n\nB\n\nFigure 3\n\n\n\n65\n\n0 20 40 60 80 100\n10\n20\n30\n40\n50\n60\n70\n80\n90\n\n100\nU\n\ns\nn\n\nic\n a\n\nc\nid\n\n r\ne\nle\n\na\ns\ne\nd\n\n (\n%\n\n)\n\nTime (hours)\n\n Figure 4\n\n\n\n65\n\nTables\n\nTable 1: Optimisation of usnic acid loaded-nanocapsule formulations (10 ml final volume).\n\nFORMULATIONS\nNC1 NC2 NC3 NC4 NC5 NC6 NC7 NC8 NC9 NC10\n\nOrganic Phase\nPLGA (mg) 250 200 160 150 150 170 150 120 150 150\nEpikuron?? 200 (mg) 250 180 150 150 170 150 170 150 150 150\nAcetone (ml) 28 28 28 28 28 24 24 28 24 28\nSunflower oil (mg) 250 160 160 150 150 150 120 120 100 110\nUsnic acid (mg) 50 20 15 10 10 10 20 10 10 10\nAqueous phase\n\nPH 7.4 phosphate buffer (ml) 50 50 50 50 50 50 50 50 50 50\nPoloxamer (mg) 250 180 150 150 170 150 170 150 150 150\n\n\n\n66\n\nTable 2: Accelerated stability testing of PLGA-nanocapsules containing usnic acid.\n\nUSNIC ACID LOADED-NANOCAPSULESACCELERATED STABILITY\n\nTESTING NC1 NC2 NC3 NC4,\n\nNC5\n\nNC6, NC7 NC8, NC9 NC10\n\nMechanical stress\n\n(150 strokes/min\n\nat 37\u00baC for 48 h)\n\nInstable Instable Instable Stable Instable Stable Stable\n\nCentrifugation\n\n(6,000 rpm for 1 h)\n\nAggregates\n\nUA ppt\n\nCreaming\n\nUA ppt\n\nCreaming Creaming Creaming Redispersible\n\nCreaming\n\nStable\n\nFreeze-thawing cycles\n\n(16 h at -18\u00baC and 8 h at 25\u00baC) 1 6 10 15 18 25 45\n\n*UA ppt= precipitated usnic acid\n\n\n\n67\n\nTable 3. Physicochemical characterisation of PLGA-nanocapsules containing usnic acid (NC10).\n\nPHYSICOCHEMICAL ASSAYS                                                                    NANOCAPSULE\n                                                                                                               CHARACTERISTICS\n\nMacroscopic aspect Yellow pale milky suspension\nwith bluish opalescent reflect\n\nMicroscopic aspect (SEM) Spherical shaped and\nhomogenous particles\n\nMean diameter of particles (nm) 367 \u00b1 81\nUsnic acid Content (%) 101.7 \u00b1 1.70\nEncapsulation rate (%) 99.5 \u00b1 0.16\nACCELERATED STABILITY TESTING\nCentrifugation (6,000 rpm for 1 h) Stable\nFreeze-thawing cycles\n(16 h at -18\u00baC and 8 h at 25\u00baC)\n\nStable at 45th cycles\n\nMechanical stress\n (150 strokes/min at 37\u00baC for 48 h)\n\nStable\n\n\n\n104\n\nCAP\u00cdTULO II\n\n\n\n105\n\nATIVIDADE CITOT\u00d3XICA DE NANOC\u00c1PSULAS DE PLGA\nCONTENDO \u00c1CIDO \u00daSNICO SOBRE C\u00c9LULAS NCI-H292\n\nTrabalho a ser submetido ao \u201cToxicology in Vitro\u201d\n\n\n\n106\n\nATIVIDADE CITOT\u00d3XICA DE NANOC\u00c1PSULAS DE PLGA CONTENDO \u00c1CIPDO\n\n\u00daSNICO SOBRE C\u00c9LULAS, LINHAGEN NCI-H292\n\nNoemia Pereira dos Santos 1,2, Eug\u00eania Cristina Gon\u00e7alves Pereira3, Nic\u00e1cio Henrique da\n\nSilva4, Nely Kika Honda5 , Jos\u00e9 Figueredo Silva1, Silene Carneiro Nascimento6, Nereide Stela\n\nSantos-Magalh\u00e3es1*\n\n1 Universidade Federal de Pernambuco (UFPE), Laborat\u00f3rio de Imunopatologia Keizo Asami (LIKA),\n\nAv. Prof. Moraes Rego, 1235 Cidade Universit\u00e1ria, Recife- PE, Brasil\n2Doutorado em Ci\u00eancias Biol\u00f3gicas, UFPE, Recife - PE, Brasil\n3 Departamento de Geografia -UFPE, Recife - PE, Brasil\n4 Departamento de Bioqu\u00edmica \u2013UFPE, Laborat\u00f3rio de Qu\u00edmica de Produtos Naturais, Recife - PE,\n\nBrasil\n5 Universidade Federal de Mato Grosso do Sul (UFMS), Departamento de Qu\u00edmica,  Laborat\u00f3rio de\n\nQu\u00edmica de Produtos Naturais, Mato Grosso do Sul \u2013MGS, Brasil\n6 Departamento de Antibi\u00f3ticos -UFPE, Setor de Farmacologia e Cancerologia Experimental, Recife -\n\nPE, Brasil\n\nKey Words: Usnic acid nanocapsules, PLGA, lichen, citotoxicity.\n\n* Corresponding author\nDr. Nereide Stela Santos Magalh\u00e3es\nUniversidade Federal de Pernambuco\nGrupo de Sistemas de Libera\u00e7\u00e3o Controlada de Medicamentos\nLaborat\u00f3rio de Imunopatologia Keiso Asami (LIKA)\nAv. Prof. Moraes Rego, 1235, Cidade Universit\u00e1ria.\n50670-901, Recife-PE, Brasil\nTel: + 55 - 081- 3271 8587; fax: +55 - 081- 3271 8485\nE-mail: nssm@ufpe.br\n\n\n\n107\n\nAbstract\n\nThe usnic acid, a low-molecular-weigh lichen constituent, has extensively been studied\n\nmainly because of its substantial antimitotic activity. Its antibacterial and antimycotic\n\nproperties, as well as its activity against human neoplasic cell lines are well-known. However,\n\napplications of usnic acid in anticancer therapy have been rather limited due to its high in vivo\n\ntoxicity. Alternative nanoparticulated carriers have been developed aiming to decrease toxic\n\neffects of anticancer compounds towards normal tissues and to increase their efficiency\n\nagainst tumors. The aim of this work was investigate the citotoxicity of encapsulated usnic\n\nacid into PLGA-nanocapsules in comparison with free usnic acid. PLGA-nanocapsules\n\ncontaining usnic acid was prepared by interfacial deposition of preformed polymer method.\n\nCytotoxicity of free and encapsulated usnic acid was analysed on NCI-H 292 cells. The\n\ncytotoxic effects of usnic acid were evaluated by the MTT colorimetric method after 72 hours\n\nof cell incubation. Cell morphological abnormalities were observed by microscopy using the\n\nGiemsa technique. Concentrations required to inhibit 50% of cell growth (IC50) were 10 and\n\n11.5 \u00b5g/ml, for free and encapsulated usnic acid, respectively. The cells treated with\n\nencapsulated usnic acid formed a monolayer almost similar to that of the control. However, a\n\ncytoplasmic vacuolisation and a condensed appearance of mitotic cells were identified. These\n\nresults suggested that the encapsulation could protect cells against toxic effects of UA.\n\n\n\n108\n\nIntrodu\u00e7\u00e3o\n\nO \u00e1cido \u00fasnico (UA) \u00e9 um dos metab\u00f3litos mais abundante e comum, dotado de diversas\n\noutras propriedades interessantes (Cocchieto et al., 2002). Com base na literatura, o \u00e1cido\n\n\u00fasnico parece ser um produto exclusivo de liquens. Nenhum derivado sint\u00e9tico \u00e9 mais ativo\n\ndo que sua forma natural conhecida.\n\nUma s\u00e9ria limita\u00e7\u00e3o no uso pr\u00e1tico do UA \u00e9 sua baixa solubilidade em solventes\n\norg\u00e2nicos e \u00e1gua (Erba, et al., 1998). o sucesso de sua aplica\u00e7\u00e3o biol\u00f3gica \u00e9 limitado\n\nprincipalmente a sua baixa solubilidade. Em particular, as pontes de hidrog\u00eanio\n\nintramolecular presentes na sua estrutura contribuem para sua natureza lipof\u00edlica e esse fator \u00e9\n\nrespons\u00e1vel pelo seu efeito citot\u00f3xico, o qual pode ser atribu\u00edda a presen\u00e7a da fra\u00e7\u00e3o ?-\n\ntricetona na mol\u00e9cula (Takai et al., 1979; Muller, 2001).\n\nCorrech\u00e9 et al., (1998) demonstraram que modifica\u00e7\u00f5es estruturais na mol\u00e9cula de UA,\n\nn\u00e3o provocaram aumento de sua a\u00e7\u00e3o citot\u00f3xica, inibindo totalmente o crescimento de\n\nlinf\u00f3citos de f\u00edgado em cultura de c\u00e9lulas.\n\nLodetti et al., 2000, estudando a a\u00e7\u00e3o citot\u00f3toxica in vitro em culturas prim\u00e1rias de\n\nqueratin\u00f3citos gengival e fibroblastos e em c\u00e9lulas KB evidenciaram que o UA livre, ou\n\ncomo um componente de formula\u00e7\u00e3o oral contra c\u00e1rie, n\u00e3o apresentou sinais de\n\ncitotoxicidade.\n\nA encapsula\u00e7\u00e3o \u00e9 uma op\u00e7\u00e3o atrativa de libera\u00e7\u00e3o controlada para uma variedade de\n\ndrogas (Perachia et al., 1997a,b; Barratt, 2000, Whelan, 2001). Esta proporciona uma melhor\n\nestabilidade do f\u00e1rmaco, protegendo-o das condi\u00e7\u00f5es de estocagem; aumenta o efeito\n\nterap\u00eautico; modifica seu perfil farmacocin\u00e9tico; aumenta a concentra\u00e7\u00e3o da droga\n\nadministrada e reduz os riscos de efeitos adversos (Guinebreti\u00e8re et al., 2002)\n\nSabemos que uma grande vantagem destes sistemas polim\u00e9ricos para libera\u00e7\u00e3o\n\ncontrolada de f\u00e1rmacos reside no fato de que, no processo de complexa\u00e7\u00e3o f\u00e1rmaco-pol\u00edmero,\n\no f\u00e1rmaco preserva sua atividade farmacol\u00f3gica. Assim sendo, a parte ativa da mol\u00e9cula n\u00e3o \u00e9\n\n\n\n109\n\nalterada quimicamente. Portanto, o uso destes carreadores como injet\u00e1veis coloidais\n\nproporciona uma libera\u00e7\u00e3o s\u00edtio espec\u00edfica, aumentando a penetra\u00e7\u00e3o intracelular e\n\nprotegendo a droga de degrada\u00e7\u00e3o (Zambaux et al., 1998).\n\nA cultura de c\u00e9lulas tem sido utilizada com freq\u00fc\u00eancia na pesquisa de produtos\n\nnaturais, semi-sint\u00e9ticos e de s\u00edntese, permitindo a an\u00e1lise imediata do impacto destes\n\ncompostos sobre a c\u00e9lula, fornecendo respostas r\u00e1pidas, importantes na sele\u00e7\u00e3o destes novos\n\nf\u00e1rmacos antineopl\u00e1sicos (Bellamy, 1992; Carvalho, 1996). Diversas linhagens celulares\n\nutilizadas nas pesquisas biol\u00f3gicas multiplicam-se facilmente, apresentando grande n\u00famero\n\nde c\u00e9lulas uniformes. A linhagem NCI-H292 foi derivada da met\u00e1stase de n\u00f3dulos linf\u00e1ticos\n\nde carcinoma mucoepiderm\u00f3ide pulmonar. Estas c\u00e9lulas foram isoladas em um meio definido\n\nquimicamente (HITES), com posteriores adapta\u00e7\u00f5es para crescimento em meio suplementado\n\ncom soro. O sistema celular mant\u00e9m suas caracter\u00edsticas em cultura, determinada pela sua\n\nultraestrutura e express\u00e3o de m\u00faltiplos marcadores de diferencia\u00e7\u00e3o escamosa. Novos\n\nregistros afirmam que esta linhagem originou-se de fragmentos sub-gen\u00f4micos transfectados\n\nno interior de c\u00e9lulas humanas em estudos do papel do HBV, e seus genes individuais na\n\npatog\u00eanese do c\u00e2ncer de f\u00edgado e hepatite viral (Morier et al., 1996).\n\nEstudos pr\u00e9vios de nanoencapsula\u00e7\u00e3o de \u00e1cido \u00fasnico em nanoc\u00e1psulas de \u00e1cido\n\nl\u00e1ctico-co-glic\u00f3lico (PLGA) revelaram que a efici\u00eancia da taxa de encapsula\u00e7\u00e3o foi quase\n\n100%. O processo de liofiliza\u00e7\u00e3o aumentou a estabilidade sobre 36 meses quando\n\narmazenadas a 4\u00b0C \u00b1 1\u00b0C. O perfil cin\u00e9tico de libera\u00e7\u00e3o in vitro, revelou que nanoc\u00e1psulas\n\nde PLGA contendo \u00e1cido \u00fasnico pode ser proposto como uma alternativa de sistema de\n\nlibera\u00e7\u00e3o do \u00e1cido \u00fasnico (Santos et al., 2002).\n\nNeste estudo foi avaliada a a\u00e7\u00e3o citot\u00f3xica do \u00e1cido \u00fasnico livre e encapsulado em\n\nnanoc\u00e1psulas de PLGA, utilizando a linhagem celular obtida de c\u00e2ncer de pulm\u00e3o humano\n\nNCI - H292.\n\n\n\n110\n\nMateriais e M\u00e9todos\n\nMateriais\n\nPoli (D, L-\u00e1cido L\u00e1tico-co-\u00e1cido glic\u00f3lico) pol\u00edmero (PLGA) 50/50 foi comprado na\n\nBirmingham Polymers (USA); Fosfatidilcolina de soja (Epikuron? 200), foi obtido da Lucas\n\nMeyer (Germany); Poloxamer 188, (Pluronic ? F 68) foi generosamente cedido pela ICI\n\n(France); \u00f3leo de girassol foi obtido no Sigma Chemical (USA); fosfato de pot\u00e1ssio\n\nmonob\u00e1sico e hidr\u00f3xido de s\u00f3dio foram comprados na Merck (USA); acetona, clorof\u00f3rmio,\n\nxilol, dimetilsulf\u00f3xido (DMSO), e acetonitrila e metanol grau CLAE (Cromatografia L\u00edquida\n\nde Alta Efici\u00eancia), foram obtidos da Aldrich (USA); Meio Essencial M\u00ednimo, Eagle\n\nmodificado Dulbecco\u2019s (DMEM) foi comprado no Sigma Chemical; o soro fetal bovino,\n\npenicilina 1000 UI/ml, estreptomicina 250 mg/ml, L-glutamina 200 Mm foram obtidos na\n\nGIBCO (New York, USA); o corante Azul de Tripan foi obtido na Merck; o UA foi extra\u00eddo\n\ne purificado de Cladonia substellata no Laborat\u00f3rio de Qu\u00edmica da Universidade Federal de\n\nMato Grosso do Sul, Brasil e cedidos gentilmente pela Prof. Dra. Nely Kika Honda. O\n\nmaterial liqu\u00eanico foi coletado sobre solos arenosos em Mamanguape, Para\u00edba e identificadas\n\npelas caracter\u00edsticas morfol\u00f3gicas e qu\u00edmicas do talo. Parte do material foi acondicionado em\n\nenvelopes de papel em quantidades suficientes para dep\u00f3sito em herb\u00e1rio (UFP), e o restante\n\nfoi enviado para ser submetido ao processo de extra\u00e7\u00e3o e purifica\u00e7\u00e3o do UA.\n\nC\u00e9lulas neopl\u00e1sicas\n\nA linhagem celular utilizada nos ensaios in vitro foi a NCI-H 292, derivadas de c\u00e2ncer\n\nde pulm\u00e3o, foi obtida do Banco de C\u00e9lulas do Rio de Janeiro (BCRJ, N\u00ba CR023) e mantida\n\nde acordo com o protocolo estabelecido pelo laborat\u00f3rio de cultura de  c\u00e9lulas do\n\nDepartamento de Antibi\u00f3ticos da UFPE.\n\n\n\n111\n\nM\u00e9todos\n\nObten\u00e7\u00e3o de nanoc\u00e1psulas de PLGA contendo \u00e1cido \u00fasnico\n\nNanoc\u00e1psulas de PLGA contendo \u00e1cido \u00fasnico (UA-NC) foram obtidas segundo o m\u00e9todo de\n\ndeposi\u00e7\u00e3o interfacial do pol\u00edmero pr\u00e9-formado proposto por Fessi et al. (1989). Uma mistura\n\norg\u00e2nica constitu\u00edda pelo pol\u00edmero PLGA, fosfatidilcolina de soja, \u00f3leo de girassol e o \u00e1cido\n\n\u00fasnico dilu\u00eddos em acetona, foram introduzidos lentamente na fase aquosa constitu\u00edda de\n\ntamp\u00e3o fosfato pH 7,4 e poloxamer, sob agita\u00e7\u00e3o moderada. As nanoc\u00e1psulas foram formadas\n\nimediatamente ap\u00f3s a mistura, e permaneceu em agita\u00e7\u00e3o por 30 minutos. Ap\u00f3s a suspens\u00e3o\n\ncoloidal foi concentrada sob press\u00e3o reduzida a um volume de 20% do inicial, no intuito de se\n\nevaporar o solvente org\u00e2nico e ajustes da concentra\u00e7\u00e3o final do UA.\n\nCaracteriza\u00e7\u00e3o f\u00edsico-qu\u00edmica das formula\u00e7\u00f5es de nanoc\u00e1psulas de PLGA contendo UA.\n\nAs an\u00e1lises f\u00edsico-qu\u00edmicas de UA-NC foram realizadas imediatamente ap\u00f3s prepara\u00e7\u00e3o e ent\u00e3o\n\nsubmetidas a intervalos de tempo regular. Diversos par\u00e2metros tais como aspecto macrosc\u00f3pico e microsc\u00f3pico,\n\nvaria\u00e7\u00e3o de pH e determina\u00e7\u00e3o da taxa de encapsula\u00e7\u00e3o foram realizados.\n\nAtividade Citot\u00f3xica in vitro sobre c\u00e9lulas NCI-H292\n\nO estudo da atividade citot\u00f3xica foi realizado pelo m\u00e9todo de cultura de tecidos com\n\nc\u00e9lulas da linha cont\u00ednua NCI-H 292 em fase exponencial de crescimento. As c\u00e9lulas foram\n\nmantidas em meio DMEM, suplementado com 10% de soro fetal bovino (GIBCO), 1% de\n\nsolu\u00e7\u00e3o de antibi\u00f3tico (penicilina 1000 UI/ml + estreptomicina 250 mg/ml) e 1% de L-\n\nglutamina 200 Mm (Carvalho, 1996)\n\nA viabilidade celular, foi determinada utilizando o corante vital Azul de Tripan 0,4%\n\np/v, em PBS (Weisenthal, 1983).\n\nUma suspens\u00e3o celular (105 c\u00e9lulas/ml) foi distribu\u00edda em placa de cultura com 96\n\npo\u00e7os (220 \u00b5l/ po\u00e7o). As placas foram incubadas a 37 \u00b0C em estufa (Sedas, Mil\u00e3o-It\u00e1lia), com\n\n\n\n112\n\natmosfera \u00famida enriquecida com 5 % de CO2. Ap\u00f3s 24h de incuba\u00e7\u00e3o o UA livre e UA-NC\n\ndilu\u00eddos em DMSO  e DMEM respectivamente, e adicionado \u00e0 placa de cultura (22 \u00b5l/po\u00e7o)\n\nobtendo-se as concentra\u00e7\u00f5es finais no po\u00e7o de 20, 10, 5 e 2,5 \u00b5g/ml. Foram realizados\n\ncontroles com DMSO e DMEM. 72 h ap\u00f3s o tratamento, os efeitos citot\u00f3xicos das amostras\n\ntestes foram avaliados de acordo com o protocolo do National C\u00e2ncer Institute (NCI) (Geran\n\net al., 1972), utilizando o m\u00e9todo colorim\u00e9trico de MTT (3- [4,5-dimetiltiazol-2-il]-2,5-\n\ndifeniltetraz\u00f3lio), conforme Mosmann, 1983, modificado por Alley et al., 1988.\n\nOs resultados foram avaliados pela determina\u00e7\u00e3o da inibi\u00e7\u00e3o prolifera\u00e7\u00e3o celular em\n\nrela\u00e7\u00e3o ao controle. Cada teste foi repetido, tr\u00eas vezes para confirma\u00e7\u00e3o dos\n\nresultados e submetidos a c\u00e1lculos estat\u00edsticos (Teste Turkey).\n\nAvalia\u00e7\u00e3o in vitro das altera\u00e7\u00f5es morfol\u00f3gicas em c\u00e9lulas NCI-H292\n\nAltera\u00e7\u00f5es morfol\u00f3gicas nas culturas de c\u00e9lulas NCI H292 foram analisadas por\n\nmicroscopia \u00f3ptica utilizando a t\u00e9cnica de Giemsa.\n\nUma suspens\u00e3o celular (105 c\u00e9lulas/ml), foi distribu\u00edda em placa de cultura com 12\n\npo\u00e7os (180 \u00b5l/ po\u00e7o). As placas foram incubadas a 37 \u00b0C em estufa (Sedas, Mil\u00e3o-It\u00e1lia), com\n\natmosfera \u00famida enriquecida com 5 % de CO2. Ap\u00f3s 24h de incuba\u00e7\u00e3o foram adicionadas (20\n\n\u00b5l/po\u00e7o) de solu\u00e7\u00e3o de UA livre e UA-NC dilu\u00eddos em DMSO e DMEM respectivamente, nas\n\nconcentra\u00e7\u00f5es finais de 5 e 2,5 \u00b5g/ml. Ap\u00f3s 72 h de reincuba\u00e7\u00e3o, o meio de cultura foi\n\naspirado e as lam\u00ednulas contendo c\u00e9lulas aderidas foram lavadas em solu\u00e7\u00e3o tamponada,\n\nfixada com metanol absoluto, rehidratadas e expostas a solu\u00e7\u00e3o corante (Giemsa).\n\nConsecutivamente as lam\u00ednulas foram desidratadas em acetona 100 %, acetona/clorof\u00f3rmio\n\n(1:1) e diafanizadas em clorof\u00f3rmio P.A. 100%. As lam\u00ednulas foram montadas em l\u00e2minas de\n\nvidro, com  aux\u00edlio de ENTELLAN? (MERCK), e observadas em um microsc\u00f3pio \u00f3ptico\n\n(Olympus CH-2, Japan).\n\n\n\n113\n\nResultados\n\nCitotoxidade in vitro sobre c\u00e9lulas NCI-H292\n\nA figura 1 revela uma pronunciada redu\u00e7\u00e3o na prolifera\u00e7\u00e3o das c\u00e9lulas NCI-H 292\n\nquando incubadas a 20 \u00b5g/ml de UA livre e UA-NC, respectivamente. Nesta concentra\u00e7\u00e3o,\n\nverificou-se uma redu\u00e7\u00e3o de aproximadamente 80% na viabilidade celular nas amostras\n\ntestadas. Quando esta cultura foi exposta a uma concentra\u00e7\u00e3o de 10\u00b5g/ml da subst\u00e2ncia teste\n\nlivre e encapsulada, observou-se um decr\u00e9scimo de 48% e 49% respectivamente, na\n\nviabilidade celular. Uma significante a\u00e7\u00e3o citot\u00f3xica foi tamb\u00e9m evidenciada, quando estas\n\nc\u00e9lulas foram incubadas com 5 \u00b5g/ml do UA livre e encapsulado, uma redu\u00e7\u00e3o em torno de\n\n28% e 22,5%, respectivamente. Finalmente quando submeteram-se estas c\u00e9lulas ao tratamento\n\ncom UA livre e UA-NC (2,5 \u00b5g/ml), n\u00e3o foi verificado efeito citot\u00f3xico.\n\nNa seq\u00fc\u00eancia, para se determinar alguma possibilidade de efeito citot\u00f3xico atribu\u00eddo\n\nao copol\u00edmero utilizado na prepara\u00e7\u00e3o de nanoc\u00e1psulas a viabilidade celular foi tamb\u00e9m\n\navaliada sobre a incuba\u00e7\u00e3o de c\u00e9lulas com diferentes concentra\u00e7\u00f5es de nanoc\u00e1psulas livre de\n\ndrogas, ou nanoc\u00e1psulas brancas. De acordo com os resultados obtidos, nenhuma a\u00e7\u00e3o\n\ncitot\u00f3xica foi observada sobre incuba\u00e7\u00e3o desta formula\u00e7\u00e3o com c\u00e9lulas NCI\u2013H292. Estes\n\nresultados demonstraram ser independente das concentra\u00e7\u00f5es estudadas.\n\n Conforme os resultados descritos acima, pode-se perceber que as concentra\u00e7\u00f5es\n\nrequeridas para inibir 50 % da prolifera\u00e7\u00e3o celular (CI 50) foram 10 e 11,25 \u00b5g/ml -1 para o\n\nUA livre e encapsulado, respectivamente.\n\nAvalia\u00e7\u00e3o in vitro das altera\u00e7\u00f5es morfol\u00f3gicas em c\u00e9lulas NCI-H292\n\nEste estudo foi realizado no intuito de se analisar as altera\u00e7\u00f5es morfol\u00f3gicas do UA livre e encapsulado (5\n\n- 2,5\u00b5g/ml) sobre a cultura celular NCI-H292 quando incubados a 37 \u00b0C no per\u00edodo de 72h.\n\n\n\n114\n\nNos testes de avalia\u00e7\u00e3o morfol\u00f3gica, observou-se que as c\u00e9lulas NCI-H292\n\nproliferam-se aderidas \u00e0 superf\u00edcie formando monocamada. As c\u00e9lulas apresentam tamanho e\n\nformas variados, sendo algumas ov\u00f3ides ou fusiformes. Tamb\u00e9m foram evidenciadas c\u00e9lulas\n\ncom um ou mais nucl\u00e9olos, c\u00e9lulas multinucleadas com citoplasma fracamente bas\u00f3filo,\n\ngranuloso com pequenos vac\u00faolos e n\u00facleos redondos e ovulados em textura discreta (Figura\n\n2a e 2b).\n\nAnalisando morfologicamente a cultura celular, quando submetida a tratamento com\n\nUA livre a 2,5 \u00b5g/ml, evidenciou-se que as c\u00e9lulas em geral mantiveram o mesmo aspecto.\n\nTodavia observou-se citoplasma irregular, vacuoliza\u00e7\u00e3o citoplasm\u00e1tica e prolifera\u00e7\u00e3o em\n\nforma de monocamada come\u00e7ando a desfazer-se (Figura 2c).\n\nConsecutivamente, incubando as c\u00e9lulas NCI-H292 com o UA livre a 5 \u00b5g/ml,\n\ndesenvolveram altera\u00e7\u00f5es mais acentuadas na ader\u00eancia e forma celular, observando-se,\n\nportanto, uma dispers\u00e3o celular mais evidente, citoplasma irregular e vacuoliza\u00e7\u00e3o que al\u00e9m\n\nde citoplasm\u00e1tica, comprometia tamb\u00e9m os n\u00facleos. Evidenciou-se tamb\u00e9m a presen\u00e7a de\n\npequenos grupos celulares isolados, citoplasma bastante escasso, n\u00facleos condensados e\n\nc\u00e9lulas anucleadas e presen\u00e7a evidente de c\u00e9lulas mortas (Figura 2d).\n\nEm contraste, quando esta cultura foi incubada com UA-NC a 5 \u00b5g/ml, obse rvou-se que\n\na prolifera\u00e7\u00e3o celular em forma de monocamada apresentou-se quase semelhante ao controle.\n\nA vacuoliza\u00e7\u00e3o citoplasm\u00e1tica foi pouco evidente, e uma houve discreta condensa\u00e7\u00e3o\n\naparecendo c\u00e9lulas mit\u00f3ticas (Figura 3b).\n\nN\u00e3o obstante, nenhum efeito significativo foi evidenciado a n\u00edvel morfol\u00f3gico nas\n\nc\u00e9lulas NCI-H 292 tratadas com nanoc\u00e1psulas de PLGA brancas (NC) (Figura 3a), quando\n\ncomparadas ao controle.\n\n\n\n115\n\nDiscuss\u00e3o\n\nO UA \u00e9 um composto arom\u00e1tico, que pode ser obtido de diversas esp\u00e9cies de l\u00edquens.\n\nEste composto natural tem demonstrado diferentes atividades biol\u00f3gicas e fisiol\u00f3gicas que\n\npodem apresentar grande relev\u00e2ncia na farmacologia e cl\u00ednica. Devido a sua relevante a\u00e7\u00e3o\n\nantimic\u00f3tica e antiproliferativa, existe potencial interesse de seu uso na terapia do c\u00e2ncer\n\n(Correch\u00e9 et al.,1998; Campanella et al., 2002). N\u00e3o obstante, o sucesso de sua aplica\u00e7\u00e3o\n\ncl\u00ednica \u00e9 limitado a sua dotada a\u00e7\u00e3o citot\u00f3xica e pouca solubilidade em \u00e1gua e solventes\n\norg\u00e2nicos (Correch\u00e9 et al., 1998; Erba et al., 1998). O principal objetivo deste estudo foi\n\ndesenvolver sistemas de libera\u00e7\u00e3o polim\u00e9ricos para o UA, com a capacidade de aumentar o\n\n\u00edndice terap\u00eautico e evitar efeitos adversos.\n\nNeste estudo foi realizada a compara\u00e7\u00e3o da a\u00e7\u00e3o citot\u00f3xica in vitro do UA livre e\n\nencapsulado em nanoc\u00e1psulas de PLGA sobre c\u00e9lulas do c\u00e2ncer de pulm\u00e3o, linhagem NCI-\n\nH292. Os resultados obtidos demonstraram claramente que a concentra\u00e7\u00e3o do UA desenvolve\n\num importante papel sobre sua a\u00e7\u00e3o citot\u00f3xica. Correch\u00e9 et al. (1998) realizando ensaios in\n\nvitro de citotoxidade frente \u00e0 cultura de linf\u00f3citos de ba\u00e7o de ratos Hoffmam, evidenciaram\n\numa quase completa inibi\u00e7\u00e3o do crescimento celular, quando a cultura foi incubada com o UA\n\ne seus derivados nas concentra\u00e7\u00f5es de 10 a 80 \u00b5g/ml. Cardarelli et al. (1997) tamb\u00e9m\n\nreportaram que a propriedade do UA sobre a prolifera\u00e7\u00e3o de c\u00e9lulas da linhagem HE-50 e\n\nK562 foi dose e tempo dependente.\n\nCorrelacionando o efeito citot\u00f3xico in vitro, obtido nas diferentes concentra\u00e7\u00f5es\n\nestudadas de UA livre e UA-NC, observou-se que os valores da IC50 para o UA livre e\n\nencapsulado apresentou-se na mesma ordem de magnitude. N\u00e3o obstante, nas an\u00e1lises\n\nmorfol\u00f3gicas da linhagem NCI \u2013H292, evidenciou-se que o UA livre (5\u00b5g/ml) provocou uma\n\nacentuada redu\u00e7\u00e3o da prolifera\u00e7\u00e3o celular, intensa vacuoliza\u00e7\u00e3o citoplasm\u00e1tica e condensa\u00e7\u00e3o\n\nnuclear.  Por outro lado, tratando estas mesmas c\u00e9lulas com UA-NC (5\u00b5g/ml), evidenciou-se\n\n\n\n116\n\numa prolifera\u00e7\u00e3o celular em forma de monocamada quase semelhante ao controle,\n\nvisualizando-se, portanto, uma discreta condensa\u00e7\u00e3o  de c\u00e9lulas mit\u00f3ticas em toda cultura.\n\nO aumento da atividade de f\u00e1rmacos hidrof\u00f3bicos, mediados por sua incorpora\u00e7\u00e3o\n\ndentro de nanoc\u00e1psulas de PLGA pode ser explicado pelo fato que este sistema pode atuar\n\ncomo reservat\u00f3rio, protegendo a droga de hidr\u00f3lises, e prover n\u00e3o somente uma libera\u00e7\u00e3o\n\nsustentada do \u00e1cido \u00fasnico, mas tamb\u00e9m contribuir para manuten\u00e7\u00e3o de sua atividade.\n\nSimilares resultados tamb\u00e9m foram relatados por Fonseca et al. (2002). Os autores reportam o\n\nestudo de nanopart\u00edculas de PLGA contendo paclitaxel (Taxol?), anticancer\u00edgeno bastante\n\navaliado na terapia do c\u00e2ncer. Nos testes citot\u00f3xicos in vitro realizados com este f\u00e1rmaco\n\nencapsulado em c\u00e9lulas do c\u00e2ncer de pulm\u00e3o, linhagem NCI-H62, observou-se um eficiente\n\nefeito citot\u00f3xico; utilizando uma reduzida concentra\u00e7\u00e3o do f\u00e1rmaco (dez vezes menor) quando\n\ncomparado ao composto livre.\n\nSoma et al. (2000) reportam a a\u00e7\u00e3o citot\u00f3xica de nanopart\u00edculas de\n\npolialquilcianocrilato contendo Ciclosporina A (CyA) e Doxorrubicina (Dox) frente a c\u00e9lulas\n\nP388. Neste ensaio se observou alto valor de IC50, quando esta cultura foi tratada com os\n\nf\u00e1rmacos encapsulados. Estes resultados podem ser em decorr\u00eancia do aumento de resist\u00eancia\n\nda linha celular estudada frente a Dox e CyA. N\u00e3o obstante, evidenciou-se que sua atividade\n\nfoi preservada, quando ambos f\u00e1rmacos foram incubadas no meio de cultura incorporado na\n\nmesma formula\u00e7\u00e3o de nanopart\u00edculas, resultando tamb\u00e9m num aumento da efic\u00e1cia do\n\nf\u00e1rmaco, quando comparado aos mesmos em solu\u00e7\u00e3o.\n\nSubseq\u00fcentes estudos com a Doxorrubicina conjugada com o copol\u00edmero PLGA (Dox-\n\nPLGA) e incorporada em nanopart\u00edculas, demonstraram uma libera\u00e7\u00e3o sustentada do f\u00e1rmaco,\n\nap\u00f3s sua internaliza\u00e7\u00e3o celular. Nestes resultados foram evidenciadas baixas taxas de inibi\u00e7\u00e3o\n\ndo crescimento quando culturas de c\u00e9lulas HepG2 foram incubadas com Dox-PLGA\n\nencapsulado. Mesmo ocorrendo uma grande capta\u00e7\u00e3o das nanopart\u00edculas dentro das c\u00e9lulas, a\n\ncis\u00e3o hidrol\u00edtica das cadeias do PLGA apresentou uma libera\u00e7\u00e3o sustentada dos olig\u00f4meros de\n\n\n\n117\n\nDOX-PLGA dentro da \u00e1rea citoplasm\u00e1tica. Assim sendo, 48 h de incuba\u00e7\u00e3o celular foi um\n\nper\u00edodo insuficiente para libera\u00e7\u00e3o das nanopart\u00edculas localizadas dentro das  c\u00e9lulas (Yoo et\n\nal., 2000).\n\nO mecanismo de libera\u00e7\u00e3o do f\u00e1rmaco das nanopart\u00edculas \u00e9 de crucial\n\nimport\u00e2ncia na extens\u00e3o da atividade do composto (Fonseca et al., 2002). Desta\n\nforma pode-se observar dois tipos distintos, mas n\u00e3o vias exclusivas que podem\n\njustificar o aumento da a\u00e7\u00e3o citot\u00f3xica de f\u00e1rmacos anti-tumorais incorporados\n\ndentro de sistemas nanopart\u00edculas: a) os carreadores podem adsorver sobre a\n\nmembrana celular, facilitando o aumento da concentra\u00e7\u00e3o do f\u00e1rmaco pr\u00f3ximo \u00e0\n\nsuperf\u00edcie celular, gerando assim um gradiente de concentra\u00e7\u00e3o que favorece a\n\naflu\u00eancia do f\u00e1rmaco dentro da c\u00e9lula; b) c\u00e9lulas tumorais (as quais em muitas\n\nsitua\u00e7\u00f5es exibem elevada atividade endoc\u00edtica) podem internalizar nanopart\u00edculas,\n\npermitindo a libera\u00e7\u00e3o do f\u00e1rmaco no interior das c\u00e9lulas, contribuindo todavia para\n\num aumento da concentra\u00e7\u00e3o do f\u00e1rmaco pr\u00f3ximo ao s\u00edtio de a\u00e7\u00e3o.\n\nConclus\u00f5es\n\nA a\u00e7\u00e3o citot\u00f3xica observada nas c\u00e9lulas NCI-H292, quando tratadas com UA livre e\n\nencapsulado em nanoc\u00e1psulas de PLGA, apresentou-se na mesma ordem de magnitude. N\u00e3o\n\nobstante, uma redu\u00e7\u00e3o significante no efeito citot\u00f3xico foi visualizada microscopicamente,\n\nquando as c\u00e9lulas foram tratadas com as nanoc\u00e1psulas contendo \u00e1cido \u00fasnico. Baseado nestes\n\ndados \u00e9 poss\u00edvel considerar que a formula\u00e7\u00e3o desenvolvida neste estudo pode ser considerada\n\num sistema promissor para libera\u00e7\u00e3o in vivo do \u00e1cido \u00fasnico livre.\n\n\n\n118\n\nAgradecimentos\n\nO primeiro autor foi mantido pela bolsa de estudo PhD CAPES. E C P e N S S M s\u00e3o gratos\n\nao Conselho Brasileiro de Desenvolvimento de Pesquisa Tecnol\u00f3gica - CNPq, pela concess\u00e3o\n\nde financiamento individual.\n\nRefer\u00eancias bibliogr\u00e1ficas\n\nAlley M C, Scudiero D A, Monsk  A, Hursey  M L, Czerwinski M J, Fine D L, Abbott B J,\n\nMayo J G, Shoemaker R H. and Boyd M R. (1988) Feasibility of drug screening with panels\n\nof human tumor cell lines using a microculture tetrazolium assay. Cancer Research 48, 589-\n\n601.\n\nBellamy , W. T. (1992) Prediction of reponses to drug Therapy of Cancer Drug 44 (5), 690-\n\n708.\n\nBarrat G. M. (2000) Therapeutic applications of colloidal drug carriers. Pharmaceutical\n\nScience Technology Today 3(5), 163-171.\n\nCampanella L, Delfini M, Ercole P, Iacoangeli A. and Risuleo G. (2002) Molecular\n\ncharacterization and action of usnic acid: a drug that inhibits proliferations of mouse\n\npolyomavirus in vitro and whose main target is RNA transcription. Biochemistry 84, 329-334.\n\nCardarelli M, Serino G, Campanella L, Ercole P, Nardone F, Alesiani O. and Rossiello F.\n\n(1997) Antimitotic effects of usnic acid on different biological systems. Cellular and\n\nMolecular Life Science 53(8), 667-672.\n\n\n\n119\n\nCarvalho T.U. (1996) Cultura de c\u00e9lulas animais. In: Benchimol. Eddited by M. Attias, M.\n\nCunha N.L. &amp; Silva  T.U. M\u00e9todos de estudo da c\u00e9lula. pp. 47-58. Rio de Janeiro, Editora\u00e7\u00e3o\n\nEletr\u00f4nica Fenorte/Uenf.\n\nCorrech\u00e9 E R, Carrasco M, Escudero M E, Vel\u00e1zquez L, Guzm\u00e1n, A M S, Giannini, F, Enriz\n\nR.D, Ja\u00faregui E A, Ce\u00f1al J P. and Giordano O.S. (1998) Study of citotoxity and antimicrobial\n\nactivities of usnic acid derivatives. Fitoterapia LXIX (6), 493-501.\n\nCocchietto M, Skert N. and  Nimis  P. L. (2002) A review on usnic acid, an interesting\n\nnatural compound. Naturwissenschaften 89, 137-149.\n\nErba E, Pocar D. and Rossi L.M. (1998) New esters of R- (+)-usnic acid. II F\u00e1rmaco 53, 718-\n\n720.\n\nFessi H,  Puisieux F, Devissaguet J P,  Ammoury N E. and Benita S. (1989) Nanocapsules\n\nformation by interfacial polymer deposition following solvent displacement. Internacional\n\nJournal Pharmaceutics 55, 1-4.\n\nFonseca C, Sim\u00f5es S. and Gaspar R. (2002) Poclitaxel-loaded PLGA nanoparticles:\n\npreparation, physicochemical characterisation and in vitro anti-tumoral activity. Journal of\n\nControlled Release 83, 273-286.\n\nGuinebreti\u00e9re S, Brianon S, Fessi H, Teodorescu V.S. and Blanchin M.G. (2002)\n\nNanocapsules of biodegradable polymers: preparation and characterization by direct high\n\nresolution electron microscopy. Materials Science Engineering  C21, 137-142.\n\n\n\n120\n\nGeran, R. I.; Greenberg, N. H.; Macdonald, M. M.; Schumacher, A. M.; Abbott, B. J. (1972)\n\nProtocols for screening chemical agents and natural products against animal and other\n\nbiological systems, 3 ed. Cancer Chemotherapy Reports, 3, Part III, 2.\n\nLodetti G, Gigola P, Bertasi BD, Ambrosca F, Ponchio G, Fishbach M. and Losio M N.\n\n(2000) Valutazione in vitro della citossicit\u00e1 indotta da prodotti per I\u2019igiene orale contenenti\n\nacido usnico, agente antimicrobiano naturale estratto da\u00ed licheni. Gimmoc 4, 67-72.\n\nMosmann, T. (1983) Rapid colorimetric assay for cellular growth and survival: application to\n\nproliferation and citotoxicity assays. Journal of Immunology Methods  65, 55-63.\n\nMorrier L, P\u00e9rez P, Cancio C, S\u00e1von Z, Gonz\u00e1lez Z and  Goyenechea A. (1996) A\n\ncomparaci\u00f3n de la l\u00ednea NCI-H292 com otras l\u00edneas cont\u00ednuas para la multiplicaci\u00f3n de virus\n\nrespiratoridos. Revista Cubana de Medicina Tropical 48, 171-173.\n\nMuller K. (2001) Pharmaceutically relevant metabolites from lichens. Applied Microbiology\n\nBiotechnolology 56, 9-16.\n\nPerachia MT, Vautier C, Puisieux  F. and Couvreur, P. (1997a) Development of statically\n\nstabilized poly (isobutyl 2-cyanocrylate) nanoparticles by chemical coupling of poly (ethylene\n\nglycol). Journal of Biomedical and Materials Research 34, 317-326.\n\nPerachia MT, Gref R, Minamitake Y, Domb A, Lotan N. and Langer R. (1997b) PEG-coated\n\nnanospheres from anphiphilic diblock and multiblock copolymers: investigation of their drug\n\nencapsulation and release characteristics. Journal of Controlled Release 46, 223-231.\n\n\n\n121\n\nSantos NP, Nascimento SC, Pereira EC, Silva NH, Honda NK,  Santos-Magalh\u00e3es NS (2003)\n\nUsnic acid-loaded PLGA-nanocapsules: Preparation, physicochemical characterization and In\n\nvitro kinetics release. Journal of Nanobiotechology (no prelo).\n\nSoma CE, Dubernet C, Bentolila D, Benita S. and Couvreur P (2000) Reversion of multidrug\n\nresistance by co-encapsulation of doxorubicin and cyclosporin A in polyalkylcyanocrylate\n\nnanoparticles. Biomaterials 21, 1-7.\n\nWeisenthal LM, Marsden JA, Dill PL. and  Macaluso CK (1983) A novel dye exclusion method for testing in\n\nvitro chemosensitivity of human tumors. Cancer Research 43, 749-757.\n\nWhelan J. (2001) Nanocapsules for controlled drug delivery. Drug Discovery Today 6(23),\n\n1183-1184.\n\nYoo HS, Lee KH, Oh JE. and Park T.G. (2000) In vitro and In vivo anti-tumor activities of\n\nnanoparticles based on doxorubicin-PLGA conjugates. Journal of Controlled Release, 68,\n\n419-431.\n\nZambaux MF, Bonneaux F, Gref R, Maincent P, Dellacherie E, Alonso MJ, Labrude P. and\n\nVigneron C. (1998) Influence of experimental parameters on the characteristics of poly(lactid\n\nacid) nanoparticles prepared by a double emulsion method. Journal of Controlled Release 50,\n\n31-40.\n\n\n\n122\n\nLista de Figuras\n\nFigura 1. Determina\u00e7\u00e3o da IC50 do \u00e1cido \u00fasnico livre e encapsulado em nanoc\u00e1psulas de\n\nPLGA sobre c\u00e9lulas NCI -H 292 utilizando o teste de Turkey, admitindo-se um intervalo de\n\nconfian\u00e7a de 99% (p &lt;0,05): UA= \u00e1cido \u00fasnico livre, UA-NC= nanoc\u00e1psulas de PLGA\n\ncontendo \u00e1cido \u00fasnico, NC= nanoc\u00e1psulas de PLGA brancas.\n\n\n\n123\n\n(a) (b)\n\n(c) \n\n(d)\n\nFigura 2. Aspectos morfol\u00f3gicos de c\u00e9lulas NCI H-292 (40 X) ap\u00f3s tratamento com \u00e1cido\n\n\u00fasnico livre: controle (a) 100X (b) 200X; \u00e1cido \u00fasnico a 2,5\u00b5g/ml (c); \u00e1cido \u00fasnico a 5\u00b5g/ml\n\n(d). Legenda: RMC= redu\u00e7\u00e3o da monocamada celular; VC= vacuoliza\u00e7\u00e3o citoplasm\u00e1tica CD=\n\nc\u00e9lulas desnudas; NC= c\u00e9lulas mortas.\n\nMC\nCP\n\nCB\n\n\n\n124\n\n(a) (b)\n\nFigura 3. Aspectos morfol\u00f3gicos de c\u00e9lulas NCI H-292 (40 X) ap\u00f3s tratamento com\n\nnanoc\u00e1psulas contendo \u00e1cido \u00fasnico: nanoc\u00e1psulas de PLGA brancas (a) nanoc\u00e1psulas de\n\nPLGA contendo \u00e1cido \u00fasnico (5\u00b5g/ml) (b). Legenda: MC= monocamada celular; CMIT=\n\nc\u00e9lulas mit\u00f3ticas.\n\n\n\n125\n\nCAP\u00cdTULO III\n\n\n\n126\n\nATIVIDADE ANTITUMORAL DE NANOC\u00c1PSULAS DE PLGA\nCONTENDO \u00c1CIDO \u00daSNICO FRENTE AO TUMOR SARCOMA-180\n\nTrabalho a ser submetido ao\n\u201cEuropean Journal of Pharmaceutics and Biopharmaceutics\u201d\n\n\n\n127\n\nATIVIDADE ANTITUMORAL DE NANOC\u00c1PSULAS DE PLGA CONTENDO\n\u00c1CIDO \u00daSNICO FRENTE AO TUMOR SARCOMA-180\n\nNoemia Pereira dos Santos 1,2, Eug\u00eania Cristina Gon\u00e7alves Pereira3, Nic\u00e1cio Henrique da\n\nSilva4, Nely Kika Honda5 , Jos\u00e9 Figueredo Silva1, Silene Carneiro Nascimento6, Nereide Stela\n\nSantos-Magalh\u00e3es1*\n\n1 Universidade Federal de Pernambuco (UFPE), Laborat\u00f3rio de Imunopatologia Keizo Asami (LIKA),\n\nAv. Prof. Moraes Rego, 1235 Cidade Universit\u00e1ria, Recife- PE, Brasil\n2Doutorado em Ci\u00eancias Biol\u00f3gicas, UFPE, Recife - PE, Brasil\n3 Departamento de Geografia -UFPE, Recife - PE, Brasil\n4 Departamento de Bioqu\u00edmica \u2013UFPE, Laborat\u00f3rio de Qu\u00edmica de Produtos Naturais, Recife - PE,\n\nBrasil\n5 Universidade Federal de Mato Grosso do Sul (UFMS), Departamento de Qu\u00edmica,  Laborat\u00f3rio de\n\nQu\u00edmica de Produtos Naturais, Mato Grosso do Sul \u2013MGS, Brasil\n6 Departamento de Antibi\u00f3ticos -UFPE, Setor de Farmacologia e Cancerologia Experimental, Recife -\n\nPE, Brasil\n\nKey Words: Drug delivery, nanoparticles,  nanocapsules, PLGA, lichen,  usnic acid, cancer,\n\nantitumour.\n\n* Corresponding author\n\nDra. Nereide Stela Santos-Magalh\u00e3es\n\nUniversidade Federal de Pernambuco\n\nGrupo de Sistemas de Libera\u00e7\u00e3o Controlada de Medicamentos\n\nLaborat\u00f3rio de Imunopatologia Keiso Asami (LIKA)\n\nAv. Prof. Moraes Rego, 1235, Cidade Universit\u00e1ria.\n\n50670-901, Recife-PE, Brasil\n\nTel: + 55 \u2013081- 3271 8587; fax: +55-081 \u20133271 8485\n\nE-mail: nssm@ufpe.br\n\n\n\n128\n\nABSTRACT\n\nDespite the substantial antimycotic and antibacterial properties  of the usnic acid, even against human neoplasic\n\ncell lines, the therapeutical applications of such low molecular weight lichens remains rather limited. In fact, the\n\nhigh in vitro/ in vivo usnic acid toxicity has denied its use in anticancer therapy. Colloid carriers are particularly\n\nuseful for formulating new drugs derived from biotechnology (peptides, proteins, genes and anticancer drugs)\n\nbecause they can provide protection from degradation in biological fluids and promote their penetration into\n\ncells. They also have applications with respect to small hydrophobic molecules, because they can provide an\n\nultradispersed dosage form without the use of irritating solvents and allow fast drug dissolution. The aim of this\n\nwork was investigate the antitumoral activity of encapsulated usnic acid into PLGA-nanocapsules. Nanocapsules\n\ncontaining usnic acid were prepared by interfacial deposition of preformed polymer method. Antitumoral\n\nactivity was verified against solid tumour sarcoma \u2013180 in Swiss mice, and it was estimated by the tumour\n\ninhibition. Results of antitumoral activity demonstrated that the encapsulation of usnic acid into PLGA-\n\nnanocapsules promoted a 68% increase of tumour inhibition as compared with free usnic acid treatment.\n\nVacuolisation of hepatocytes and a mild lymphocyte infiltration in portal spaces were observed in animals\n\ntreated with free usnic acid. However, no histological changes were noticed in the kidneys of treated animals.\n\nThis work showed that encapsulation of UA into PLGA-nanocapsules improved antitumoral activity. Current\n\nstudies are being carried out in our laboratory to investigate in vivo toxicity of PLGA-nanocapsules containing\n\nUA. Theses results suggest the encapsulation cam be a potential alternative to allow the use of UA in cancer\n\ntherapy.\n\nINTRODU\u00c7\u00c3O\n\nA atividade antitumoral do \u00e1cido \u00fasnico foi descoberta h\u00e1 mais de duas d\u00e9cadas. O (+)\n\nAU isolado de esp\u00e9cies Cladoniaceaes foram reportados sendo ativos frente ao sistema\n\ncarcinoma de Lewis (1).\n\n\n\n129\n\nEstudos preliminares da atividade antitumoral do \u00e1cido \u00fasnico sobre o carcinoma de\n\npulm\u00e3o de Lewis em camundongos, evidenciaram que a sobrevida dos animais aumentou\n\nentre 35 a 52 % sobre o grupo controle n\u00e3o tratado (2).\n\nSabe-se, portanto, que a efici\u00eancia da atual quimioterapia do c\u00e2ncer \u00e9 limitada\n\nprincipalmente pela toxicidade associada com as drogas anticancer\u00edgenas aos tecidos normais,\n\n(3). O uso de nanopart\u00edculas biodegrad\u00e1veis para libera\u00e7\u00e3o controlada de drogas\n\nanticancer\u00edgenas tem apresentado vantagens no aumento da efic\u00e1cia terap\u00eautica e redu\u00e7\u00e3o dos\n\nefeitos adversos sist\u00eamicos (4).\n\nNestas ultimas d\u00e9cadas, in\u00fameros estudos t\u00eam corroborado que carreadores col\u00f3idais\n\nou polim\u00e9ricos podem modificar o perfil de distribui\u00e7\u00e3o do f\u00e1rmaco no organismo. Estes\n\nvetores medicamentosos protegem os princ\u00edpios ativos l\u00e1beis da penetra\u00e7\u00e3o celular de\n\nsubst\u00e2ncias hidrof\u00edlicas e proporcionam a libera\u00e7\u00e3o do f\u00e1rmaco no s\u00edtio de a\u00e7\u00e3o desejada\n\n(\u00f3rg\u00e3o, tecido ou c\u00e9lula), podendo potencializar a a\u00e7\u00e3o terap\u00eautica e tamb\u00e9m reduzir a\n\nquantidade de droga a ser administrada para obten\u00e7\u00e3o da resposta biol\u00f3gica, e com isso\n\nelimina ou minimiza os efeitos colaterais (4, 5, 6). Portanto, o objetivo deste estudo foi\n\ndesenvolver sistema de libera\u00e7\u00e3o de droga polim\u00e9rica para o \u00e1cido \u00fasnico aumentando sua\n\nefic\u00e1cia antitumoral.\n\nRecentes estudos da a\u00e7\u00e3o citot\u00f3xica in vitro do \u00fasnico livre e encapsulado frente\n\nc\u00e9lulas do c\u00e2ncer de pulm\u00e3o, linha celular NCI-H292, demonstraram claramente que o efeito\n\ncitot\u00f3xico  foi dose dependente (7). N\u00e3o obstante, acentuadas redu\u00e7\u00f5es dos efeitos citot\u00f3xicos\n\nforam visualizadas morfologicamente na cultura celular estudada, quando tratadas como \u00e1cido\n\n\u00fasnico encapsulado em nanoc\u00e1psulas de PLGA(\u00e1cido d,l-l\u00e1tico-co-glic\u00f3lico).  \u00c9 prov\u00e1vel que\n\na formula\u00e7\u00e3o desenvolvida pode ser considerada um sistema promissor para libera\u00e7\u00e3o in vivo\n\ndo \u00e1cido \u00fasnico.\n\nPara este prop\u00f3sito nanoc\u00e1psulas de PLGA contendo \u00e1cido \u00fasnico foram\n\ndesenvolvidas pelo m\u00e9todo de deposi\u00e7\u00e3o interfacial do pol\u00edmero. O PLGA foi utilizado,\n\n\n\n130\n\ndevido sua biocompatibilidade e biodegrada\u00e7\u00e3o, caracter\u00edsticas estas adequadas para\n\nprop\u00f3sitos farmac\u00eauticos. A atividade antitumoral do \u00e1cido \u00fasnico incorporado em\n\nnanoc\u00e1psulas de PLGA foi investigada frente ao tumor sarcoma-180 em camundongos,\n\navaliando-se o tempo de sobrevida.  Analises hematol\u00f3gica e histopatol\u00f3gica dos \u00f3rg\u00e3os e\n\ntumores dos animais tratados foram investigadas.\n\nMATERIAIS E M\u00c9TODOS\n\nMateriais\nPoli (D, L-\u00e1cido L\u00e1tico-co-\u00e1cido glic\u00f3lico) pol\u00edmero (PLGA) 50/50 foi comprado na\n\nBirmingham Polymers (USA); Fosfatidilcolina de soja (Epikuron? 200), foi obtido da Lucas\n\nMeyer (Germany); Poloxamer 188, (Pluronic ? F 68) foi generosamente cedido pela ICI\n\n(France); \u00f3leo de girassol foi obtido no Sigma Chemical (USA); fosfato de pot\u00e1ssio\n\nmonob\u00e1sico e hidr\u00f3xido de s\u00f3dio foram comprados na Merck (USA); acetona, clorof\u00f3rmio,\n\nxilol, dimetilsulf\u00f3xido (DMSO), e acetonitrila e metanol grau CLAE (Cromatografia L\u00edquida\n\nde Alta Efici\u00eancia), foram obtidos da Aldrich (USA); Meio Essencial M\u00ednimo, Eagle\n\nmodificado Dulbecco\u2019s (DMEM) foi comprado no Sigma Chemical; o soro fetal bovino,\n\npenicilina 1000 UI/ml, estreptomicina 250 mg/ml, L-glutamina 200 Mm foram obtidos na\n\nGIBCO (New York, USA); o corante Azul de Tripan foi obtido na Merck; o UA foi extra\u00eddo\n\ne purificado de Cladonia substellata no Laborat\u00f3rio de Qu\u00edmica da Universidade Federal de\n\nMato Grosso do Sul, Brasil e cedidos gentilmente pela Prof. Dra. Nely Kika Honda. O\n\nmaterial liqu\u00eanico foi coletado sobre solos arenosos em Mamanguape, Para\u00edba e identificadas\n\npelas caracter\u00edsticas morfol\u00f3gicas e qu\u00edmicas do talo. Parte do material foi acondicionado em\n\nenvelopes de papel em quantidades suficientes para dep\u00f3sito em herb\u00e1rio (UFP), e o restante\n\nfoi enviado para ser submetido ao processo de extra\u00e7\u00e3o e purifica\u00e7\u00e3o do UA.\n\n\n\n131\n\nAnimais experimentais\n\nOs animais utilizados foram camundongos albinos su\u00ed\u00e7os, (mus-musculus), f\u00eameas com\n\nidade de 35 a 60 dias e peso m\u00e9dio de 30,0 g, provenientes do Biot\u00e9rio do Laborat\u00f3rio de\n\nImunopatologia Keiso Asami-Lika-UFPE, considerando-se peso, sanidade e aspecto geral. Os\n\nanimais foram mantidos \u00e0 temperatura ambiente a 28 \u00b0C \u00b1 2 \u00b0C, sob ciclo dia/noite natural\n\n(12h luz e 12h escuro), com livre acesso de \u00e1gua e alimento durante o experimento e\n\ndistribu\u00eddos em grupos segundo delineamento experimental.\n\nM\u00e9todos\n\nObten\u00e7\u00e3o de nanoc\u00e1psulas de PLGA contendo \u00e1cido \u00fasnico\n\nNanoc\u00e1psulas de PLGA contendo \u00e1cido \u00fasnico (UA-NC) foram obtidas segundo o m\u00e9todo de\n\ndeposi\u00e7\u00e3o interfacial do pol\u00edmero pr\u00e9-formado proposto por (8). Uma mistura org\u00e2nica\n\nconstitu\u00edda pelo pol\u00edmero PLGA, fosfatidilcolina de soja (Epikuron? 200), \u00f3leo de girassol e\n\no \u00e1cido \u00fasnico, dilu\u00eddos em acetona, foi introduzido lentamente na fase aquosa constitu\u00edda de\n\ntamp\u00e3o fosfato pH 7,4 e poloxamer, sob agita\u00e7\u00e3o moderada. As nanoc\u00e1psulas foram formadas\n\nimediatamente ap\u00f3s a mistura, e permaneceu em agita\u00e7\u00e3o por 30 minutos. Ap\u00f3s a suspens\u00e3o\n\ncoloidal foi concentrada sob press\u00e3o reduzida a um volume de 20% do inicial, no intuito de se\n\nevaporar o solvente org\u00e2nico e ajustes da concentra\u00e7\u00e3o final do UA.\n\nCaracteriza\u00e7\u00e3o f\u00edsico-qu\u00edmica das formula\u00e7\u00f5es de nanoc\u00e1psulas de PLGA\n\ncontendo \u00e1cido \u00fasnico\n\nAs an\u00e1lises f\u00edsico-qu\u00edmicas de UA-NC foram  realizadas imediatamente ap\u00f3s prepara\u00e7\u00e3o e ent\u00e3o\n\nsubmetidas a intervalos de tempo regular. Diversos par\u00e2metros tais como aspecto macrosc\u00f3pico e microsc\u00f3pico,\n\nvaria\u00e7\u00e3o de pH e determina\u00e7\u00e3o da taxa de encapsula\u00e7\u00e3o foram realizadas.\n\n\n\n105\n\nAtividade antitumoral de UA-NC\n\nEste estudo foi realizado com o objetivo de avaliar a atividade antitumoral in vivo de\n\nUA-NC frente ao tumor sarcoma-180. C\u00e9lulas do tumor asc\u00edtico (5,0 x 106 c\u00e9lulas ml \u20131)\n\nforam inoculadas via subcut\u00e2nea (s.c) na regi\u00e3o dorsal direita do camundongo.\n\nO tratamento foi iniciado, 24 h ap\u00f3s inocula\u00e7\u00e3o por 7 dias consecutivos. Inje\u00e7\u00f5es de\n\nsolu\u00e7\u00f5es de \u00e1cido \u00fasnico livre, UA-NC e o placebo foram administrados intraperitonealmente\n\nnuma dose equivalente a 15 mg/ 10 g de peso vivo do animal. A solu\u00e7\u00e3o de \u00e1cido \u00fasnico foi\n\npreparada em solu\u00e7\u00e3o est\u00e9ril de NaCl a 0,9% contendo Tween 80 a 0,05% (v/v). Os animais\n\ndo grupo controle foram tratados com solu\u00e7\u00e3o de NaCl a 0,9 est\u00e9ril, em id\u00eanticas condi\u00e7\u00f5es.\n\nAp\u00f3s uma semana de tratamento, foram realizadas coletas de sangue para an\u00e1lises\n\nhematol\u00f3gicas e finalmente os animais foram sacrificados. Tumores foram removidos e\n\npesados e os \u00f3rg\u00e3os (f\u00edgado, rins e ba\u00e7o) foram dissecados e submetidos a estudos\n\nhistopatol\u00f3gicos. A inibi\u00e7\u00e3o tumoral foi determinada a partir do peso m\u00e9dio dos grupos de\n\nanimais tratados em rela\u00e7\u00e3o ao grupo controle n\u00e3o tratado.\n\nPara o c\u00e1lculo da m\u00e9dia dos pesos dos tumores dos grupos controle foi desconsiderado\n\naqueles cujos pesos corresponderam a 0,39 g ou menos, denominados \u201cno-takes\u201d (9).\n\nEstudo histopatol\u00f3gicas de tumores e \u00f3rg\u00e3os\n\nOs \u00f3rg\u00e3os dos animais (f\u00edgado, ba\u00e7o e rins)  e tumor foram submetidos a an\u00e1lises histopatol\u00f3gicas. Os\n\ntecidos foram mantidos em solu\u00e7\u00e3o tamponada de formalina a 10% at\u00e9 inclus\u00f5es em parafina. Cortes (4 \u00b5m) da\n\namostra de tecidos, fixados em Hematoxilina e corados em Eosina (HE) foram analisados por microsc\u00f3pio\n\n\u00f3ptico (Olympus BH-2, Japan).\n\nAn\u00e1lises hematol\u00f3gicas\n\nAs amostras de sangue dos camundongos foram submetidas a determina\u00e7\u00f5es de \u00edndices hematim\u00e9tricos\n\ntais como: hemat\u00f3crito e n\u00famero total de hem\u00e1cias e leucograma (contagem total e diferencial de leuc\u00f3citos).\n\n\n\n106\n\nEstudo da sobrevida de camundongos transplantados com S-180 e tratados com\n\nnanoc\u00e1psulas de PLGA contendo \u00e1cido \u00fasnico\n\nEste estudo foi realizado em camundongos transplantados com S-180 com objetivo de se avaliar a\n\nsobrevida dos animais tratados com a solu\u00e7\u00e3o de  UA livre e UA-NC. Foram constitu\u00eddos quatro grupos de dez\n\nanimais. Decorridos, 24 horas do implante, os animais foram submetidos a tratamento durante uma semana, e\n\npermaneceram em observa\u00e7\u00e3o at\u00e9 a morte. Foi analisados o comportamento (depressivo ou excitado), aspectos\n\nde pelagem, perdas de peso, dispin\u00e9ia e presen\u00e7a de fezes na regi\u00e3o peri-anal.\n\nAn\u00e1lise estat\u00edstica\n\nOs dados experimentais representam a m\u00e9dia e o erro padr\u00e3o da m\u00e9dia (m\u00e9dia \u00b1 desvio\n\npadr\u00e3o) dos valores obtidos para cada grupo.\n\nOs resultados obtidos foram submetidos \u00e0 an\u00e1lise de vari\u00e2ncia e os efeitos dos\n\ntratamentos foram avaliados pelo teste F (p &lt;0,05). As compara\u00e7\u00f5es das m\u00e9dias dos\n\ntratamentos foram realizadas pelo teste de Turkey (p &lt;0,05). Letras iguais n\u00e3o diferem\n\nsignificativamente (p &lt;0,05).\n\nRESULTADOS E DISCUSS\u00c3O\n\nAtividade antitumoral de nanoc\u00e1psulas de PLGA contendo \u00e1cido \u00fasnico\n\nRecentes investiga\u00e7\u00f5es v\u00eam demonstrando que o perfil de distribui\u00e7\u00e3o de f\u00e1rmacos\n\nanticancer\u00edgenos pode ser controlado pela sua encapsula\u00e7\u00e3o em sistemas coloidais\n\nsubmicr\u00f4nicos (nanopart\u00edculas). Estes vetores proporcionam o aumento da efic\u00e1cia\n\nantitumoral reduzindo, portanto, os efeitos colaterais (1).\n\nPara comparar a efic\u00e1cia relativa do \u00e1cido \u00fasnico livre e encapsulado em nanoc\u00e1psulas\n\nde PLGA, uma semana ap\u00f3s o tratamento dos camundongos, foram realizadas pesagens da\n\nmassa tumoral de sarcoma-180, obtidos atrav\u00e9s de implantes das c\u00e9lulas por via subcut\u00e2nea.\n\n No tratamento foi utilizada uma dose de 15 mg/kg, correspondente a d\u00e9cima parte da DL50 (9).\n\n\n\n107\n\nA varia\u00e7\u00e3o m\u00e9dia na massa tumoral (10 animais/grupo), ap\u00f3s os diferentes tratamentos\n\nrealizados, foi expresso na Figura 1. O grupo n\u00e3o tratado (controle) revelou um progressivo\n\naumento do crescimento tumoral. No 8\u00b0 dia ap\u00f3s implanta\u00e7\u00e3o das c\u00e9lulas tumorais, o peso\n\nm\u00e9dio do grupo controle foi 1,017 \u00b1 0,15 g. Administra\u00e7\u00e3o de nanoc\u00e1psulas de PLGA\n\nresultou em aumento espont\u00e2neo na massa tumoral similar ao que foi observado no grupo\n\ncontrole (0,995 \u00b1 0,05 g). O tratamento dos animais com o \u00e1cido \u00fasnico livre, resultou em\n\nredu\u00e7\u00e3o gradual no tamanho do tumor (0,613 \u00b1 0,019 g). Comparativamente, o grupo tratado\n\ncom \u00e1cido \u00fasnico encapsulado em nanoc\u00e1psulas, demonstrou uma r\u00e1pida regress\u00e3o na massa\n\ntumoral de 0,281 \u00b1  0,013 g.\n\nEstes resultados demonstram claramente que a encapsula\u00e7\u00e3o apresentou maior efeito regressivo do que\n\no \u00e1cido \u00fasnico livre. Em termos de inibi\u00e7\u00e3o tumoral pode-se evidenciar que o grupo tratado com UA-NC,\n\napresentou uma inibi\u00e7\u00e3o de 69,7 \u00b1 6 % em rela\u00e7\u00e3o ao controle. A encapsula\u00e7\u00e3o potencializou a sua a\u00e7\u00e3o\n\ninibit\u00f3ria em 22 %, quando comparado ao \u00e1cido \u00fasnico livre, o qual exibiu uma inibi\u00e7\u00e3o de apenas de 43,03 \u00b1\n\n4,2 % em rela\u00e7\u00e3o ao controle (Figura 2).\n\nEstes resultados s\u00e3o corroborados pelos diversos trabalhos na literatura que demonstram o efeito\n\npotencializador de nanoencapsula\u00e7\u00e3o sobre a atividade de f\u00e1rmacos anticancer\u00edgenos. Recentes estudos t\u00eam\n\ncomprovado que o uso de pol\u00edmeros biodegrad\u00e1veis para prepara\u00e7\u00e3o de micro/nanopart\u00edculas para libera\u00e7\u00e3o\n\ncontrolada de f\u00e1rmacos anticancer\u00edgenos tem apresentando grandes vantagens no aumento da efici\u00eancia\n\nterap\u00eautica e redu\u00e7\u00e3o dos efeitos adversos via sist\u00eamica (4).\n\nPesquisando a efic\u00e1cia anti-tumoral de nanopart\u00edculas de quitosana contendo\n\ndoxorrubicina complexada a dextrana em modelo de tumor murino (3), foi constatado que a\n\nconjuga\u00e7\u00e3o da dextrana a este anticancer\u00edgeno reduziu a toxicidade do f\u00e1rmaco livre,\n\napresentando uma potencializa\u00e7\u00e3o da atividade antitumoral.\n\nEstudos realizados da atividade antitumoral da Doxorrubicina conjugada com PLGA\n\n(DOX-PLGA) e encapsulada em nanopart\u00edculas, relatam que uma simples inje\u00e7\u00e3o de\n\nnanopart\u00edculas contendo DOX-PLGA demonstrou atividade antitumoral similar a di\u00e1rias\n\naplica\u00e7\u00f5es de DOX livre, demonstrado que a mistura de DOX a olig\u00f4meros de PLGA\n\nliberados das nanopart\u00edculas tem significante atividade antitumoral (11).\n\n\n\n108\n\nInje\u00e7\u00f5es acumulativas sobre tumor sarcoma de Ewing de nanoc\u00e1psulas contendo\n\noligonucleot\u00eddeos antisense (14,4 nmol) inibiram gradualmente a massa tumoral quando\n\ncomparada ao tratamento di\u00e1rio deste composto livre (12).\n\nEstudos da atividade antitumoral de microesferas de PLGA contendo metotrexate\n\n(MTX), demonstraram que, uma simples aplica\u00e7\u00e3o de MXT livre n\u00e3o foi ativa no decr\u00e9scimo\n\ndo volume tumoral do sarcoma-180, todavia uma redu\u00e7\u00e3o tumoral significativa foi observada\n\nnos animais tratados com o MXT encapsulado (13).\n\nEstudo histopatol\u00f3gicos de tumores e \u00f3rg\u00e3os tratados com \u00e1cido \u00fasnico livre e\n\nencapsulado\n\nO tratamento dos animais com o UA livre e encapsulado provocaram uma menor\n\ndensidade de c\u00e9lulas tumorais. No tecido tumoral foram evidenciadas necroses em\n\ndesenvolvimento, n\u00facleos picn\u00f3ticos descaracterizados, c\u00e9lulas em constante divis\u00e3o e focos\n\nde \u00e1reas de necroses, principalmente nas regi\u00f5es centrais do tumor (Figura 3b e c). N\u00e3o\n\nobstante, intensas \u00e1reas de necroses foram verificadas no tumor dos animais tratados com\n\nUA-NC (Figura 3c).\n\nAnalisando o tecido do f\u00edgado dos animais submetidos a tratamento com o UA livre,\n\nobservou-se que os hepat\u00f3citos apresentaram intensa vacuoliza\u00e7\u00e3o citoplasm\u00e1tica,\n\ndemonstrando-se bastante descaracterizados. Tamb\u00e9m foi evidenciada a presen\u00e7a de um\n\ninfiltrado leucocit\u00e1rio na regi\u00e3o porta do animal, aglomerados de c\u00e9lulas linfocit\u00e1rias em\n\ntorno do ducto, bem como a presen\u00e7a de neutr\u00f3filos em toda extens\u00e3o do tecido. Estes\n\nresultados sugerem que o tratamento com UA livre provocou o desenvolvimento de um\n\nprocesso inflamat\u00f3rio ao n\u00edvel de hepat\u00f3citos. Por outro lado, quando os animais foram\n\nsubmetidos ao tratamento com UA-NC, observou-se apenas os hepat\u00f3citos apresentaram-se\n\nmorfologicamente descaracterizados (Figura 4).\n\nN\u00e3o foram evidenciadas altera\u00e7\u00f5es histol\u00f3gicas ao n\u00edvel de rins e ba\u00e7o em todos os grupos tratados com\n\nUA livre e encapsulado.\n\n\n\n109\n\nAvalia\u00e7\u00e3o dos par\u00e2metros hematol\u00f3gicos dos animais tratados com \u00e1cido \u00fasnico livre e\n\nencapsulado.\n\nOs dados obtidos dos \u00edndices hematim\u00e9ticos das amostras de sangue coletadas nos\n\ncamundongos implantados com sarcoma-180 tratados com \u00e1cido \u00fasnico livre (UA),\n\nnanoc\u00e1psulas de PLGA contendo \u00e1cido (UA-NC) e o placebo (NC) foram submetidos \u00e0\n\nan\u00e1lise de vari\u00e2ncia e os efeitos dos tratamentos foram avaliados pelo teste F (p &lt;0.05). As\n\ncompara\u00e7\u00f5es das m\u00e9dias dos tratamentos foram realizadas pelo teste de Turkey (p &lt;0.05).\n\nLetras iguais n\u00e3o diferem significativamente (p &lt;0,05).\n\nOs resultados da contagem diferencial de leuc\u00f3citos do grupo n\u00e3o tratado, controle\n\nnegativo (-), est\u00e3o de acordo com o padr\u00e3o referenciado na literatura (14, 15) (Tabela 1).\n\nAs an\u00e1lises da vari\u00e1vel hem\u00e1cia totais (Figura 5), revelaram que o tratamento com UA livre, provocou\n\numa diminui\u00e7\u00e3o significativa nos valores das hem\u00e1cias totais (p &lt;0,05), quando comparado ao grupo controle (-)\n\ne (+), respectivamente. Vale ressaltar, que os animais tratados com UA-NC e NC, permaneceram com taxas de\n\nhem\u00e1cias totais semelhantes ao controle (+). O tratamento com UA livre provocou uma dr\u00e1stica redu\u00e7\u00e3o no\n\nn\u00famero de hem\u00e1cias, sugerindo uma a\u00e7\u00e3o t\u00f3xica do mesmo sobre as hem\u00e1cias.\n\nOs \u00edndices de hemat\u00f3critos, leuc\u00f3citos totais e diferenciais (neutr\u00f3filos, bas\u00f3filos,\n\neosin\u00f3filos e mon\u00f3citos) n\u00e3o demonstraram diferen\u00e7as nos tratamentos realizados, quando\n\ncomparado ao controle (+) (p &lt;0,05). Por outro lado, os valores de linf\u00f3citos reduziram\n\nsignificativamente, quando os animais foram tratados com UA livre, em rela\u00e7\u00e3o ao grupo\n\ncontrole (+). Vale ressaltar que o tratamento com UA-NC, beneficiou ainda mais os animais,\n\nreduzindo significativamente a contagem diferencial de linf\u00f3cito, quando comparado ao\n\ncontrole (+), n\u00e3o apresentando, portanto, diferen\u00e7as significativas (p &lt;0,05) aos valores do\n\ncontrole (-) ou seja, animais sadios (Figura 6). Estes dados complementam os resultados\n\nevidenciados microscopicamente no tecido hep\u00e1tico dos animais tratados com UA-NC, os\n\nquais exibiram redu\u00e7\u00e3o do n\u00famero de c\u00e9lulas leucocit\u00e1rias em toda extens\u00e3o do tecido,\n\nquando comparado aos animais tratados com UA livre. Sup\u00f5e-se, desta maneira, que o\n\n\n\n110\n\ntratamento com UA-NC beneficie o animal reduzindo os prov\u00e1veis processos inflamat\u00f3rios\n\ncausados pelo UA livre.\n\nAvalia\u00e7\u00e3o da sobrevida de camundongos transplantados com sarcoma-180 e tratados\n\ncom nanoc\u00e1psulas de PLGA contendo \u00e1cido \u00fasnico\n\nNo estudo de sobrevida dos camundongos transplantados com sarcoma-180, foi\n\nobservado que na primeira semana de tratamento, os animais tratados UA livre e encapsulado\n\napresentaram-se clinicamente est\u00e1veis. A partir a segunda semana, 50 % dos animais tratados\n\ncom a suspens\u00e3o de UA morreram, chegando aos 100 % de \u00f3bitos, vinte e um dias ap\u00f3s o\n\nimplante do tumor. Estes apresentaram p\u00ealos eri\u00e7ados, perda de peso, reflexos reduzidos,\n\ndispn\u00e9ia e, conseq\u00fcentemente, morte.\n\nNos grupos de animais tratados com UA-NC, 50 % de \u00f3bitos foram evidenciados a\n\npartir do vig\u00e9simo dia de tratamento, notando-se tamb\u00e9m que 13 % de animais permaneceram\n\nvivos durante 30 dias. Neste mesmo per\u00edodo, os camundongos apresentaram um quadro\n\ncl\u00ednico semelhante aos grupos que receberam a suspens\u00e3o de UA, sendo, portanto, averiguada\n\nque a dispn\u00e9ia ocorreu nos indiv\u00edduos de forma mais acentuada. O grupo controle, onde os\n\nanimais foram tratados com a solu\u00e7\u00e3o de NaCl a 0,9% a presen\u00e7a de \u00f3bitos foi evidenciada a\n\npartir da segunda semana ap\u00f3s o implante. Ao vig\u00e9simo dia, observou 50 % de \u00f3bitos,\n\nchegando a 100 % ap\u00f3s vinte e cinco dias. Estes resultados demonstraram que UA-NC\n\naumentou a sobrevida dos animais, em torno de 30 %, quando comparado ao grupo controle\n\nde animais n\u00e3o tratados (Figura 7).\n\nEstudando a atividade antitumoral de microesferas de PLGA contendo MTX contra\n\ntumor sarcoma-180 em camundongo, (13), foi evidenciado um aumento duplicado no tempo\n\nde sobrevida do grupo de animais que receberam MTX encapsulado (18 \u00b1 2,7 dias), em\n\nrela\u00e7\u00e3o \u00e0queles que receberam uma simples  inje\u00e7\u00e3o subcut\u00e2nea de MTX livre (8 \u00b1 0,7 dias).\n\n\n\n111\n\nAnalisando a atividade antitumoral de DOX livre, complexada a dextrana (DOX-\n\nDXR), e DOX-DXR encapsulada em nanopart\u00edculas de hidrogel (3) foi relatado um aumento\n\nna sobrevida dos animais tratados com DOX-DXR encapsulada em 50 %, quando comparado\n\naos grupos tratados com a solu\u00e7\u00e3o de DOX-DXR, no mesmo per\u00edodo estudado.\n\nA melhor performance desenvolvida pelo grupo que recebeu nanopart\u00edculas,\n\nespecialmente em rela\u00e7\u00e3o \u00e0 expectativa de vida, pode ser atribu\u00edda a alta acumula\u00e7\u00e3o de\n\nnanopart\u00edculas nos tecidos tumorais, e a gradual libera\u00e7\u00e3o do f\u00e1rmaco no s\u00edtio ativo. A\n\nencapsula\u00e7\u00e3o reduz a toxicidade da droga livre, resultando em sua \u00f3tima efic\u00e1cia (3,1).\n\nCONCLUS\u00d5ES\n\nA encapsula\u00e7\u00e3o do \u00e1cido \u00fasnico em nanoc\u00e1psulas de PLGA foi capaz de manter e potencializar a a\u00e7\u00e3o\n\nantitumoral em 22 %, aumentando o tempo de sobrevida dos animais em torno de 30 %, quando comparado ao\n\n\u00e1cido \u00fasnico livre. Intensas \u00e1reas de necroses foram evidenciadas nas regi\u00f5es centrais do tumor, principalmente\n\nnos animais tratados com nanoc\u00e1psulas de PLGA contendo \u00e1cido \u00fasnico. \u00c9 prov\u00e1vel que o tratamento com o\n\n\u00e1cido \u00fasnico encapsulado beneficie o animal, reduzindo, portanto, suas a\u00e7\u00f5es t\u00f3xicas ao n\u00edvel de hepat\u00f3citos.\n\nTabela 1. Valores leucocit\u00e1rios de camundongos segundo a literatura\n\nContagem diferencial (103/mm3)Contagem Total\n(Leuc\u00f3citos/mm3) Neutr\u00f3filos Bas\u00f3filos Eosin\u00f3filos linf\u00f3citos mon\u00f3citos\n\nSouza, 1993 3.500 e 7.500 19.0 0.0 0.5 65.0 e\n80.0\n\n0.0 e 0.7\n\nYoshida, 2000 4.900 e 9.000 28.6 - 1.0 e 1.5 57.0 e\n80.0\n\n0.9 e 2.7\n\nControle (-)* 6.300 e 7.000 10.0 e 30.0 0.0 0.0 50.4 e\n55.2\n\n0.3 e 0.13\n\n* Animais sadios do laborat\u00f3rio\n\n\n\n112\n\nFigura 1. Varia\u00e7\u00e3o da massa tumoral dos animais tratados com \u00e1cido \u00fasnico livre e\n\nencapsulado contra tumor s\u00f3lido sarcoma-180: NC= nanoc\u00e1psulas de PLGA brancas; UA=\n\n\u00e1cido \u00fasnico livre; UA-NC= nanoc\u00e1psulas de PLGA contendo \u00e1cido \u00fasnico. Os efeitos dos\n\ntratamentos foram avaliados pelo teste F (p &lt;0,05). As compara\u00e7\u00f5es das m\u00e9dias foram\n\nrealizadas pelo teste de Turkey (p &lt;0,05). Letras iguais n\u00e3o diferem significativamente (p&lt;\n\n0,05).\n\nc\n\n\n\n113\n\n0\n10\n20\n30\n40\n50\n60\n70\n80\n\nNC UA UA-NC\n\nGrupos\n\nIn\nib\n\ni\u00e7\n\u00e3\no\n\n t\nu\n\nm\no\n\nra\nl \n(%\n\n)\n\nFigura 2. Avalia\u00e7\u00e3o da atividade antitumoral do \u00e1cido \u00fasnico livre e encapsulado contra\n\ntumora sarcoma-180: NC= nanoc\u00e1psulas de PLGA brancas; UA= \u00e1cido \u00fasnico livre; UA-\n\nNC= nanoc\u00e1psulas de PLGA contendo \u00e1cido \u00fasnico.\n\n\n\n114\n\nFigura 3. An\u00e1lises histol\u00f3gicas do tumor sarcoma-180 nos animais tratados (H &amp; E \u2013 50X):\na) controle; b) \u00e1cido \u00fasnico livre; c) nanoc\u00e1psulas de PLGA contendo \u00e1cido \u00fasnico. Legenda:\nNP= N\u00facleos picn\u00f3ticos, NC= Necrose.\n\nc\n\na\n\nb\n\nNC\n\nNC\n\nc\n\n\n\n115\n\nFigura 4. An\u00e1lises histol\u00f3gicas do f\u00edgado nos animais tratados (H &amp; E \u2013 50X): a) controle; b)\n\n\u00e1cido \u00fasnico livre; c) nanoc\u00e1psulas de PLGA contendo \u00e1cido \u00fasnico. Legenda: IL= Infiltrado\n\nleucocit\u00e1rio,  HD= Hepat\u00f3citos descaracterizados, VC= Vacuoliza\u00e7\u00e3o citoplasm\u00e1tica.\n\nHD\n\nVC\n\nIF\n\nHD\n\na\n\nb\n\nc\n\n\n\n116\n\nFigura 5. Contagem de hem\u00e1cias totais (Hem/mm3) da amostra de sangue de camundongos\n\nsubmetidos a tratamentos com \u00e1cido \u00fasnico livre e encapsulado comparado a animais n\u00e3o\n\ntratados. As compara\u00e7\u00f5es das m\u00e9dias foram realizadas pelo teste de Turkey (p &lt;0,05). Letras\n\niguais n\u00e3o diferem significativamente (p &lt;0,05).\n\nLegenda: Controle (+) = animais transplantados com sarcoma-180 n\u00e3o tratados; UA= \u00e1cido\n\n\u00fasnico livre; UA-NC = nanoc\u00e1psulas de PLGA contendo \u00e1cido \u00fasnico;  NC= nanoc\u00e1psulas de\n\nPLGA brancas; Controle (-) = animais sadios do laborat\u00f3rio.\n\n\n\n117\n\nFigura 6. Contagem diferencial de linf\u00f3citos (103/mm3) da amostra de sangue de\n\ncamundongos submetidos a tratamentos com \u00e1cido \u00fasnico livre e encapsulado comparado a\n\nanimais n\u00e3o tratados. As compara\u00e7\u00f5es das m\u00e9dias foram realizadas pelo teste de Turkey (p&lt;\n\n0,05). Letras iguais n\u00e3o diferem significativamente (p &lt;0,05).\n\nLegenda: Controle (+) = animais transplantados com sarcoma-180 n\u00e3o tratados; UA= \u00e1cido\n\n\u00fasnico livre; UA-NC= nanoc\u00e1psulas de PLGA contendo \u00e1cido \u00fasnico;  NC= nanoc\u00e1psulas de\n\nPLGA brancas; Controle (-) = animais sadios do laborat\u00f3rio.\n\n\n\n110\n\n0%\n\n20%\n\n40%\n\n60%\n\n80%\n\n100%\n\n120%\n\n1 6 11 16 21 26\n\nTempo (dias)\n\nA\nn\n\nim\na\n\nis\n v\n\niv\no\n\ns\n (\n\n%\n)\n\nControle  UA UA-NC\n\nFigura 7. Avalia\u00e7\u00e3o da sobrevida de camundongos vivos transplantados com sarcoma-180 ap\u00f3s o tratamento com \u00e1cido \u00fasnico livre e\n\nencapsuladocom rela\u00e7\u00e3o ao controle (animais n\u00e3o tratados) : UA= \u00e1cido \u00fasnico livre; UA-NC= nanoc\u00e1psulas de PLGA contendo \u00e1cido \u00fasnico.\n\n\n\nRREFER\u00caNCIAS BIBLIOGR\u00c1FICAS\n\n[1] K. Muller, Pharmaceutically relevant metabolites from lichens, Appl. Microbiol.\n\nBiotechnol. 56 (2001) 9- -16.\n\n[1] I. Brigger, C. Dubernet, P. Couvreur, Nanoparticles in cancer therapy and diagnosis, Adv.\n\nDrug Del. Rev. 54 (2002) 631- -351.\n\n[2] M. Takai, Y. Uehara, J.A. Beisler, usnic acid derivatives as potential antineoplastic agents.\n\nJ. Med. Chem. 22(11) (1979) 1380- -1384.\n\n[3] S. Mitra, U. Gaur, P.C. Ghosh, A.N. Maitra, Tumor targeted delivery of encapsulate\n\ndextran-doxorubicin conjugate using chitosan nanoparticles as carrier, J. Control. Rel. 74\n\n(2001) 317- -323.\n\n[4] S-S. Feng, L. Mu, B.H. Chen, D. Pack, Polymeric nanospheres fabricated with natural\n\nemulsifiers for clinical administration of an anticancer drug paclitaxel (Taxol?), Mat. Sc.\n\nEngineering, 20 (2002) 85- -92.\n\n[5] B. Magenheim, S. Benita, Nanoparticles characterization: a comprehensive\n\nphysicochemical approach. S.T. P. Pharm. Sci. 1(4) (1991) 221- -241.\n\n[6] M-L. Hans, A.M. Lowman, Biodegradable nanoparticles for drug delivery and targeting.\n\nC S S Mat. Sci. 1 (2002) 212- -218.\n\n[7] N-P. Santos, S-C. Nascimento, E-C. Pereira, N-H. Silva, N-K. Honda, N.S. Santos-\n\nMagalh\u00e3es, J. Tox Vitro. (no prelo), 2003.\n\n[8] H. Fessi, F. Puisieux, J-P. Devissaguet, N.E. Ammoury, S. Benita, Nanocapsules\n\nformation by interfacial polymer deposition following solvent displacement, Int. J. Pharm. 55\n\n(1989) 1- -4.\n\n[9] R-I. Geran, N.H. Greenberg, M.M.  Macdonald, A.M. Schumacher, B. J. Abbott, Protocols\n\nfor screeening chemical agents and natural products against animal and other biological\n\nsystems, Cancer Chemoth. Report. 3 (1972) 112p.\n\n\n\n2\n\n[10] E-C. Pereira, S.C. Nascimento, R.C. Lima, N.H. Silva,  A.F. Oliveira, E. Bandeira, M.\n\nBoitard, H. Beriel, C. Vicente, M. E.  Legaz, Analysis of usnea Fasciata crude extracts with\n\nantineoplasic activity. Tokai Exp. Clin. M\u00e9d. 19(1,2) (1994) 47 - -52.\n\n[11] H-S. Yoo, K.H. Lee, J.E. Oh, T.G. Park, In vitro and In vivo anti-tumor activities of\n\nnanoparticles based on doxorobucin-PLGA conjugates, J. Control. Releas. 68 (2000) 419-431.\n\n[12] G. Lambert, J.R. Bertrand, E. Fattal, F. Subra, H. Pinto-Alphandary, C. Malvy, P.\n\nCouvreur, EWS Fli-1 Antisense nanocapsules inhibits Ewing sarcoma-related tumor in mice,\n\nBiochem. Biophys. Res. Commun.  279 (2000) 401- -409.\n\n[13] U-V. Singh, N. Udupa, In vitro characterization of methotrexate loaded poly (lactic-co-\n\nglycolic) acid microspheres and antitumor efficacy in Sarcoma-180 mice bearing tumor.\n\nPharm. Acta Helvetiae, 72 (1997) 165- -173.\n\n[14] M.C.B Sousa, Influ\u00eancia da dose esquema de administra\u00e7\u00e3o de Corynebacterium parvum\n\ninativado, CEPA DAUFPE n.187, sobre o eritograma, leucograma e perfil prot\u00e9ico de\n\ncamundongos, Mus musculus, tese de mestrado, UFPE,Brasil 1993, 114p.\n\n[15] H-S. Yoshida, Valores hematol\u00f3gicos e bioqu\u00edmicos em linhagens de camundongos\n\nisog\u00eanica A/NELL, Balb/c, C57BL/6 e heterog\u00eanica su\u00ed\u00e7a., Revista Bras. M\u00e9d. Vet., 22:3\n\n(2000) 122- -124.\n\n\n\n3\n\nAGRADECIMENTOS\n\nO primeiro autor foi mantido pela bolsa de estudo PhD CAPES. E.C.P. e N.S.S.M. s\u00e3o gratos\n\nao Conselho Brasileiro de Desenvolvimento de Pesquisa Tecnol\u00f3gica -CNPq, pela concess\u00e3o\n\nde financiamento individual.\n\n\n\n4\n\nCONCLUS\u00d5ES\n\n\n\n5\n\n3. CONCLUS\u00d5ES\n\n\u2022 Nanoc\u00e1psulas de PLGA contendo \u00e1cido \u00fasnico foram obtidas numa concentra\u00e7\u00e3o\n\nm\u00e1xima de 1mg/ml, devido \u00e0 limitada solubilidade do UA no \u00f3leo de girassol.\n\n\u2022 O m\u00e9todo de deposi\u00e7\u00e3o interfacial do pol\u00edmero utilizado na fabrica\u00e7\u00e3o de\n\nnanoc\u00e1psulas de PLGA contendo UA foi eficiente. Foram obtidas part\u00edculas esf\u00e9ricas\n\ncom di\u00e2metro m\u00e9dio de 367 \u00b1 81 nm, na forma de suspens\u00e3o coloidal, apresentando\n\num conte\u00fado de \u00e1cido \u00fasnico de 100% com uma taxa de encapsula\u00e7\u00e3o de 99%,\n\ncaracter\u00edsticas de f\u00e1rmacos lipof\u00edlicos. Estes dados indicam que a integridade do UA\n\nfoi preservada durante o processo de fabrica\u00e7\u00e3o.\n\n\u2022 As suspens\u00f5es de nanoc\u00e1psulas fabricadas, conservaram suas propriedades f\u00edsico-\n\nqu\u00edmicas e mantiveram estabilidade por 120 dias quando armazenadas a 4\u00b0C \u00b1 1\u00b0C.\n\nQuando liofilizadas permaneceram est\u00e1veis mantendo o conte\u00fado de UA durante \u00b1 36\n\nmeses.\n\n\u2022 O perfil cin\u00e9tico de libera\u00e7\u00e3o in vitro demonstrou que nanoc\u00e1psulas de PLGA\n\ncontendo \u00e1cido \u00fasnico poder\u00e3o ser utilizadas como sistema de libera\u00e7\u00e3o controlada.\n\n\u2022 As concentra\u00e7\u00f5es requeridas para inibir 50% do crescimento celular (IC50) das c\u00e9lulas\n\nde c\u00e2ncer de pulm\u00e3o NCI-H 292, apresentaram-se na mesma ordem de magnitude para\n\no \u00e1cido \u00fasnico livre e encapsulado, respectivamente.\n\n\u2022 Microscopicamente, o \u00e1cido \u00fasnico livre provocou uma intensa redu\u00e7\u00e3o da prolifera\u00e7\u00e3o\n\ncelular e vacuoliza\u00e7\u00e3o citoplasm\u00e1tica na cultura celular estudada. Por outro lado\n\nvisualizou-se uma acentuada redu\u00e7\u00e3o destes efeitos citot\u00f3xicos quando as c\u00e9lulas NCI-\n\nH 292 foram  tratadas com nanoc\u00e1psulas de PLGA contendo \u00e1cido \u00fasnico.\n\n\u2022 A encapsula\u00e7\u00e3o do \u00e1cido \u00fasnico foi capaz de manter e potencializar sua a\u00e7\u00e3o antitumoral em torno 22 %\n\nem rela\u00e7\u00e3o ao acido \u00fasnico livre, aumentando o tempo de sobrevida dos animais transplantados com o\n\nsarcoma-180.\n\n\n\n6\n\n\u2022 O tratamento dos animais com o acido \u00fasnico livre e encapsulado provocou uma menor densidade das\n\nc\u00e9lulas tumorais, evidenciado-se intensas \u00e1reas de necroses, principalmente nas regi\u00f5es centrais do\n\ntumor dos animais tratados com nanoc\u00e1psulas de PLGA contendo \u00e1cido \u00fasnico.\n\n\u2022 A encapsula\u00e7\u00e3o do \u00e1cido \u00fasnico em nanoc\u00e1psulas de PLGA reduziu as a\u00e7\u00f5es t\u00f3xicas representadas ao\n\nn\u00edvel de hepat\u00f3citos. N\u00e3o foram notadas altera\u00e7\u00f5es morfol\u00f3gicas em n\u00edvel de rins em todos os grupos\n\ntratados.\n\n\u2022 Sup\u00f5e-se que o tratamento com o \u00e1cido \u00fasnico encapsulado provoque diferen\u00e7as significativas (p\n\n>0,05) nos \u00edndices hematim\u00e9tricos das amostras de sangue dos camundongos implantados com tumor\n\nsarcoma-180, quando comparados ao grupo de animais n\u00e3o tratados.\n\n\u2022  A encapsula\u00e7\u00e3o do \u00e1cido \u00fasnico pode ser uma alternativa promissora a ser explorada para a terapia do\n\nc\u00e2ncer.\n\n\n\n7\n\nREFER\u00caNCIAS BIBLIOGR\u00c1FICAS\n\n\n\n8\n\n4. REFER\u00caNCIAS BIBLIOGR\u00c1FICAS\n\nAbo-Khatwa, A. N.; Al-Robai, A. A.; Al-Jawhari, D. A. Lichens acid as uncouplers of\n\noxidative phosphorylation of mouse-liver mitochondria. Saudi Arabia. Natural Toxins,\n\n4(2): 96-102, 1996.\n\nAl-Bekairi, A. M.; Quareshi, S.; Chaudhry, M. A.; Krishna, D. R.; Shah, A. H.\n\nMitodepressive, clatogenic and biochemics effects of (+)-usnic acid in mice. J.\n\nEthnopharm., 33:217-220, 1991.\n\nAlexopoulos, C. J.; Mins, C.W. Introductory Micology, New York, J. Wiley e Sons, 632p,\n\n1979.\n\nBarrat, G. M. Therapeutic applications of colloidal drug carriers. PSTT, 3(5) 163-171, 2000.\n\nBerlion, M. Mise au point d\u201dun syst\u00e8me de selection de substances antitumorales: application\n\n\u00e1 l\u2019\u00e9tude d\u2019analogues structuraux de la G\u00e9op\u00e9taline. Grenoble, Th\u00e8se (Doctorat) -\n\nUniversit\u00e9 Joseph Fourier, U.F.R. de Pharmacie, Fran\u00e7a - 385p. 1988.\n\nBellamy, W. T. Prediction of Responses to Drug Therapy of Cancer. Drug, 44 (5) 690-708,\n\n1992.\n\nBrasseur, F.; Couvreur,P.; Kante, B.; Deckerspassau, L.; Roland, M.; Deckers, C.; Speiser, P.\n\nActinomycin D adsorbed on polymethylcyanocrylate nanoparticles:Increased efficiency\n\nagainst na experimental tumor. Eur. J. C\u00e2ncer, 16: 1441-1445, 1980.\n\nBrasileiro-Filho, G. Patologia Geral. 2. ed., Rio de Janeiro, Guanabara Koogan, 1998.\n\nCampanella, L.; Delfini, M.; Ercole, P.; Iacoangeli, A.; Risuleo, G. Molecular characterization\n\nand action of usnic acid: a drug that inhibits proliferations of mouse polyomavirus in vitro\n\nand whose main target is RNA transcription. Biochemistry, 84: 329-334, 2002.\n\nCardarelli, M.; Serino, G.; Campanella, L.; Ercole, P.; Nardone, F.; Alesiani, O.; Rossiello, F.\n\nAntimitotic effects of usnic acid on different biological systems. Cel. Mol. Life Sci., 53(8)\n\n667-672, 1997.\n\n\n\n9\n\nCarvalho, T.U. Cultura de c\u00e9lulas animais. In: Benchimol, M.; Attias, M.; Cunha-Silva, N. L.;\n\nCarvalho, T.U. M\u00e9todos de estudo da c\u00e9lula. Rio de Janeiro. Editora\u00e7\u00e3o Eletr\u00f4nica\n\nFenorte/Uenf, 47-58. 1996.\n\nCorrech\u00e9, E. R.; Carrasco, M.; Escudero, M.E.; Vel\u00e1zquez, L.; Guzm\u00e1n, A. M.S.; Giannini,\n\nF.; Enriz, R.D.; Ja\u00faregui, E.A.; Ce\u00f1al, J.P.; Giordano, O.S. Study of citotoxity and\n\nantimicrobial activities of usnic acid derivatives. Fitoterapia, LXIX (6):493-501, 1998.\n\nCocchietto, M.; Skert, N.; Nimis, P.L. A review on usnic acid, an interesting natural\n\ncompound. N. Naturwissenschaften, 89:137-149, 2002.\n\nCouvrer, P.; Kante, B.; Lenaerts, V.; Scailteur, M.; Roland, M.; Speiser, P. Tissue\n\ndistribuition of antitumor drugs associated with polyalkylcyaboacrylate. J. Pharm. Sci.,\n\n69:199-202, 1980.\n\nCouvreur, P.; Kante, B.; Roland, M.; Speiser, P. Adsorption of antineoplasic drugs to\n\npolyalkylcyanoacrylate nanoparticles and their release characteristic in a calf serum\n\nmedium. J. Pharm. Sci.,. 68: 1521-1524, 1979.\n\nCouvreur, P.; Dubernet, C.; Puisieux, F. Controlled drug delivery with nanoparticles: Current\n\npossibilities and future trends. Europ. J Pharm. and Biopharm., 41(1) 2-13, 1995.\n\nCulberson, C. F. Inproved conditions and new data for the indication of lichen products by\n\nstandrdized thin layer-chromaographic method . J. Chromatog., 72:1113-1125, 1972.\n\nF\u00e1varo, O.C. N.; Oliveira, M..M.; Rossini, A.; Kamara, C. R.; Pinto, A. V.; Pinto, M.C.\n\nSele\u00e7\u00e3o por meio de C\u00e9lulas KB de Subst\u00e2ncias e Extratos potencialmente Ativos em\n\nQuimioterapia do C\u00e2ncer. Anais Acad. Bras. Ci\u00eancias. Rio de Janeiro. 62 (3) 217-224,\n\n1990.\n\nFessi, H.; Puisieux, F.; Devissaguet, J. P.; Ammoury, N. E.; Benita S. Nanocapsules\n\nformation by interfacial polymer deposition following solvent displacement. Int. J. Pharm.\n\n55:1-4, 1989.\n\n\n\n10\n\nFranks, L. M.; Teich, N. M. O que \u00e9 C\u00e2ncer ? In: Introdu\u00e7\u00e3o a Biologia Celular e Molecular\n\ndo Cancer. Roca 1\u00aa  ed. S\u00e3o Paulo. 1-24, 1997.\n\nGoldin, A.; Schepartz, S. A.; Venditti, J. M.; Devita, V. T. Historical Development and\n\nCurrent Strategy of the National Cancer Institute Drug Development Program. In: Meth. C.\n\nRes., XVI (5) 165-229, 1979.\n\nGomes, N. G. L.; Milanez, M.C. Biologia dos Tumores. In: Gomes R. Oncologia B\u00e1sica.\n\nRevinter, Rio de Janeiro, 18-35, 1997.\n\nGiuliani, F.; Marco, A. D.; Casazza, A. M.; Savi, G. Combination Chemotherapy and surgical\n\nAdjuvant Chemotherapy on MS-2 Sarcoma and Lung Metasteses in Mice. Eur. J. Cancer,\n\n15: 715-721, 1979.\n\nGibaud, S.; Semoy, J. P.; Andreux, J. P.; Weingarten, C.; Gourtini, B.; Couvreue, P. Cells\n\ninvolved in the Capture of Nanoparticles in Hematopoietic Organs. J. Pharm. Sci., 85(9)\n\n944-950, 1996.\n\nHale, M.E. The Biology of Lichen. 3ed. London 90p, 1983.\n\nHorowitz, A. T.; Barenholz, Y.; and Gabizon, A. In vitro citotoxity of lipossomes-\n\nencapsulated doxorubicin: dependence on liposome composition and drug release.\n\nBiochim. Biophys. Acta, 1109:203-209, 1992.\n\nIng\u00f3lfsdottir, K.; Hjalmarsd\u00f3ttir, A; Steingrimsson, O. In vitro susceptibility of Helicobacter\n\npylori to protolichesterinic acid from the lichen Cetraria islandica. Antimicrob. Agents\n\nChemother., 41:215-217, 1997.\n\nIngolfsd\u00f3ttir, K.; Chung, G. A.; Sk\u00falason, A. C.; Gissurarson, S. R.; Vilhelmsd\u00f3ttir M.\n\nAntimycobacterial activity of lichen metabolites in vitro Eur. J. Pharm. Sci., 6:141-144,\n\n1998.\n\nIng\u00f3lfsd\u00f3ttir, K. Molecules of Interest Usnic Acid. Phytochemistry 61:729-736 2002.\n\nJain R. A. The manufacture techniques of various drug loaded biodegradable poly (lactide-co-\n\nglycolide) (PLGA) devices. Biomaterials, 21: 2475-2490, 2000.\n\n\n\n11\n\nJohnson, R. B.; Feldot, G.; Lardy, H. A. The mode of action of the antibiotic usnic acid. Ach.\n\nBiochem., 28:317-323, 1950.\n\nLambert, G.; Bertrand, J. R.; Fattal, E.; Subra, F.; Pinto-Alphandary, H.; Malvy, C.;\n\nCouvreur, P. EWS Fli-1 Antisense nanocapsules inhibits Ewing sarcoma-related tumor in\n\nmice. Biochem. Biophys. Res. Commun. 279: 401-409, 2000.\n\nLauterwein, M.; Oethinger, M.; Belsner, K.; Peter, T.; Marre, R. In vitro activities of the\n\nlichen secondary metabolites vulpinic and (+)-usnic acid against aerobic and anaerobic\n\nmicroorganisms. Antimicrob. Agent. Chemoth. 39:2541-2543, 1995.\n\nLodetti, G.; Gigola, P.; Bertasi, B.; D\u00b4Ambrosca, F.; ponchio, G.; Fishbach, M.; Losio M. N.\n\nValutazione in vitro della citossicit\u00e1 indotta da prodotti per I\u2019igiene orale contenenti acido\n\nusnico, agente antimicrobiano naturale estratto da\u00ed licheni. Gimmoc., 4:67-72, 2000.\n\nMayer, L. D.; Bally, M. B.; Loughrey, H. Masin, D. Cullis, P.R. Lipossomal Vincristine\n\npreparations which exhibit decreased drug toxicity and increased activity against murine\n\nL1210 and P388 tumors. Canc. Res., 50:575-579, 1990.\n\nMitchel, J. C.; Armitage, J. S.; Varcourver, D. Dermatitis venenata from lichens. British\n\nColumbia. Arch. Environ. Health, 11:701-709, 1965.\n\nMitra, S.; Gaur, U.; Ghosh, P. C.; Maitra, A. N. Tumour targeted delivery of encapsulate\n\ndextran-doxorubicin conjugate using chitosan nanoparticles as carrier. J. Control. Rel.,\n\n74:317-323, 2001.\n\nMorier L.; P\u00e9rez, L.; Cancio, R.; Sav\u00f3n, C.; Gonz\u00e1lez, Z.; Goyenechea, A. Comparaci\u00f3n de la\n\nl\u00ednea NCI-H292 com otras l\u00edneas continuas para la multiplicaci\u00f3n de virus respiratoridos.\n\nRev. Cubana Med. Tropical, 48 (3): 171-173, 1996.\n\nMuller, K. S.; Kumar, K.C. Lichen Metabolites. 2. Antiproliferative and Cytotoxic Activity of\n\nGyrophoric Usnic and Diffractaic Acid on Human Keratinocyte Growth. J. Nat. Prod. 62:\n\n821-823, 1999.\n\n\n\n12\n\nMuller K. Pharmaceutically relevant metabolites from lichens. Appl. Microbiol. Biotechnol.,\n\n56: 9-16, 2001.\n\nNash, T.H. Lichen Biology. Cambridge University. Press. 1\u00aa  ed. 303p, 1996.\n\nNeedham, D.; Dewhirst, M. W. The development and testing of a new temperature-sensitive\n\ndrug delivery system for the treatment of solid tumors. Adv. Drug Deliv. Rev., 53: 285-305,\n\n2001.\n\nNishioka, Y.; Yoshino H. Lymphatic targeting with nanoparticulate system. Adv. Drug Deliv.\n\nRev., 47. 55-64, 2001.\n\nOkuyama, E.; Umeyama, K.; Yamazaki, M.; Kinoshidta Y.; Yamamoto, Y. Usnic acid and\n\ndiffractaic acid as analgesic and antipyretic components of Usnea diffacta. Planta Med,\n\n61(2): 113-115, 1995.\n\nOussoren, C.; Eling,W. M. C.; Crommelin, D. J. A.; Storm, G.; Zuidema, J. The influence of\n\nthe route of administration and lipossome composition on the potential of lipossomes to\n\nprotect tissue against local toxcity of two antitumor drugs. Bioch. Biophy. Acta., 1369:159-\n\n172, 1998.\n\nOlivier, J. C.; Vauthier, M.; Taverna, M.; Ferrier, D.; Couvreur, P. Prepation and\n\ncharacterization of biodegradable poly (isobutylcyano acrylate) nanoparticles with the\n\nsurface modified by the adsorption of proteins. Colloids Surf. B: Biointerf., 4:349-356,\n\n1995.\n\nPerachia, M. T.; Vautier, C.; Puisieux, F.; Couvreur, P. Development of sterically stabilized\n\npoly (isobutyl 2-cyanocrylate) nanoparticles by chemical coupling of poly (ethylene\n\nglycol). J. Biomed. Mat. Res., 34:317-326, 1997.\n\nRodrigues, O. G. Estudo in vitro para avalia\u00e7\u00e3o das altera\u00e7\u00f5es morfol\u00f3gicas das c\u00e9lulas\n\nHep2, NCIH-292 e TVT Canino produzidas por imunoparvum e in vivo para verifica\u00e7\u00e3o\n\ndos seus efeitos terap\u00eauticos, 2001. 127p. Tese (Doutorado) Ci\u00eancias Biol\u00f3gicas\n\nUniversidade Federal de Pernambuco, UFPE.\n\n\n\n13\n\nSantos-Magalh\u00e3es, N.S. Pontes, A. Pereira, V.M.W. Caetano, M. N. P. Colloidal carriers for\n\nbenzantine penicillin G: Nanoemulsions an nanocapsules. Int. J. Pharm. 208, 71-80, 2000.\n\nScirpa, P. Scambia, G. Masciullo, V. Battaglia, F. Foti, E. Lopez, R. Villa, P. Malecore, M.\n\nMancuso, S. A zinc sulphate and usnic acid preparation used as post-surgical adjuvant\n\ntherapy in genital lesion by human papillomarivus. Minerva Ginicol 51: 255-260. 1999.\n\nSoppimath, K. S. Aminabhavi, T. M. Kulkarmi, A. R. Rudzinski, W. E. J. Biodegradable\n\npolymeric nanoparticles as drug delivery devices. J. Control. Rel., 70: 1-20, 2001.\n\nSingh, U. V Udupa, N. In vitro characterization of methotrexate loaded poly (lactic-co-\n\nglycolic) acid microspheres and antitumor efficacy in Sarcoma-180 mice bearing tumor.\n\nPharm. Acta Helvetiae, 72: 165-173, 1997.\n\nSousa, M. R. Q. Estudo dos Efeitos da lapachona sobre c\u00e9lulas da linhagem Hep-2, carcinoma\n\nde Ehrlich e sarcoma-180, 2000. 95p. Tese (Doutorado) Ci\u00eancias Biol\u00f3gicas, Universidade\n\nFederal de Pernambuco, UFPE.\n\nSwarbrick, J. Advances in controlled drug delivery. STP Pharm. Sciennce, 6(1) 53-60, 1996.\n\nTakai, M. Uehara, Y. Beisler, J.A. Usnic Acid Derivatives as Potential Antineoplastic Agents.\n\nJ. Med. Chem. 22(11): 1380-1384, 1979.\n\nTaguchim, H.; Sankawa, U.; Shibata, S. Biosynthesis of natural products. VI Biosynthesis of\n\nusnic acid in lichen (1). A general scheme of biosynthesis of usnic acid. Chem. Pharm.\n\nBull. 17:2054-2060, 1969.\n\nVauthier-Holtzscherer, C. Benabbou, S. Spenlehauer, M.; Veillard, M.; Couvreur, P.\n\nMethodology for the prepatation of ultra-dispersed polymer systems. STP Pharma. Sci., 1\n\n(2) 10-116, 1991.\n\nVavasseur, A. Gautier, H. Thibaud, M. C. Lasc\u00e8ve, G. Effects of usnic acid on the oxygen\n\nexchange properties of mesophyll cell protoplast from Commelina communis L. J. Plant\n\nPhysiol., 139: 90-94, 1991.\n\n\n\n14\n\nVenkataramana, D. Krishna, K. High-performance liquid chromatographic determination of\n\nusnic acid in plasma. J. Chromatogr., 575: 167-170, 1992.\n\nVenkataramana D. Krishna, D. R. Pharmaceutics of d(+)-usnic acid in rabbits after\n\nintravenous administration and oral administration. Drug metab. Disposition, 20:6. 909-\n\n911, 1992b.\n\nVenkataramana D. &amp; Krishna, D. R. Pharmaceutics of d(+)-usnic acid in rabbits after\n\nintravenous administration. Eur. J. Drug Metab, 18:2 161-163, 1993\n\nVicente, C. Fisiologia de las substancias liqu\u00eanicas. Madrid: Allandra, 162p. 1975.\n\nVicente, C. Cifuentes, B. L-usnate and permeability. Cryptog. Bryol. Lichenol. 2(2):213-222,\n\n1981.\n\nVicente, C.; Xavier-Filho, L. Est\u00fadio biol\u00f3gico e farmacol\u00f3gico de los antibi\u00f3ticos de origen\n\nliqu\u00eanico. In:  Simp\u00f3sio Nacional de Farmacologia e Qu\u00edmica de produtos Naturais. Jo\u00e3o\n\nPessoa. Anais do 2 SINPRONAT. UFPB. LTF. 431p. 1983.\n\nVirtanen, O.; Karki, N. On the Toxicity of Usnic Acid preparation with the Trade Name usno.\n\nSuomen Kehruistileliti, 29:225-226, 1956.\n\nVinjayakumar, C.S.; Viswanathan, S.; Reddy, M.K.; Parvathavarthini, S.; Kundu, A B.;\n\nSukumar, E. Anti-inflamtory activity of (+) \u2013unisc acid. Fitoterapia, 71:564-566, 2000.\n\nYamamoto, Y.; Kinoshita, Y.; Matsubara, H.; Kinoshita, K.; Koyama, K.; Takahashi, K.;\n\nKurokawa, T.; Yoshimura, I. Screening of biological activities and isolation of biological-\n\nactive compounds from lichens. Recent. Res. Devel. Phytochem. 2:23-33. 1998.\n\nYanomoto, Y.; Miura, Y.; Kinoshita, Y.; Higuchi, M.; Yamada, Y.; Murakami, A; Ohigashi,\n\nH.; Koshimuzi, K. Screning of tissue cultures and thalli and some of their active\n\nconstituentes for inhibition of tumor promoter-induced Epstein-Barr virus activation.\n\nChem. Pharm. Bull., 43(8) 1388-1390, 1995.\n\nYoo, H. S. Lee, K.H. Oh, J. E. Park, T. G. In vitro and In vivo anti-tumor activities of\n\nnanoparticles based on doxorubicin-PLGA conjugates. J. Control. Rel., 68: 419-431, 2000\n\n\n\n15\n\nYoung, S.; Hallowes, R. C. Tumours of the mammary gland. part.1. In: Pathology of Tumours\n\nin Laboratory animals. Turusorv,. V. S. 31-51, 1973.\n\nWhelan, J. Nanocapsules for controlled drug delivery. DDT. 6(23):1183-1184, 2001.\n\n\n\n16\n\nANEXOS\n\n\n\n17\n\nANEXO I\nNormas de publica\u00e7\u00f5es dos peri\u00f3dicos selecionados\n\n\n\n18\n\nJOURNAL OF NANOBIOTECHNOLOGY\n\nInstructions for Journal of Nanobiotechnology authors\n\nTo facilitate rapid publication and to minimize administrative costs, Journal of\nNanobiotechnology accepts only online submission. The submission process is compatible\nwith version 3.0 or later of Internet Explorer and Netscape Navigator web browsers, and can\nbe used from either PC, Mac, or Unix platforms.\nFiles can be submitted as a batch, or one by one. The submission process can be interrupted at\nany time - when users return to the site, they can carry on where they left off.\nSee below for examples of acceptable word processor and graphics file formats. Additional\nfiles of any type, such as movies, animations, or original datafiles, can also be submitted as\npart of the publication.\nAssistance with the process of manuscript preparation and submission is available from the\ncustomer support team (info@biomedcentral.com)\n\nPublication\nOnce an article is accepted, it is published in Journal of Nanobiotechnology immediately as a\nprovisional PDF file. The paper will subsequently be published in both fully browseable web\nform, and as a formatted PDF; the article will then be available through Journal of\nNanobiotechnology, BioMed Central and PubMed Central, and will also be included in\nPubMed.\n\nEditorial policies\nSubmission of a manuscript to Journal of Nanobiotechnology implies that all authors have\nread and agreed to its content, and that readily reproducible materials described in the\nmanuscript will be freely available to any scientist wishing to use them for non-commercial\npurposes. Nucleic acid sequences, protein sequences, and atomic coordinates should be\ndeposited in an appropriate database in time for the accession number to be included in the\npaper.\n\nAuthors are required to ensure that no material submitted as part of a manuscript infringes\nexisting copyrights, or the rights of a third party. The paper should not already have been\npublished in a journal and should not be under consideration by any other journal, but it can\nalready have been deposited on a preprint server. Authors who publish in Journal of\nNanobiotechnology retain copyright to their work (more information).\n\nSubmission of a manuscript reporting experimental research on humans or animals implies\nthat authors have obtained approval for their research from the appropriate ethics committee\nor government body regulating animal or human research. A statement to this effect must be\nincluded in the Methods section of your manuscript.\n\nGeneral information\nThe following word processor file formats are acceptable for the main manuscript document:\nMicrosoft Word (version 2 and above)\nWordPerfect (version 5 and above)\nRich text format (RTF)\nPortable document format (PDF)\nDeVice Independent format (DVI)\n\n\n\n19\n\nUsers of other word processing packages should save or convert their files to RTF before\nuploading. Many free tools are available which ease this process.\nIf you use TeX you should submit your manuscript as a DVI file, as this will give better\nresults than converting to RTF.\nNote that figures must be submitted as separate image files, not as part of the submitted PDF\nor DVI file.\n\nArticle types\nWhen submitting your manuscript, you will be asked to assign a type to your article:\n\"Research\" or one of a number of more specialist types. Please decide which of the types is\nmost appropriate to your article and structure it appropriately. For a description of each of the\narticle types and details of how such articles should be structured please follow the links:\nResearch\nReview\nShort Communication\n Manuscript sections for Research articles\nManuscripts for Research articles submitted to Journal of Nanobiotechnology should be\ndivided into the following sections:\n\nTitle page\nThis should list the title of the article, the full names, institutional addresses, and email\naddresses for all authors. The corresponding author should also be indicated.\n\nAbstract\nThis should not exceed 250 words and must be structured into separate sections headed\nBackground, Results and Conclusions. Please do not use abbreviations or cite references,\nfigures or tables in the abstract.\n\nBackground\nThe background section should be written from the standpoint of researchers without\nspecialist knowledge in that area and must clearly state - and, if helpful, illustrate - the\nbackground to the research and its aims. The section should end with a very brief statement of\nwhat is being reported in the article.\n\nResults and Discussion\nThe Results and Discussion may be combined into a single section or presented separately.\nThey may also be broken into subsections with short, informative headings.\n\nConclusions\nThis should state clearly the main conclusions of the research and give a clear explanation of\ntheir importance and relevance. Summary illustrations may be included.\n\nMethods\nThis should be divided into subsections if several methods are described.\n\nList of abbreviations\nIf abbreviations are used in the text either they should be defined in the text where first used,\nor a list of abbreviations can be provided, which should precede the authors' contributions and\nacknowledgements.\n\n\n\n20\n\nAuthors' contributions\nIn order to give appropriate credit to each author of a paper, the individual contributions of\nauthors to the manuscript should be specified in this section. We suggest the following kind of\nformat (please use initials to refer to to each author's contribution): AB carried out the\nmolecular genetic studies, participated in the sequence alignment and drafted the manuscript.\nJY carried out the immunoassays. MT participated in the sequence alignment. ES participated\nin the design of the study and performed the statistical analysis. FG conceived of the study,\nand participated in its design and coordination. All authors read and approved the final\nmanuscript.\n\nAcknowledgements\nThese should be kept to a minimum. Authors should obtain permission to acknowledge from\nall those mentioned in the acknowledgements.\n\nReferences\nAll references should be cited consecutively in the text, using numbers in square brackets.\nAny references cited only in the tables or figure legends should be listed after references cited\nin the text.\n\nOnly papers that have been published, or are in press, or are available through public e-\nprint/preprint servers may be included in the reference list.\nSubmitted manuscripts, personal communications (which can be included only with\npermission), unpublished manuscripts and unpublished data should not be cited in the\nreference list, although they may be referred to in the text (e.g. J. Smith, personal\ncommunication, 2001).\nJournal abbreviations should follow MEDLINE standards. For each reference, name all\nauthors unless there are more than ten, in which case name the first ten followed by et al. Page\nnumbers for journal articles should be given in full (e.g. 5672-5679, not 5672-9). References\nshould be laid out in BioMed Central style (see below).\nWe encourage authors to use a recent version of EndNote (version 5 or 6) or Reference\nManager (version 10) when formatting their reference list, as this allows references to be\nautomatically extracted. You should upload the manuscript file containing your EndNote or or\nReference Manager-formatted bibliography as a .doc file. Please ensure you do not convert to\nanother format (e.g. RTF or PDF). Further details about EndNote and Reference Manager are\navailable on our site, which include information about how to upgrade.\n\nStyle files for EndNote and Reference Manager that conform to the BioMed Central style are\navailable:\nEnd Note - version 4 and 5 compatible:\nPC version\nMac version (.sit file)\nEnd Note - version 3 compatible:\nPC version\nMac version (.hqx file)\nReference Manager - version 9.5 compatible:\nPC version\nUsers of other reference management programs should be able to select other journal styles\nthat output a numeric list styled similarly to the guide below.\nJournal article\nChomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium\nthiocyanate-phenol-chloroform extraction. Anal Biochem 1987, 162: 156-159\n\n\n\n21\n\nComplete book\nSambrook J, Fitsch EF, Maniatis T : Molecular Cloning: A Laboratory Manual. Cold Spring\nHarbor, Cold Spring Harbor Press 1989\nArticle or chapter in a book\nWessely S, Wood F: Peer review of grant applications: a systematic review. In: Peer review in\nHealth Sciences (Edited by Godlee F, Jefferson T) London, BMJ Books 1999, 14-31\nBook with institutional author\nAdvisory Committee on Genetic Modification: Annual Report London 1999\nArticle in journal supplement\nBreedveld FC: New insights into the pathogenesis of rheumatoid arthritis. J Rheumatol 1998,\n53 (suppl): S3-S7\nLinks\nMouse Tumor Biology Database -[http://tumor.informatics.jax.org/cancer_links.html]\nPublished abstract\nZvaifler NJ, Burger JA, Marinova-Mutafchieva L, Taylor P, Maini RN: Mesenchymal cells,\nstromal derived factor-1 and rheumatoid arthritis [abstract]. Arthritis Rheum 1999, 42: s250\nIn press articles\nKharitonov SA, Barnes PJ: Clinical aspects of exhaled nitric oxide. Eur Respir J, in press\nArticle in conference proceedings\nJones X: Zeolites and synthetic mechanisms. In Proceedings of the First National Conference\non Porous Sieves: 1996 June 27-30; Baltimore. Edited by Smith Y. Stoneham: Butterworth-\nHeinemann; 1996:16-27\nWhole conference proceedings\nSmith Y (Ed): Proceedings of the First National Conference on Porous Sieves: 1996 June 27-\n30; Baltimore. Stoneham: Butterworth-Heinemann; 1996\n\nFigure legends\nThe figure legends should be included in the main manuscript text, immediately following the\nreferences, rather than being a part of the figure file. The following information should be\nprovided, for each figure: Figure number (in sequence, using Arabic numerals - ie Figure 1, 2,\n3 etc); Short title of figure (maximum 15 words); detailed legend, up to 300 words.\n\nMicrosoft Word template\nAlthough we can accept manuscripts prepared as Microsoft Word, Word Perfect, RTF or PDF\nfiles, we have designed a Microsoft Word template that can be used to generate a standard\nstyle and format for your article. It can be used if you have not yet started to write your paper,\nor if it is already written and needs to be put into Journal of Nanobiotechnology style.\n\nDownload the template (Mac and Windows compatible Word 1998/2000) from our site, and\nsave it to your hard drive. Double click the template to open it.\n\nHow to use the Journal of Nanobiotechnology template\nThe template consists of a standard set of headings that make up a Journal of\nNanobiotechnology Research manuscript, along with dummy fragments of body text. Follow\nthese steps to create your manuscript in the standard format:\n\nReplace the dummy text for Title, Author details, Institutional affiliations, and the other\nsections of the manuscript with your own text (either by entering the text directly or by\ncutting and pasting from your own manuscript document).\nIf there are sections which you do not need, delete them (but check the rest of the Instructions\nfor Authors to see which sections are compulsory).\n\n\n\n22\n\nIf you need an additional copy of a heading (e.g. for additional figure legends) just copy and\npaste.\nFor the references, you may either manually enter the references using the reference style\ngiven, or use bibliographic software to insert them automatically. We provide style files for\nEnd Note and Reference Manager.\n\nFor extra convenience, you can use the template as one of your standard Word templates. To\ndo this, put a copy of the template file in Word's 'Templates' folder, normally C:\\Program\nFiles\\Microsoft Office\\Templates on a PC. The next time you create a new document in Word\nusing the File menu, the template will appear as one of the available choices for a new\ndocument.\n\nNote - EndNote 6 includes a full set of structured article templates for BioMed Central\njournals. Users of EndNote are encouraged to upgrade to EndNote 6 and make use of these\ntemplates. More information is available here.\n\nGeneral information\nIllustrations should be provided as separate files, not embedded in the text file. Each figure\nshould include a single illustration, which should be submitted as a separate graphics file.\nThere is no charge for the use of color figures.\nIf a figure consists of separate parts, it is important that a single composite illustration file\nshould be submitted which contains all parts of the figure.\nPhotographs should be provided with a scale bar if appropriate.\nScaling/resolution\nIllustrations should be designed such that all information is legible when scaled to a\nhorizontal width of 600 pixels, since this is the default size for a Journal of\nNanobiotechnology (and PubMed Central) illustration on the web. High-quality versions of\nfigures will also be generated and stored by Journal of Nanobiotechnology, however, so\nimage files should be submitted at a resolution of 300 dpi or greater if possible.\nText within figures should use either Arial or Helvetica fonts, although Courier may also be\nused if a monospaced font is required. Text too should be designed to be legible when the\nillustration is scaled to a width of 600 pixels.\nFormats\nThe following file formats can be accepted:\nEPS (preferred format for diagrams)\nPDF (also especially suitable for diagrams)\nPNG (preferred format for photos or images)\nMicrosoft Word (version 5 and above; figures must be A4 portrait, single page only)\nPowerPoint (figures must be a single page)\nTIFF\nJPEG\nBMP\nJournal of Nanobiotechnology is not able to process figures submitted in GIF format.\n\nPlease note that it is the responsibility of the author(s) to obtain permission from the copyright\nholder to reproduce figures or tables that have previously been published elsewhere.\n\nIf the large size of TIFF or EPS figures is an obstacle to online submission, authors may find\nthat conversion to JPEG format before submission results in significantly reduced file size\n(and upload time), while retaining acceptable quality. JPEG is a 'lossy' format, however. In\norder to maintain acceptable image quality, it is recommended that JPEG files are saved at\nHigh or Maximum quality.\n\n\n\n23\n\nFiles should not be compressed with tools such as Zipit or Stuffit prior to submission. These\ntools will in any case produce negligible file-size savings for JPEGs and TIFFs, which are\nalready compressed.\n\nImage conversion tools\nThere are many software packages, many of them freeware or shareware, capable of\nconverting to and from different graphics formats, including PNG.\n\nGood general tools for image conversion include GraphicConverter on the Macintosh,\nPaintShop Pro, for Windows, and ImageMagick, which is available on Macintosh, Windows\nand UNIX platforms.\n\nNote that bitmap images (e.g. screenshots) should not be converted to EPS since this will\nresult in a much larger file size than the equivalent JPEG, TIFF, PNG or BMP, with no\nincrease in quality. EPS should only be used for images produced by vector drawing\napplications such as Adobe Illustrator or CorelDraw. Most vector drawing applications can\nsave in EPS format. If images have been originally prepared in an Office application, such as\nWord or PowerPoint, then the Office files should be directly uploaded to the site, rather than\nconverted to JPEG or another format that may be of reduced quality.\n\nGeneral information\nEach table should be numbered in sequence using Arabic numerals (ie Table 1, 2, 3 etc).\nTables should also have a title that summarizes the whole table, maximum 15 words. Detailed\nlegends may then follow.\n\nSmaller tables considered to be integral to the manuscript can be pasted into the end of the\ndocument text file. These will be typeset and displayed in the final published form of the\npaper. Such tables should be formatted using the 'Table object' in a word processing program\nto ensure that columns of data are kept aligned when the file is sent electronically for review.\nThis will not always be the case if columns are generated by simply using tabs to separate\ntext. Columns and rows of data should be made visibly distinct by ensuring the borders of\neach cell display as black lines.\n\nAlternatively, larger datasets can be uploaded separately as additional files. Additional files\nwill not be displayed in the final, published form of the paper; however a link will be\nprovided to the files as supplied by the author.\n\nTabular data provided as additional files can be uploaded as an Excel spreadsheet (.xls) or\ncomma separated values (.csv). As with all files, please use the standard file extensions.\n\n General information\nAlthough Journal of Nanobiotechnology does not restrict the length and quantity of data in a\npaper, there may still be occasions where an author wishes to provide data sets, tables, movie\nfiles, or other information as additional information. These files can be uploaded using the\n'Additional Material files' button in the manuscript submission process.\nThe maximum file size for additional files is 10 MB, and files will be virus-scanned on\nsubmission.\n\nAny additional files will be linked into the final published article in the form supplied by the\nauthor, but will not be displayed within the paper. They will be made available in exactly the\nsame form as originally provided.\n\n\n\n24\n\nIf additional material is provided, please list the following information in a separate section of\nthe manuscript text, immediately following the tables (if any):\nFile name\nFile format (including name and a URL of an appropriate viewer if format is unusual)\nTitle of data\nDescription of data\nAdditional datafiles should be referenced explicitly by file name within the body of the\narticle, e.g. 'See additional file 1: Movie1 for the original data used to perform this analysis'.\nFormats and uploading\nIdeally, file formats for additional files should not be platform-specific, and should be\nviewable using free or widely available tools. The following are examples of suitable formats.\nAdditional documentation\nPDF (Adobe Acrobat)\nAnimations\nSWF (Shockwave Flash)\nMovies\nMOV (QuickTime)\nMPG (MPEG)\nTabular data\nXLS (Excel spreadsheet)\nCSV (Comma separated values)\nAs with figure files, files should be given the standard file extensions. This is especially\nimportant for Macintosh users, since the Mac OS does not enforce the use of standard\nextensions. Please also make sure that each additional file is a single table, figure or movie\n(please do not upload linked worksheets or PDF files larger than one sheet).\n\nGeneral information\nCurrently, Journal of Nanobiotechnology can only accept manuscripts\n\nwritten in English. Spelling should be US English or British English, but not\na mixture.\n\nGene names should be in italic, but protein products should be in plain type.\nThere is no explicit limit on the length of articles submitted, but authors are encouraged to be\nconcise. There is also no restriction on the number of figures, tables or additional files that\ncan be included. Authors should include all relevant supporting data with each article.\n\nJournal of Nanobiotechnology will not edit submitted manuscripts for style or language;\nreviewers may advise rejection of a manuscript if it is compromised by grammatical errors.\nAuthors are advised to write clearly and simply, and to have their article checked by\ncolleagues before submission. Non-native speakers of English may choose to make use of a\ncopyediting service such as that provided by Biology Editors, Manuscript Presentation\nService and English Manager Science Editing. In-house copyediting will be minimal.\n\nHelp and advice on scientific writing\nTim Albert has produced for BioMed Central a list of tips for writing a scientific manuscript.\nMedBioWorld also provides a list of resources for science writing.\n\nAbbreviations\nAbbreviations should be used as sparingly as possible. They can be defined when first used or\na list of abbreviations can be provided preceding the acknowledgements and references.\n\n\n\n25\n\nTypography\n\nPlease use double line spacing.\nType the text unjustified, without hyphenating words at line breaks.\nUse hard returns only to end headings and paragraphs, not to rearrange lines.\nAll pages should be numbered.\nUse the Journal of Nanobiotechnology reference format.\nFootnotes to text should not be used.\nGreek and other special characters may be included. If you are unable to reproduce a\nparticular special character, please type out the name of the symbol in full. Please ensure that\nall special characters used are embedded in the text, otherwise they will be lost during the\nconversion to PDF.\nUnits\nSI Units should be used throughout (litre and molar are permitted, however).\n\n\n\n26\n\nTOXICOLOGY IN VITRO\n\nGuide for Authors\n\nGeneral Information\nThe Journal's main purpose will be the publication of papers reporting and interpreting\noriginal toxicological research involving the application or development of in vitro\ntechniques. Brief Communications documenting important new findings warranting\nexpeditious publication will also be considered, as will concise interpretative Reviews of\ntoxicological topics of contemporary significance. Letters to the Editor will be limited to\ncomments on contributions already published in the Journal; if a letter is accepted, a response\n(for simultanous publication) will be invited from the authors of the original contribution.\nSubmission of a paper will be held to imply that it reports original unpublished research, that\nit is not under consideration for publication elsewhere and that, if accepted for Toxicology in\nVitro, it will not be published again, either in English or in any other language, without the\nEditors' consent.\nThree copies of the manuscript should be submitted, one being the original, accompanied by a\nsigned covering letter providing, if possible, a fax number. Manuscripts should be sent to:\nProfessor D. Acosta (USA and Canada); Professor B.J. Blaauboer (Europe, except UK); Ms\nS. Hill (UK and all others); at the following addresses:\n\nPROFESSOR DANIEL ACOSTA, University of Cincinnati, College of Pharmacy, 3223\nEden Avenue, Cincinnati, OH 45267-0004, USA\n\nPROFESSOR BAS J. BLAAUBOER, Institute for Risk Assessment Sciences (IRAS),\nDivision of Toxicology (RITOX), Utrecht University, PO Box 80.176, 3508 TD Utrecht, The\nNetherlands\n\nMS S. HILL, Managing Editor, BIBRA International, Woodmansterne Road, Carshalton,\nSurrey SM5 4DS, UK\n\nManuscript Format\nManuscripts should be written in clear and concise English; incomprehensible submissions\nwill be returned to authors for revision. Manuscripts should be typed on one side of the paper\nonly and double spaced throughout, with at least 2.5-cm margins. All pages must be\nnumbered, including the Title Page, which should carry the title of the paper, the surnames\nand initials of the authors, the names and address of the institutions where the work was done\n(with the affiliation of each author clearly indicated) and a short running title not exceeding\n45 letters and spaces. Titles consisting of declarative or interrogative sentences are not\nacceptable. Provision of telephone and or/fax numbers will assist the processing of\ncontributions.\n\nManuscripts of original papers should be organized into the following sections, each\ncommencing on a separate sheet:\n\nAbstract-a self-contained summary of the objectives, results and significance of the study,\nnot exceeding 200 words. Uninformative sentences such as \"the significance of the results is\ndiscussed\" are not acceptable.\n\n\n\n27\n\nIntroduction-a concise and clear statement on the background, purposes and significance of\nthe work.\n\nMaterials and Methods-a detailed descripton of the experimental design and of any new or\nimproved methods. Well-established methods and techniques may be identified by reference\nonly.\n\nResults-presented concisely with the aid of tables or figures where appropriate. Duplication\nbetween this section and the Discussion must be avoided.\n\nDiscussion-a succinct interpretation of the data. Extensive literature reviews and highly\nspeculative comments are discouraged.\n\nAcknowledgements-providing recognition of sources of funding and donations of materials,\nand including any thanks the authors may wish to accord for advisory, technical or other\nassistance, since authorship should be limited to those who have made a major contribution to\nthe study and to the preparation of the paper. Authors are advised to obtain approval for the\nwording of any acknowledgement from those whose help is noted.\n\nReferences-listed strictly in alphabetical order and including the names of all authors of the\ncited work. References to published papers should provide authors' names and initials, year of\npublication, full title of the paper, title of the journal (in full), volume number, and the first\nand last page numbers of the paper:\n\ne.g. Wright A., Cowie H., Gormley I.P. and Davies J.M.G. (1986) The in vitro Cytotoxicity of\nasbestos fibres: 1. P388D1 cells. American Journal of Industrial Medicine 9, 371-384.\n\nReferences to books should include authors' names and initials, year of publication, title,\nedition, appropriate page number(s) and name and location of the publisher:\n\ne.g. Foussereau J., Benezra C. and Maibach M. (1982) Occuptational Contact Dermatitis.\nClinical and Chemical Aspects. p. 277. Munksgaard, Copenhagen.\n\nFor multi-author books, the names and initials of the relevant authors, year of publication, title\nof the relevantchapter, title of the book, names and initials of all editors, numbers of first and\nlast pages of the cited chapter and name and location of the publisher should be given:\n\ne.g. Mather J.P. and Phillips D.M. (1984) Primary culture of testicular somatic cells. In\nMethods for Serum-free Culture of Cells of the Endocrine System. Edited by D.W. Barnes,\nD.A. Sirbasku &amp; G.H. Sato. pp. 29-45. Alan R. Liss, New York.\n\nCitations of references in the text should give the surname(s) of the author(s), together with\nthe year of publication. For references with more than two authors, the name of the first\nfollowed by et al. should be cited. For papers with the same author(s) and year, the references\nshould be distinguished in the text and reference list by the letters a, b etc. following the year\n(but still in alphabetical order). Authors names must not be typed in upper case letters in\neither text or reference list.\n\nReferences may be listed if they are 'in press', but the journal that has accepted the paper for\npublication must be identified. Submitted papers or papers in preparation should not be listed;\nsuch work should be mentioned in the text only, as 'unpublished data' or 'personal\ncommunication' (with surnames, initials and year).\n\n\n\n28\n\nThese sections should be followed by the tables in numerical order, each on a separate sheet,\nand finally by a typed list of the legends to the figures (see below).\n\nElectronic submission\nAuthors should submit an electronic copy of their paper with the final version of the\nmanuscript. The electronic copy should match the hardcopy exactly. Always keep a backup\ncopy of the electronic file for reference and safety. Full details of electronic submission and\nformats can be obtained from http://authors.elsevier.com.\n\nSubmission on Disk after Acceptance for Publication\n\nElsevier Science now publishes all manuscripts using electronic production methods and\nstrongly encourages submission on disk. Please send the electronic files of your article along\nwith the hardcopy of the accepted version. To ensure fast and easy processing of your\nsubmission, please adhere to the following guidelines:\n\n1. Save text and graphics on separate disks.\n2. Label all disks with your name, a short version of the article title, the journal to be\npublished in, and the filenames. Please also include details of the software and platform (PC,\nMac, UNIX, etc) used to create your files.\n3. Ensure that the files on the disk match the hardcopy exactly. In cases of a discrepancy, the\nhardcopy version will be used as the definitive version.\n\nTables and Figures\nThese should be intelligible without reference to the text and should be planned to fit the page\nsize of the Journal. Tables and figures should be numbered, in arabic numerals, in the\nsequence in which they are mentioned in the text. The same data may not be reproduced in\nboth a table and a figure. Each table must have a title and on each column there should be a\nheading that clearly identifies the data therein. Illustrations and diagrams should be kept to a\nminimum; the figure number must appear only on the reverse side, together with the author's\nname and an arrow marking the top. Three copies of any half-tones (unmounted and on glossy\npaper) are required; for line drawings, an original (in black drawing ink or computer laser\noutput on good quality paper) or a glossy print is required for reproduction, together with two\nclear photocopies for the referees. No information that can be included in the legend should\nappear on the figure and the following standard symbols are preferred for line drawings:\n(closed triangle), (open triangle), (closed square), (open square), (closed circle), (open circle),\n(open circle with a dot in the middle), +, (open diamond).\n\nThe legends for photomicrographs must state the staining method and magnification. Authors\nshould bear in mind that the figures they submit may be subjected to photographic reduction.\nThe cost for illustrations in colour will be the responsibility of the contributor(s) (an estimate\nmay be obtained from the Editorial Office at BIBRA).\n\nIf figures that have already been published under copyright are to be reproduced in the Journal\n(e.g. in reviews), copies of letters from the first publisher and the original author giving\npermission for such reproduction must always accompany the submitted manuscript.\n\nFootnotes\nThese should include the definitions of any abbreviations used in the text and any author's\ncurrent address, if different from that on the title page. Other footnotes, as distinct from\nliterature references, should be avoided in the text as far as possible. When they are essential,\n\n\n\n29\n\nthey should be identified by the symbols *   \u00a7  in that order. All the footnotes except those for\ntables should be typed on a separate sheet, with an indication of the manuscript page to which\nthe footnote refers.\n\nNomenclature\nThe metric system is the standard for all measurements. Test chemicals and enzymes must be\nclearly identified, wherever possible with the aid of CAS Registry and EC numbers.\n\nAbbreviations\n\nThese should be used sparingly; they should be defined when first used in the paper but also\nlisted in alphabetical order under Abbreviations as a footnote to the title page (see above).\n\nPage proofs\nThese will be sent to the first-named author for correction unless an alternative recipient is\nnamed on the submitted manuscript. They should be retuend to the Editorial Office at BIBRA\nwithin 48 hours. Corrections to the proofs must be limited to printers' errors only.\n\nReprints\nA reprint order form will accompany the page proofs. This must be returned to the Editorial\nOffice at BIBRA with the proofs. No payment should be included with the order as an invoice\nwill be sent later.\n\n\n\n30\n\nEUROPEAN JOURNAL OF PHARMACEUTICS AND\nBIOPHARMACEUTICS\n\n Guide for Authors\nThe European Journal of Pharmaceutics and Biopharmaceutics considers full manuscripts for\npublication as research papers, notes and review articles. Submission requirements specify\nthat papers should be original, unpublished and not under consideration for publication\nelsewhere. The scope of the journal includes pharmaceutics, pharmaceutical technology,\nbiopharmaceutics, pharmacokinetics, controlled release systems, industrial pharmacy, drug\ndelivery, quality control, GMP, regulatory aspects, analytical issues, microbiology and related\nfields.\nPapers must be written in English. Organization of the manuscript must follow the style of the\nJournal. One original and three copies of the text with disk must be submitted. Please include\nfull contact information - corresponding author name, e-mail address, telephone and fax\nnumbers, and full postal address. Typing should be double spaced on A4 paper or equivalent\n21.59 (27.94 cm). The pages should be numbered consecutively. Separate sheets should be\nused for the title page, abstract, tables and figures.\nPapers from outside America should be sent to: Prof. Robert Gurny, School of Pharmacy,\nUniversity of Geneva, 30, quai E.-Ansermet, CH-1211 Geneva 4, Switzerland; E-mail:\nejpb@pharm.unige.ch\nPapers from America should be sent directly to: Prof. James W. McGinity, The University of\nTexas at Austin, College of Pharmacy, Austin, TX 78712, USA.\nElectronic Manuscripts.\nElectronic manuscripts have the advantage that there is no need for the rekeying of text,\nthereby avoiding the possibility of introducing errors and resulting in reliable and fast delivery\nof proofs.\nAfter final acceptance for publication, your revised manuscript must be submitted again on\ndisk, together with three identical printed hard copies, to the accepting Editor. It is important\nthat the file on disk and the printed copies be identical.\n\nThe preferred file storage medium is a 3.5 inch disk in MS-DOS format, although other\nsystems are acceptable, e.g., NEC and Apple (in this case, save your file in the usual manner;\ndo not use the option 'save in MS-DOS format').\n\nEnsure that the letter \"l\" and digit \"1\" (also letter \"O\" and digit \"0\") have been used properly,\nand format your article (tabs, indents, etc.) consistently. Characters not available on your\nword processor (Greek letters, mathematical symbols, etc.) should not be left open but\nindicated by a unique code (e.g., gralpha, @, #, etc., for the Greek letter ). Such codes should\nbe used consistently throughout the entire text. Please make a list of such codes and provide a\nkey. Do not allow your word processor to introduce word splits and do not use a 'justified'\nlayout. Please adhere strictly to the general instructions on style/arrangement and, in\nparticular, the reference style of the journal. It is very important that you save your file in the\nword processor format. If your word processor features the option to save files \"in flat\nASCII\", please do not use it. Format your disk correctly and ensure that only the relevant file\n(one complete article only) is on the disk. Also, specify the type of computer and word\nprocessing package used, label the disk with your name and the name of the file on the disk.\n\nAdditional instructions on how to prepare your manuscript can be found at:\nhttp://authors.elsevier.com . More in-depth guidelines for submitting artwork/illustrations can\nbe found at: http://authors.elsevier.com/artwork .\n\n\n\n31\n\nReview of manuscripts\n\nUpon receipt, a manuscript will be peer-reviewed. The reviewers' relevant comments and the\neditor's decision will be communicated to the authors.\nResearch papers\nTITLE\nIt should be carefully chosen to provide precise information about the contents and include\nimportant keywords. The title should be followed by the full name(s) of the author(s) and by\nhis (her, their) affiliation(s). Different affiliations should be indicated by suitable superscripts.\n\nTo ensure identification of the corresponding author, please indicate full name, full postal\naddress, e-mail address, phone and facsimile on the cover of the manuscript.\n\nKEYWORDS\nIndicate 5 to 10 English keywords. They should be carefully selected in order to improve\naccessibility of scientific information in the manuscript. Keywords commonly used in\ninternational abstracting services will be preferred.\n\nABSTRACT\nIt should contain a brief and clear description of the aim of the paper, its principal results and\nmajor conclusions (100--200 words). The abstract should include all keywords pertinent to the\nsubject.\n\nRESEARCH PAPERS\nShould contain the following sections: Introduction, Theoretical Development (if applicable),\nMaterials and Methods, Results, Discussion (or Results and Discussion) and References. For\npurely theoretical papers, appropriate sections may be selected.\n\nINTRODUCTION\nIt should define the purpose of the research and reveal its connections with the principal work\nof other authors in the field.\n\nMATERIALS AND METHODS\nIt should include materials, standard techniques and procedures relevant to the study.\nPublished procedures and techniques should be cited unless significant modifications are\ninvolved. Exact specification of relevant materials and equipment must be given. Chemical\nterms must conform with IUPAC rules. Trademarks of commercial products must be labelled\nusing a superscripted `(r)'. Names of products and equipment mentioned in the Materials and\nMethods section must be accompanied by the name of the manufacturer or distributor,\nlocation and state or country. This information must be stated in parentheses in the text, and\nnot as a footnote. Any potential hazards connected with materials and procedures must be\nmentioned. A precise and detailed description should be given of those steps which are of\nvital importance in carrying out any repetition of the work. The Declarations of Helsinki and\nTokyo for humans, and the European Community guidelines as accepted principles for the use\nof experimental animals, must be adhered to. Therefore, EJPB will only consider manuscripts\nthat describe experiments that have been carried out under approval of an institutional or local\nethics committee. Authors must state in the manuscript that the protocol complies with the\nparticular recommendation and that approval of their protocols was obtained.\n\nEquations must be part of the text and consecutively numbered on the right hand side using\nnumbers in parentheses. References to equations in the text are also to be made with\nparentheses, e.g. using Eq. (3), etc.\n\n\n\n32\n\nOrganic formulas, both in figures and in the text, should be numbered in boldface arabic\nnumerals.\nSI units must be used throughout.\n\nRESULTS\nResults may be presented in tables, figures or schemes which must be\n\nreferred to in the accompanying text, using appropriate numbering, e.g.\nFig. 1, Table 2.\n\nDISCUSSION\nIt should focus on the interpretation of the results. It might be appropriate to combine\nRESULTS AND DISCUSSION in one section. If necessary at all, use CONCLUSIONS only\nto illustrate the general implication of the results and do not summarize the previous text.\n\nTABLES\nTables must be presented on separate sheets in consecutive order using Arabic numerals. The\ntable headings must include a descriptive title and additional information to make the table\nself-explanatory. Some information may be given by using lower-case letter designations\nreferring to footnotes at the bottom of the table. Indicate SI units of measure in parentheses.\n\nFIGURES\nFigures must be presented on separate sheets in consecutive order using Arabic numerals.\nEach figure should be provided with an instructive title and explanatory information. The\nlegend should be typed separately from the figures. To ensure identification of the figures,\nindicate figure number and name of author using soft pencil. Submit original drawings in\nblack ink on good quality white paper. High-contrast photographs are equally acceptable. A\nlimited number of colour photographs are accepted free of charge with prior permission from\nthe Editor-in-Chief. Colour photographs above this number will only be reproduced at the\nexpense of the author(s). The 2003 price for colour figures is 272 Euro for the first page and\n182 Euro for subsequent pages. One original set is required with the submission. Numbering\nand lettering of figures should be carefully selected in order to ensure readability after\nphotographic reduction of the figure. Use only standard symbols to mark datapoints.\nExplanation of curves and symbols should be in the legend rather that part of the drawing,\nunless this is detrimental to clarity. Indicate SI units of measure in parentheses.\n\nCITATIONS\nCitations of literature in the text must be presented in numerical order. Type numbers in\nparentheses and do not use superscripts. If names of authors are part of the text, use last\nnames only.\n\nREFERENCES\nReferences must be arranged as follows:\n[1] A.-L. Cornaz, P. Buri, Nasal mucosa as an absorption barrier, Eur. J. Pharm. Biopharm. 40\n(1994) 261--270.\n\n[5] C. Lanczos, Applied Analysis, Prentice-Hall, Englewood Cliffs, NJ, 1967, pp. 272--280.\n\n[10] D.M. Barends, Stability of active ingredients, in: H. M\u00fcller, W.H. Oeser (Eds.), Drug\nMaster Files, Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart, Germany, 1992, pp. 121-\n-128.\n\n[14] E.A. Balazs, Ultrapure hyaluronic acid and the use thereof, U.S. Patent 4,141,973 (1979).\n\n\n\n33\n\nThe system used by Chemical Abstracts (Chemical Abstracts Service Source Index) must be\nfollowed for the abbreviations of journals. Reference (4) is for patents, including the status,\ninternational country code, number of patent and year.\n\nACKNOWLEDGEMENTS\nAcknowledgements of financial support, gifts, technical help or other assistance may be given\nin an unnumbered paragraph under this heading preceding the references.\n\nNotes\nThe research and technical notes section of the journal (maximum 2500 words) is open to\ninteresting results worthy of publication without requiring extensive introduction and\ndiscussion. This section should contain the following subheadings: Abstract, Introduction,\nMaterials and Methods, Results and Discussion (combined). No more than 10 references\nshould be used. Tables, figures and references are to be arranged according to research papers.\nBrevity of presentation is essential for this section. Five to 10 keywords should be provided.\n\nReview articles\nThe organization and subdivision of review articles can be arranged at the author's discretion.\nTables, figures and references are to be arranged according to research papers. An abstract,\ntable of contents, and keywords are requested.\n\nCopyright regulations for authors\nUpon acceptance of an article by the Journal, author(s) will be asked to transfer the copyright\nof the article to the publisher. This transfer will ensure the widest possible dissemination of\ninformation.\n\nCorrecting proofs and reprints\nElsevier Science is now sending PDF proofs to authors by e-mail for correction. If an author\nis unable to handle this process, regular print proofs will be sent. Elsevier Science will do\neverything possible to get the article corrected and published as quickly and accurately as\npossible. Therefore, it is important to ensure that all corrections are sent back in one\ncommunication. Subsequent corrections will not be possible. Only typesetting errors may be\ncorrected; no changes in, or additions to, the accepted manuscript will be allowed. Proofs\nshould be returned to Elsevier Science within 48 hours.\n\nEJPB has no page charges. Fifty offprints of each paper will be supplied free of charge to the\ncorresponding author. Additional offprints can be ordered at prices shown on the offprint\norder form that accompanies the galley proofs.\n\nAuthor enquiries\nAll questions arising after acceptance of a manuscript by the Editor, especially those relating\nto proofs, publication and reprints, should be directed to the Publisher.\nElsevier Science Ireland Ltd\nBrookvale Plaza\nEast Park\nShannon, Co. Clare\nIreland\nTel: +353-61-709600\nFax: +353-61-709100\nE-mail:authorsupport@elsevier.ie\n\n\n\n34\n\nPlease visit the Elsevier Science Author Gateway at http://authors.elsevier.com to track\naccepted articles and set up e-mail alerts to inform you of when the article status has changed.\nInformation on artwork guidelines, copyright information, and frequently asked questions is\nalso available.\n\nA sample copy of the journal can be found on www.elsevier.com/locate/ejphabio\nNo responsibility is assumed by the Publisher for any injury and/or damage to persons or\nproperty as a matter of products liability, negligence or otherwise, or from any use or\noperation of any methods, products, instructions or ideas contained in the material herein.\nBecause of the rapid advances made in the medical sciences, independent verification of\ndiagnoses and drug dosages should be made.\n\n\n\n35\n\nANEXO II\nResumos apresentados em congressos decorrentes da Tese de Doutorado.\n\n\n\n36\n\nRESUMOS APRESENTADOS EM CONGRESSOS\n\n1. Santos, N. P.; Silva, N.H.; Pereira, E.C.Honda, N.K.; Souza, L.F.C.; Santos-\n\nMagalh\u00e3es, N.S. Encapsulation of usnic acid into PLGA Nanocapsules. In:\n\nGLA -4 - QUARTO ENCONTRO DO GRUPO LATINO AMERICANO DE\n\nLIQUEN\u00d3LOGOS, Bariloche, Argentina. Anais do Grupo de Liquen\u00f3gos\n\nLatino Americano, 1999, p110.\n\n2. Santos, N. P.; Pereira, E. C.; Honda, N.K. Santos-Magalh\u00e3es, N.S. PLGA\n\nNanocapsules Containing Usnic Acid.In:V PHARMATEC, Rio Grande do\n\nNorte. In: Anais da Association de Pharmacie Galenique Industriale, 2000, p25.\n\n3.Santos, N. P.; Cruz, D. B.; Nascimento, S. C.; Pereira, E. C.; Honda, N.\n\nK.;Santos- Magalh\u00e3es, N. S. Cytotoxic activity of usnic acid nanocapsules on\n\nNCI-H 292 Cells. In: XXX  REUNI\u00c3O ANNUAL DA SOCIEDADE\n\nBRASILEIRA DE BIOQU\u00cdMICA E BIOLOGIA MOLECULAR- SBBq,\n\nCaxanbu, Minas Gerais. Anais da XXX Reuni\u00e3o da SBBq, 2001, PH14.\n\n4. Santos, N. P.; Cruz, D. B.; Nascimento, S. C.; Pereira, E. C.; Honda, N.\n\nK.;Santos- Magalh\u00e3es, N. S..; Honda, N. K.; Figueredo, J.; Santos-Magalh\u00e3es,\n\nN. S. Cytotoxicity and Antitumoral activity of PLGA-Nanocapdules containing\n\nUsnic Acid. In: VI PHARMATEC III ANNUAL MEETING OF THE SBTF,\n\n\n\n37\n\nRecife, In: Anais da Association de Pharmacie Galenique Industriale, 2001,\n\np117-118.\n\n5. Santos, N. P.; Cruz, D. B.; Nascimento, S. C.; Pereira, E. C.; Honda, N.\n\nK.;Santos- Magalh\u00e3es, N. S..; Honda, N. K.; Figueredo, J.; Santos-Magalh\u00e3es,\n\nN. S. Usnic- acid-Loaded nanocapsules:A Citotoxity and Antitumoral Activity\n\nEvalution. In: II CONGRESSO LATINO-AMERICANO DE \u00d3RG\u00c3OS\n\nARTIFICIAIS E BIOMATERIAIS, Belo Horizonte. Proceedings of the II Latin\n\nAmerican Congress of artificial organs and Biomaterials. 2001, p5-6.\n\n6. Santos, N. P. Costa, R.M..; Cruz, D.B. , Nascimento, S.C. Pereira,E.C.; Silva,\n\nN.H. ; Honda, N.K. ; Figueredo-Silva, J. ; De Castro C.M.M.B. ; Santos-\n\nMagalh\u00e3es, N.S. Usnic acid-loaded nanocapsules exhibiting antitumoral activity\n\nIn: XXXI  REUNI\u00c3O ANNUAL DA SOCIEDADE BRASILEIRA DE\n\nBIOQU\u00cdMICA E BIOLOGIA MOLECULAR- SBBq, Caxanbu, Minas Gerais.\n\nAnais da XXXI Reuni\u00e3o da SBBq, 2002, pH53.\n\n7. Santos, N. P1.; Cruz, D.B.; Nascimento, S.C.;  Pereira,E.C.; Silva, N.H.;\n\nHonda, N.K.; Figueredo-Silva, J.; Santos-Magalh\u00e3es, N.S. A Biological activity\n\nevalution of PLGA-nanocapsules containing fumarprotocetraric acid In: XXXI\n\nREUNI\u00c3O ANNUAL DA SOCIEDADE BRASILEIRA DE BIOQU\u00cdMICA E\n\nBIOLOGIA MOLECULAR- SBBq, Caxanbu, Minas Gerais. Anais da XXXI\n\nReuni\u00e3o da SBBq. Apresenta\u00e7\u00e3o oral. 2002, pH55.\n\n\n\n38\n\n8. Santos, N. P.; Nascimento, S.C.  Pereira,E.C.; Silva, N.H.; Honda, N.K.;\n\nFigueredo-Silva, J.; Santos-Magalh\u00e3es, N.S. Biological activity of usnic acid\n\nencapsulated into PLGA-Nanocapsules. In: FIRST BRAZILIAN WINTER\n\nSCHOOL ON NANOTECHNOLOGY. Campinas, S\u00e3o Carlos, Ribeir\u00e3o Preto.\n\nAnais da Rede nanotechnology. 2002, 179-180.\n\n\n\n39\n\nANEXO III\nParecer do Comit\u00ea de \u00c9tica"}]}}}